Cover Page for Protocol 
Sponsor name:  [CONTACT_3454] A/S 
NCT number [STUDY_ID_REMOVED] 
Sponsor trial ID: NN9924-4233 
Official title of study: Efficacy and safety of oral semaglutid e versus placebo in subjects with 
type 2 diabetes mellitus treate d with diet and exercise only 
Document date: [ADDRESS_153706] of contents
Protocol ....................................................... ............................................................... .........................
Appendix A - Calcitonin monitoring .............................. ............................................................... ...
Appendix B - Adverse events requiring additional data collection ................................................
Attachment I and II............................................ ............................................................... .................
Protocol amendment 1 - CZ ....................................... ............................................................... ........
Protocol amendment 2 - Global ................................... ............................................................... ......
Protocol amendment 3 - RS....................................... ............................................................... .........CONFIDENTIALDate: Novo Nordisk
Version:
Status:Oral semaglutide
Trial ID: NN9924-4233Clinical Trial Report
Appendix 16.1.120 June 2018
1.0
Final
16.1.1 Protocol and protocol amendmentsCONFIDENTIAL
Redacted protocol 
Lncludes redaction of personal identifiable DQGFRPSDQ\
FRQILGHQWLDO information. 
. 
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 1 of 110
Protocol
Trial ID: NN9924-4233
PI[INVESTIGATOR_15597] 1 - Monotherapy
Efficacy and safety of oral semaglutide versus placebo in 
subjects with type 2 diabetes mellitus treated with
diet and exercise only
A 26-week, randomised, double-blind, placebo-controlled trial
Trial phase: 3a
Protocol originator
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153707] of abbreviations.......................................................................................................... ...............................7
1 Summary....................................................................................................................... ...........................11
2 Flow chart .................................................................................................................... ............................14
2.1 Flow chart explanatory descriptions ......................................................................................... ...17
3 Background information and rationale for the trial............................................................................ 18
3.1 Background information...................................................................................................... ........18
3.1.1 Type 2 diabetes mellitus ............................................................................................18
3.1.2 Glucagon-like peptide-1 ............................................................................................18
3.1.3 Oral semaglutide........................................................................................................193.1.4 Non-clinical data........................................................................................................1 9
[IP_ADDRESS] Semaglutide.........................................................................................19
[IP_ADDRESS] SNAC ..................................................................................................20
3.1.5 Clinical data for or al semaglutide..............................................................................21
[IP_ADDRESS] Pharmacokinetics ................................................................................21
[IP_ADDRESS] Efficacy ...............................................................................................22
[IP_ADDRESS] Safety...................................................................................................22
3.2 Rationale for the trial ..................................................................................................... ..............23
4 Objectives and endpoints...................................................................................................... ..................24
4.1 Objectives .................................................................................................................. ..................24
4.1.1 Primary Objective......................................................................................................24
4.1.2 Secondary Objectives ................................................................................................24
4.2 Endpoints ................................................................................................................... ..................24
4.2.1 Primary endpoint........................................................................................................24
4.2.2 Secondary endpoints..................................................................................................24
[IP_ADDRESS] Confirmatory seconda ry endpoints .....................................................24
[IP_ADDRESS] Supportive seconda ry endpoints..........................................................[ADDRESS_153708] ..........................................................................29
5.5 Rationale for treatment ..................................................................................................... ...........29
6 Trial population.............................................................................................................. .........................30
6.1 Number of subjects .......................................................................................................... ............30
6.2 Inclusion criteria .......................................................................................................... ................30
6.3 Exclusion criteria .......................................................................................................... ...............30CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153709] administration........................................................35
8.1.4 End-of-treatment (visit 8) and Follow-up (visit 9).....................................................368.1.[ADDRESS_153710] and follow-up (visits 8A and 9A) ..........[ADDRESS_153711] related infor mation/assessments ..................................................................................... 38
8.2.1 Demography...............................................................................................................3 8
8.2.2 Diabetes history a nd diabetes co mplications .............................................................38
8.2.3 Concomitant illness a nd medical history ...................................................................39
8.2.4 Concomitant medication............................................................................................39
8.2.5 Childbearing potential................................................................................................40
8.2.6 Tobacco use ............................................................................................................... 40
8.3 Efficacy assessments........................................................................................................ ............40
8.3.1 Blood samples for efficacy ........................................................................................40
8.3.2 Self-measured plasma glucose (SMPG) ....................................................................[ADDRESS_153712] circumference ..................................................................................................428.3.5 Patient reported outcomes questionnaires..................................................................43
8.4 Safety assessments.......................................................................................................... .............44
8.4.1 Adverse events...........................................................................................................4 4
[IP_ADDRESS] Medication error..................................................................................44
[IP_ADDRESS] Adverse events requiring additional data collection ...........................44
8.4.2 Physical examination .................................................................................................45
8.4.3 Vital signs ............................................................................................................... ...45
8.4.4 Eye examination ........................................................................................................46
8.4.5 Electrocardiogr am (12–lead) .....................................................................................46
8.4.6 Blood samples for safety............................................................................................46
8.4.7 Pregnancy testing.......................................................................................................47
8.4.8 Anti-semaglutide antibodies ......................................................................................488.4.9 Hypoglycaemic epi[INVESTIGATOR_1841] ...........................................................................................48
8.5 Laboratory assessments ...................................................................................................... .........50
8.5.1 Fasting plasma glucose ..............................................................................................51
8.6 Other assessments........................................................................................................... .............52
8.6.1 Lactate................................................................................................................... .....52
8.6.2 Pharmacokinetics.......................................................................................................52
[IP_ADDRESS] SNAC PK sampling ............................................................................53
[IP_ADDRESS] Semaglutide PK sampling ...................................................................[ADDRESS_153713] diary ............................................................................................................. .53CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153714] compliance.......................................................................................................... ............54
9 Trial supplies ................................................................................................................ ...........................54
9.1 Trial products.............................................................................................................. .................54
9.2 Labelling ................................................................................................................... ...................55
9.3 Storage ..................................................................................................................... ....................55
9.4 Drug accountability a nd destruction ......................................................................................... ...55
9.5 Auxiliary supply ............................................................................................................ ..............56
10 Interactive web/voice response system ........................................................................................ ..........56
11 Randomisation procedure and b reaking of blinded codes ..................................................................57
11.1 Breaking of blinded codes .................................................................................................. .........57
12 Adverse events, technical comp laints and pregnancies .......................................................................58
12.1 Definitions ................................................................................................................ ...................58
12.1.1 Adverse event ............................................................................................................ 58
12.1.2 Serious adverse event.................................................................................................59
12.1.3 Non-serious adverse event .........................................................................................60
12.1.4 Medication errors.......................................................................................................6 0
12.1.5 Adverse events requiring additional data collection..................................................61
12.1.6 Technical complaints .................................................................................................62
12.2 Reporting of adverse events................................................................................................ .........62
12.3 Follow-up of adverse events ................................................................................................ ........65
12.4 Technical complaints and tec hnical complaint samples ..............................................................66
12.4.1 Reporting of technical complaints .............................................................................6612.4.2 Collection, storage and shipment of technical complaint samples ............................66
12.5 Pregnancies in female subjects ............................................................................................. .......67
12.6 Precautions and/or overdose ................................................................................................ ........68
12.7 Committees related to safety............................................................................................... .........69
12.7.1 Novo Nordisk sa fety committee ................................................................................69
12.7.2 Event adjudication committee....................................................................................69
13 Case report forms............................................................................................................ ........................72
13.1 Corrections to cas e report forms........................................................................................... .......73
13.2 Case report form flow...................................................................................................... ............73
14 Monitoring procedures ........................................................................................................ ...................73
15 Data management.............................................................................................................. ......................74
16 Computerised systems......................................................................................................... ....................75
17 Statistical considerations ................................................................................................... .....................75
17.1 Sample size calculation.................................................................................................... ............77
17.2 Definition of analysis sets................................................................................................ ............79
17.3 Primary endpoint........................................................................................................... ...............82
17.3.1 Primary analysis for the primary estimand ................................................................8217.3.2 Primary analysis for th e secondary estimand.............................................................83
17.3.3 Sensitivity analyses....................................................................................................8 3
[IP_ADDRESS] Pattern mixture models........................................................................84
[IP_ADDRESS] Other sensitivity analyses....................................................................85
[IP_ADDRESS] Assessment of sensitivity analyses......................................................85CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 5 of 110
17.4 Secondary endpoints........................................................................................................ ............85
17.4.1 Confirmatory sec ondary endpoints............................................................................85
17.4.2 Supportive secondary endpoints ................................................................................86
[IP_ADDRESS] Efficacy endpoints...............................................................................86
[IP_ADDRESS] Safety endpoints ..................................................................................8817.4.2.3 Pharmacokinetic endpoints..................................................................92
17.5 Interim analysis........................................................................................................... .................92
17.6 Pharmacokinetic and/or pharmacodynamic modelling................................................................92
17.7 Health economics and/or p atient reported outcomes ...................................................................92
18 Ethics ....................................................................................................................... .................................93
18.1 Benefit-risk assessment of the trial....................................................................................... .......93
Risks and precautions .......................................................................................................... ........93
18.1.1 Benefits................................................................................................................. .....95
18.1.2 Risk and benefit conclusion.......................................................................................96
18.2 Informed consent ........................................................................................................... ..............96
18.3 Data handling.............................................................................................................. .................97
18.4 Information to sub jects during trial....................................................................................... .......97
18.5 Premature termination of the trial and/or trial site....................................................................... 97
19 Protocol compliance.......................................................................................................... ......................97
19.1 Protocol deviations ........................................................................................................ ..............97
19.2 Prevention of missing data................................................................................................. ..........98
20 Audits and inspections ....................................................................................................... .....................98
21 Critical documents ........................................................................................................... .......................98
22 Responsibilities ............................................................................................................. .........................100
23 Reports and publications..................................................................................................... .................101
23.1 Communication of results................................................................................................... .......101
23.1.1 Authorship ............................................................................................................... 102
23.1.2 Site-specific publication(s) by [CONTACT_1697](s) .........................................................102
23.2 Investigator access to data and review of results .......................................................................102
24 Retention of clinical trial docume ntation and human  biosamples....................................................103
24.1 Retention of clinical trial documentation.................................................................................. .103
24.2 Retention of human biosamples.............................................................................................. ...103
25 Institutional Review Boards/Independent Ethics Committees and regulatory authorities............104
26 Indemnity statement .......................................................................................................... ...................105
27 References ................................................................................................................... ...........................106
Appendix A – Calcitonin monitoring
Appendix B – Adverse events requiring additional data collection
Attachment I – Global list of key staff and relevant departments and suppliers
Attachment II – Country list of key staff and relevant departmentsCONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 6 of 110
Table of Figures
Page
Figure 5–1 Trial design......................................................................................................... ....................27
Figure 12–1 Reporting of adverse events......................................................................................... ...........64
Figure 17–1 Graphical illustration of the closed testing procedure ............................................................79
Figure 17–2 ADA classification of hypoglycaemia................................................................................. ...91
Table of Tables
Page
Table 5–1 Treatment of subjects................................................................................................. .............28
Table 9–1 Investigati onal medicinal products.................................................................................... .....54
Table 9–2 Storage conditions for investigational medicinal products.....................................................55
Table 12–1 Adverse events requiring completion of specific event forms and/or are subject to event 
adjudication ................................................................................................................... .........61
Table 12–2 Adverse events for adjudication ...................................................................................... ......70
Table 17–1 Assumptions used in  the sample s ize calculation ...................................................................78
Table 17–2 Calculated powers for individual hypotheses .........................................................................7 8CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153715] aspartate aminotransferase
AUC area under the curve
BG blood glucose
BMI body mass index
CK creatine kinase 
CKD-EPI [INVESTIGATOR_135512] c-reactive protein
DUN dispensing unit number
EAC event adjudication committee
ECG electrocardiogram
eCRF electronic case report form
eGFR estimated glomerular filtration rate
EMA European Medicines Agency
FAS full analysis setCONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153716] visit
GCP Good Clinical Practice
GLP-1 glucagon-like peptide-1
GLP-1 RA glucagon-like peptide-1 receptor agonists
HbA 1c glycosylated haemoglobin
HDL high-density lipoprotein
ICHInternational Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for 
Human Use
IB investigator’s brochure
ICMJE International Committee of Medical Journal Editors
IEC independent ethics committee
IMP investigational medicinal product
IND investigational new drug
IWQOL-Lite Impact of Weight on Quality of Life
IRB institutional review board
IWRS interactive web/voice response system
LDL low-density lipoprotein
LLoQ lower limit of quantification
LSFV last subject first visitCONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153717]
NYHA [LOCATION_001] Heart Association
PG plasma glucose
PGI-C Patient Global Impression of Change
PGI-S Patient Global Impression of Status
PK pharmacokinetic
PRO patient reported outcome
SAE serious adverse event
SAS safety analysis set
s.c. Subcutaneous(ly)
SF-36 short form-36
SIF safety information form
SMPG self-measured plasma glucose
SNAC N-[8-(2-hydroxybenzoyl) amino]caprylate  
STEMI ST-elevation acute myocardial infarction CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153718]
TEAE treatment-emergent adverse events 
T2DM type 2 diabetes mellitus 
UNL upper normal limit
UTN Universal Trial NumberCONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 11 of 110
1 Summary
Objectives and endpoints:
Primary Objective
To compare the effects of three dose levels of once-daily oral semaglutide (3, 7 and 14 mg) versus 
once-daily placebo on glycaemic control in subjects with type 2 diabetes mellitus treated with diet 
and exercise only.
Secondary Objectives
To compare the effects of three dose levels of once-daily oral semaglutide (3, 7 and 14 mg) versus 
once-daily placebo on body weight in subjects with type 2 diabetes mellitus treated with diet and 
exercise only.
To compare the safety and tolerability of three dose levels of once-daily oral semaglutide (3, 7 and 
14 mg) versus once-daily placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only. 
Primary endpoint
Change from baseline to week 26 in HbA
1c.
Key secondary endpoints
Change from baseline to week 26 in:
!Body weight (kg)
!Fasting plasma glucose
If a subject after week 26 achieve (yes/no):
!HbA 1c< 7.0% (53 mmol/mol) (American Diabetes Association target)
Number of treatment-emergent adverse events during exposure to trial product, assessed up to 
approximately [ADDRESS_153719], assessed up to approximately 31 weeks.
Trial design:
This is a 26-week, randomised, double-blinded, placebo-controlled, four-armed, parallel-group, 
multi-centre, multi-national trial comparing the efficacy and safety of three dose levels of once-
daily oral semaglutide and placebo in subjects with type 2 diabetes mellitus treated with diet and 
exercise only.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 12 of 110
Subjects will be randomised 1:1:1:1 to receive one of the following treatments: 
!3 mg oral semaglutide once daily
!7 mg oral semaglutide once daily 
!14 mg oral semaglutide once daily 
!placebo once daily
The randomisation will be stratified based on descent (Japanese subjects/non-Japanese subjects). 
The total trial duration for the individual subject will be approximately 33 weeks, including a 2-
week screening period followed by a 26-week randomised treatment period and a 5-week follow-up 
period. 
Trial population:
Number of subjects planned to be randomised: [ADDRESS_153720] be answered “yes”. 
!Informed consent obtained before any trial-related activities. Trial-related activities are any 
procedures that are carried out as part of the trial, including activities to determine suitability 
for the trial. 
!Male or female, age above or equal to 18 years at the time of signing informed consent.
For Japan only: Male or female, age ≥ 20 years at the time of signing informed consent.
For Algeria only: Male or female, age ≥ 19 years at the time of signing informed consent.
!Diagnosed with type 2 diabetes mellitus ≥ 30 days prior to day of screening.
!HbA 1cbetween 7.0-9.5% (53-80 mmol/mol) (both inclusive).
!Treatment with diet and exercise for ≥[ADDRESS_153721] be answered "no".
!Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing 
potential and not using an adequate contraceptive method (adequate contraceptive measure 
as required by [CONTACT_17993]). 
For Japan only: Adequate contraceptive measures are abstinence (not having sex), 
diaphragm, condom (by [CONTACT_3969]), intrauterine device, sponge, spermicide or oral contraceptives.
!Any disorder, which in the investigator’s opi[INVESTIGATOR_36174]’s safety or 
compliance with the protocol.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 13 of 110
!Family or personal history of multiple endocrine neoplasia type 2 or medullary thyroid 
carcinomas.
!History of pancreatitis (acute or chronic).
!History of major surgical procedures involving the stomach potentially affecting absorption 
of trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric by[CONTACT_13786]).
!Any of the following: myocardial infarction, stroke or hospi[INVESTIGATOR_135513] 180 days prior to the day of screening and 
randomisation.
!Subjects presently classified as being in [LOCATION_001] Heart Association Class IV.
!Planned coronary, carotid or peripheral artery revascularisation known on the day of 
screening.
!Subjects with alanine aminotransferase > 2.5 x upper normal limit.
!Renal impairment defined as estimated glomerular filtration rate <60 mL/min/1.73 m2 as per 
Chronic Kidney Disease Epi[INVESTIGATOR_36176]. 
!Treatment with any medication for the indication of diabetes or obesity in a period of 90 
days before the day of screening. An exception is short-term insulin treatment for acute 
illness for a total of ≤ 14 days.
!Proliferative retinopathy or maculopathy requiring acute treatment. Verified by [CONTACT_135533] 90 days prior to randomisation.
!History or presence of malignant neoplasms within the last 5 years (except basal and 
squamous cell skin cancer and in-situ carcinomas).
Key assessments:
Efficacy
!HbA 1c
!Body weight
!Fasting plasma glucose
Safety
!Adverse events
!Hypoglycaemic epi[INVESTIGATOR_36177]:
Investigational medicinal products:
!Test product: Semaglutide 3 mg, 7 mg and 14 mg tablets 
!Reference therapy: Placebo tabletsCONFIDENTIAL
Protocol UTN: U1111-1177-5112 Date: 20 April 2016 Status: Final Novo Nordisk
Trial ID: NN9924-[ADDRESS_153722] no.2015-005622-19 Version: 2.0 Page: 14 of 110
2 Flow chart
Trial Periods ScreeningaRandomisation TreatmentEnd-of-
treatmentFollow-
upbEnd-of-
treatment
premature 
discontinuationcFollow-up 
premature 
discontinuationc
Visit (V), Phone contact (P) V1 V2 P3 V4 V5 V6 V7 V8 V9 V8A V9A
Timing of visit (weeks) -[ADDRESS_153723]
Visit window (days) ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 +[ADDRESS_153724] RELATED
INFO/ASSESSMENTS
Informed consent x
In/exclusion criteria x x
Concomitant medication x x x x x x x x x x x
Demography x
Tobacco use x
Concomitant illness and medical history x
Diagnosis of diabetes/diabetes complications x
History of gastrointestinal disease x
History of cardiovascular disease x
History of gallbladder disease x
Randomisation x
Criteria for premature discontinuation of trial 
productxxxxx
EFFICACY
Height x
Protocol UTN: U1111-1177-5112 Date: 20 April 2016 Status: Final Novo Nordisk
Trial ID: NN9924-[ADDRESS_153725] no.2015-005622-19 Version: 2.0 Page: 15 of 110
Trial Periods ScreeningaRandomisation TreatmentEnd-of-
treatmentFollow-
upbEnd-of-
treatment
premature 
discontinuationcFollow-up 
premature 
discontinuationc
Visit (V), Phone contact (P) V1 V2 P3 V4 V5 V6 V7 V8 V9 V8A V9A
Timing of visit (weeks) -[ADDRESS_153726]
Visit window (days) ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 +[ADDRESS_153727] circumference x x x x
Fasting plasma glucose x x x x x x x
HbA 1c x x xxxx x x
Semaglutide PK xx x x x x x
SNAC PKdxx x
7-point SMPG profile x x x
Lipi[INVESTIGATOR_805] x x x x
Fasting insulin and proinsulin x x x
Fasting C-peptide x x x
Fasting glucagon x x x
CRP x x x
PRO questionnaires xexx x
SAFETY
Adverse eventsfx xxxxx x x x x
Hypoglycaemic epi[INVESTIGATOR_1841] x x x x x x x x x x
Physical examination x x x
Eye examinationgx
Vital signs x x x x x x x x x
Protocol UTN: U1111-1177-5112 Date: 20 April 2016 Status: Final Novo Nordisk
Trial ID: NN9924-[ADDRESS_153728] no.2015-005622-19 Version: 2.0 Page: 16 of 110
Trial Periods ScreeningaRandomisation TreatmentEnd-of-
treatmentFollow-
upbEnd-of-
treatment
premature 
discontinuationcFollow-up 
premature 
discontinuationc
Visit (V), Phone contact (P) V1 V2 P3 V4 V5 V6 V7 V8 V9 V8A V9A
Timing of visit (weeks) -[ADDRESS_153729]
Visit window (days) ±3 ±3 ±3 ±3 ±3 ±3 +3 +3 +[ADDRESS_153730] x
Dispense and/or collect diary x x x x x x x x x x
Protocol UTN: U1111-1177-5112 Date: 20 April 2016 Status: Final Novo Nordisk
Trial ID: NN9924-[ADDRESS_153731] no.2015-005622-19 Version: 2.0 Page: [ADDRESS_153732] not exc eed 2 weeks prior to randomisation (V2).
b Subjects, who have discontinued trial product prematurely, are not required to attend V9 (Follow-up).
cV8A and V9A are only applicable for subjects who have discontinued trial product prematurely. After visit 9A, samples for antibo dies, PK and lactate assessment should not
be taken.
d Samples should be taken 25 (+/-5) minutes and 40 (+/-5) minutes post dosing.
e The PGI-C should not be answered at V2.
fAdverse events reporting includes adverse events from the first trial-related activity after the subject has signed the informed  consent at
V1. 
gFundus photography or dilated fundoscopy performed within [ADDRESS_153733] be done pre-dose. No antibody sampling should be done for visits occurring after V9 A (subjects who have discontinued trial 
product prematurely).
jFor women of child-bearing potential: Urine pregnancy test should also be performed at any time during the trial if menstrual p eriod is missed, and/or according to local 
regulations/law.
k Samples should be taken pre-dose and 25 (+/-5) minutes and 40 (+/-5) minutes post dosing.
l Fasting for blood sampling is defined as no food or liquid within the last 8 hours prior to sampling, however water is allowed  up until 2 hours prior to sampling.
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 18 of 110
3 Background information and rationale for the trial
The trial will be conducted in compliance with this protocol, International Conference on 
Harmonisation (ICH) Good Clinical Practice (GCP)1and applicable regulatory requirements, and in 
accordance with the Declaration of Helsinki2.
In this document, the term investigator refers to the individual responsible for the overall conduct of 
the clinical trial at a trial site.
For Mexico only: the above will include the following responsibilities for the head of the 
Institution/Health Care Establishment, Ethics, Research and, when applicable, Biosafety 
Committees and sponsor within their scope of responsibility: a) Investigation follow-up b) Damages 
to health arising from the investigation development; as well as those arising from interruption or 
advanced suspension of treatment due to non-attributable reasons to the Subject; c) Timely 
compliance of the terms in which the authorization of a research for health in human beings had been issued; d) To present in a timely manner the information required by [CONTACT_135534].
3.1 Background information
For an assessment of benefits and risks of the trial, see Section 18.1.
3.1.1 Type 2 diabetes mellitus 
Type 2 diabetes mellitus (T2DM) is a progressive metabolic disease primarily characterised by 
[CONTACT_36269]. The pathogenesis is heterogeneous involving environmental, 
lifestyle and genetic factors leading to chronic hyperglycaemia caused by [CONTACT_36270], impaired insulin secretion due to abnormal beta-cell function and abnormal glucose 
metabolism in the liver3.
Optimal glycaemic control is the treatment goal in subjects with T2DM in order to prevent long-term complications associated with chronic hyperglycaemia
4. Despi[INVESTIGATOR_36178]-diabetic drugs, a significant proportion of subjects with T2DM do not achieve the recommended targets for glycaemic control
5, 6.
3.1.2 Glucagon-like peptide-1
Glucagon-like peptide-1 (GLP-1) is an incretin  hormone with a glucose-dependent stimulatory 
effect on insulin and inhibitory effect on glucagon secretion from the pancreatic islets7, 8. Subjects 
with T2DM have a decreased incretin effect9-12. However, the insulinotropic action of GLP-1 and 
thus, the ability to lower blood glucose (BG) levels, is preserved when GLP-[ADDRESS_153734] on gastric emptying; however this effect seems to diminish CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 19 of 110
upon chronic exposure14-16. These mechanisms of action make GLP-1 receptor agonists (GLP-1 
RA) an attractive pharmacological treatment for T2DM17-19.
3.1.3 Oral semaglutide 
Semaglutide is a long-acting GLP-1 RA structurally similar to liraglutide (Victoza®), a once-daily 
GLP-1 RA developed by [CONTACT_36271] T2DM. 
Compared to human native GLP-1, which has a short half-life, the semaglutide molecule has three 
minor but important modifications ensuring protraction of its action: amino acid substitutions at 
position 8 (alanine to alfa-aminoisobutyric acid, a synthetic amino acid) and position 34 (lysine to 
arginine), acylation of the peptide backbone with a sp acer and C-18 fatty di-acid chain to lysine in 
position 2620. The fatty di-acid side chain and the spacer mediate strong binding to albumin, thereby 
[CONTACT_36272]. The amino acid substitution at position 8 makes semaglutide less susceptible to degradation by [CONTACT_36273]-4 (DPP-4). The change in position [ADDRESS_153735] only one lysine in the sequence where to a spacer can be 
attached.
Semaglutide is in development for oral once-daily treatment of T2DM. As the bioavailability of 
GLP-1 RAs is low when administered orally, semaglutide has been co-formulated with the 
absorption-enhancing excipi[INVESTIGATOR_36179] N-[8-(2-hydroxybenzoyl] amino) caprylate (SNAC) to 
increase the bioavailability of semaglutide. The absorption-enhancing properties of SNAC co-
formulation is based on the  concept developed by .
SNAC facilitates the absorption of semaglutide in a strictly time- and size dependent manner, 
primarily via the transcellular route. The available data for semaglutide co-formulated with SNAC 
support that the absorption takes place in the stomach in a localised, buffered environment in close 
proximity of the tablet erosion. The absorption process is hampered if dosed with food, liquid or in 
the presence of significant stomach content. 
The absorption enhancement requires co-formulation between semaglutide and SNAC. Throughout 
this document “oral semaglutide” will refer to the drug product, that is, semaglutide co-formulated 
with 300 mg SNAC. 
3.1.4 Non-clinical data
[IP_ADDRESS] Semaglutide
The non-clinical programme for semaglutide was designed according to the ICH M3 guideline
21to 
support the clinical development. The standard non-clinical data package required to support phase 
[ADDRESS_153736] been completed. Semaglutide was generally well 
tolerated in animals (mice, rats and cynomolgus monkeys). Two potential safety issues have been 
identified and these are detailed below.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 20 of 110
Thyroid C-cell tumours in rodents
Treatment-related non-genotoxic proliferative changes in the thyroid C-cells of mice and rats were 
observed in 2-year carcinogenicity studies with semaglutide; thyroid hyperplasia was preceded by 
[CONTACT_36275]. C-cell changes have not been observed in long-term studies in non-
human primate. The observed pattern of effects in mice and rats and lack of these effects in the non-
human primate and in man suggest that the mechanism by [CONTACT_36276] C-
cells in rodents is the same as has been demonstrated for other GLP-1 RAs, including liraglutide. 
According to this mechanism, C-cell hyperplasia is mediated by [CONTACT_17978]-1 receptor and is not 
associated with RET (re-arranged during transfection) gene activation and rodents appear to be 
particularly sensitive, whereas humans are not. The relevance for human subjects is currently 
unknown, but considered to be low22.
Embryo−foetal development toxicity
Semaglutide caused embryo-foetal development toxicity in the rat through a GLP-[ADDRESS_153737] of semaglutide coincided with increased early foetal loss; however, there 
was no indication of a teratogenic potential of semaglutide in this species. 
A review of the results from the non-clinical studies can be found in the investigator’s brochure (IB)
for semaglutide (subcutaneous administration), edition 1023and the IB for oral administration of 
semaglutide (NN9924), edition 624, or any updates of these documents.
[IP_ADDRESS] SNAC
SNAC was developed as an absorption-enhancing excipi[INVESTIGATOR_36180]. The 
non-clinical programme to support clinical phase [ADDRESS_153738] been 
included at selected time points around peak concentrations of SNAC in two of the phase 3a trials CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 21 of 110
in the PI[INVESTIGATOR_36181] (NN9924-4223 and this trial) with the intention to document that 
SNAC does not impair cellular respi[INVESTIGATOR_36182]. In addition, events of lactic acidosis must be 
reported as an adverse event (AE) requiring additional data collection, please refer to section 
[IP_ADDRESS] , section 12.1.5 and appendix B .
The carcinogenicity studies demonstrated that SNAC was not carcinogenic to the transgenic rasH2 
mouse or the Sprague-Dawley rat. The doses tested covered total exposures of SNAC in plasma (in 
terms of area under the curve [AUC]) of 2-fold in the mouse and up to 44-fold in the rat when 
compared to the mean total exposure of SNAC in humans following a clinical dose of 300 mg 
SNAC/day.
A review of the SNAC results from the non-clinical studies can be found in the IB for oral 
administration of semaglutide (NN9924), edition 624, or any updates hereof.
3.1.5 Clinical data for oral semaglutide
A comprehensive clinical pharmacology programme including 12 trials has been completed, as well 
as a 26-week phase 2 dose-finding trial involving more than 600 subjects with T2DM.
For details on the individual trials, please see the IB for oral administration of semaglutide 
(NN9924) edition 624, or any updates hereof.
[IP_ADDRESS] Pharmacokinetics
In the multiple-dose trial (NN9924-3991), oral semaglutide has demonstrated a long mean terminal 
half-life (t ½) ranging from 153 to 161 hours (~1 week) and a median time to reach maximum 
observed concentration (t max) ranging from 1 to 2 hours in healthy subjects. 
In multiple-dose pharmacokinetics (PK) trials, the exposure to oral semaglutide increased with 
increasing dose. Overall, the pharmacokinetic properties of semaglutide appeared similar in healthy 
subjects and in subjects with T2DM.
Exposure of semaglutide exhibits a substantially greater dose-to-dose variation following oral 
administration compared to subcutaneous (s.c.) administration. However, when administered orally 
once daily the PK properties of semaglutide, i.e. low clearance and long half-life, will limit the 
variation in exposure at steady state.
Data obtained following investigation of different dosing conditions for oral semaglutide have 
demonstrated that subjects should take the oral semaglutide tablet in the morning in a fasting state 
and at least [ADDRESS_153739] meal of the day. 
 
 
 CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 22 of 110
 
 
  
 
 
 
In subjects with mild to severe hepatic impairment, the exposure to semaglutide appeared to be 
unaffected by [CONTACT_36277], whereas the exposure to SNAC (in terms of both 
AUC and C max) was increased for subjects with hepatic impairment as compared to subjects with 
normal hepatic function.
All tablets of oral semaglutide contain 300 mg of SNAC regardless of the semaglutide dose. SNAC 
is rapi[INVESTIGATOR_19627] a median t maxranging from 0.35 −0.5 hours in healthy subjects and from 
0.52−1.43 hours in subjects with T2DM. It is extensively metabolised and no accumulation of 
SNAC has been observed in clinical trials. 
[IP_ADDRESS] Efficacy
The efficacy of oral semaglutide in adult subjects with T2DM was investigated in a 26-week phase 
2 dose-finding trial. In this trial, placebo or one of the following doses of oral semaglutide were 
administered once daily: 2.5, 5, 10, 20 and 40 mg.
Results from the trial showed that oral semaglutide effectively lowered glycosylated haemoglobin
(HbA 1c) and body weight. Placebo-adjusted reductions in HbA 1cwere dose-dependent and 
statistically significant for all oral semaglutide treatment arms at week 26 (range: -0.40% to -
1.59%). Placebo-adjusted reductions in body weight were dose-dependent and statistically 
significant for oral semaglutide treatment doses of 10 mg and above at week 26 (range: -3.61 kg to -
6.98 kg). 
[IP_ADDRESS] Safety
In the clinical trials completed so far, no unexpected safety findings have been identified for oral 
semaglutide administered up to 40 mg once daily. Consistent with other GLP-1 RAs, commonly 
reported adverse events (AEs) included nausea and vomiting, most of them were mild to moderate
in severity. In line with findings for other GLP-1 RAs, an increase in heart rate and serum levels of 
lipase and amylase has also been observed in subjects exposed to oral semaglutide.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 23 of 110
In addition to the 13 completed clinical trials with oral semaglutide, SNAC has been investigated in 
the programme of orally administrated heparin in combination with SNAC (heparin/SNAC). The 
heparin/SNAC programme ( ) included 29 phase 1 trials (SNAC doses 
ranged from 0.172-10.5 g). In three of these trials, SNAC alone was investigated (to a maximum 
dose of 10.5 g). The trials covered formulation development, food effect, hepatic and renal 
impairment, age-effect and drug-drug interaction. The programme also included a total of three 
phase 2 and 3 trials in which the effects of orally delivered heparin solution (with >1.5 g SNAC 
three times a day) was investigated. The overall safety profile of oral semaglutide and 
heparin/SNAC indicates that SNAC is safe and well-tolerated.
For further details, please see the IB for oral administration of semaglutide (NN9924) edition 624, or 
any updates hereof.
3.[ADDRESS_153740] 
GLP-1 RA in development in a tablet formulation and it has the potential of becoming a new 
attractive treatment option early in the treatment cascade due to its effects on both hyperglycaemia 
and body weight. 
The aim of this 26-week, confirmatory phase 3a trial is to demonstrate superiority with three doses 
of oral semaglutide versus placebo on HbA 1cand body weight in T2DM subjects treated with diet 
and exercise only, and to evaluate the efficacy and safety of oral semaglutide in a monotherapy 
setting.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 24 of 110
4 Objectives and endpoints
4.1 Objectives
4.1.1 Primary Objective
To compare the effects of three dose levels of once-daily oral semaglutide (3, 7 and 14 mg) versus 
once-daily placebo on glycaemic control in subjects with type 2 diabetes mellitus treated with diet 
and exercise only.
4.1.2 Secondary Objectives
To compare the effects of three dose levels of once-daily oral semaglutide (3, 7 and 14 mg) versus 
once-daily placebo on body weight in subjects with type 2 diabetes mellitus treated with diet and 
exercise only.
To compare the safety and tolerability of three dose levels of once-daily oral semaglutide (3, 7 and 
14 mg) versus once-daily placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only.
4.2 Endpoints
Baseline refers to randomisation, and week 26 refers to 26 weeks after randomisation.
4.2.1 Primary endpoint
Change from baseline to week 26 in HbA
1c.
4.2.2 Secondary endpoints
[IP_ADDRESS] Confirmatory secondary endpoints
Change from baseline to week 26 in body weight (kg).
[IP_ADDRESS] Supportive secondary endpoints
Supportive secondary efficacy endpoints
Key supportive secondary endpoint prospectively selected for disclosure (e.g. clinicaltrials.gov and 
EudraCT) are marked with an asterix (*)
Change from baseline to week 26 in:
!Fasting plasma glucose (FPG)*
!Fasting C-peptide
!Fasting insulin and proinsulin 
!Fasting glucagonCONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 25 of 110
!Insulin resistance (homeostatic model assessment index of insulin resistance (HOMA-IR)) 
and beta-cell function (homeostatic model assessment index of beta-cell function (HOMA-B))
!C-reactive protein (CRP)
!7-point self-measured plasma glucose (SMPG) profile
– Mean 7-point profile
– Mean postprandial increment (over all meals)
!Body weight (%)
!Body mass index (BMI)
!Waist circumference
!Fasting lipid profile (total cholesterol, low-density lipoprotein (LDL) cholesterol, high-
density lipoprotein (HDL) cholesterol and triglycerides)
!Patient-reported outcomes (PROs) based on:
– Short Form (SF)-36v2
TM(acute version) health survey
– Impact of Weight on Quality of Life (IWQOL-Lite) Clinical Trial Version
– Patient Global Impression of Status (PGI-S) Items
– Patient Global Impression of Change (PGI-C) Items 
If a subject after week 26 achieve (yes/no):
!HbA 1c< 7.0% (53 mmol/mol) (American Diabetes Association (ADA) target)*
!HbA 1c≤ 6.5% (48 mmol/mol) (American Association of Clinical Endocrinologists (AACE) 
target)
!HbA 1creduction ≥ 1%-point (10.9 mmol/mol)
!Body weight loss ≥ 3% 
!Body weight loss ≥ 5% 
!Body weight loss ≥ 10% 
!HbA 1c< 7.0% (53 mmol/mol) without hypoglycaemia (treatment-emergent severe or BG-
confirmed symptomatic hypoglycaemic epi[INVESTIGATOR_1841]) and no body weight gain 
!HbA 1creduction ≥ 1%-point (10.9 mmol/mol) and body weight loss ≥ 3%
Time to event:
!Time to rescue medication
Supportive secondary safety endpoints
!Number of treatment-emergent adverse events (TEAEs) during exposure to trial product, 
assessed up to approximately 31 weeks* 
!Number of treatment-emergent severe or BG-confirmed symptomatic hypoglycaemic 
epi[INVESTIGATOR_36184], assessed up to approximately 31 weeks* 
!Treatment-emergent severe or BG-confirmed symptomatic hypoglycaemic epi[INVESTIGATOR_36237], assessed up to approximately 31 weeks (yes/no)CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 26 of 110
Change from baseline to week 26 in:
!Haematology 
!Biochemistry 
!Calcitonin
!Pulse
!Systolic blood pressure
!Diastolic blood pressure
!Electrocardiogram (ECG) category
!Physical examination
Change from pre-dose to post-dose (25 and 40 minutes) at week 4 and 26 in:
!Lactate
Any occurrence of anti-semaglutide antibodies (yes/no) up to approximately 31 weeks:
!Anti-semaglutide binding antibodies
!Anti-semaglutide neutralising antibodies 
!Anti-semaglutide binding antibodies cross reacting with native GLP-1
!Anti-semaglutide neutralising antibodies cross reacting with native GLP-1
Anti-semaglutide binding antibodies up to approximately 31 weeks:
!Anti-semaglutide binding antibody levels
Supportive secondary pharmacokinetic endpoints
!Semaglutide plasma concentrations for population PK analysis
!SNAC plasma concentrations CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 27 of 110
5 Trial design
5.1 Type of trial
This is a 26-week, randomised, double-blinded, placebo-controlled, four-armed, parallel-group, 
multi-centre, multi-national trial comparing the efficacy and safety of three dose levels of once-
daily oral semaglutide and placebo in subjects with T2DM treated with diet and exercise only.
Subjects will be randomised 1:1:1:1 to receive one of the following treatments:
!3 mg oral semaglutide once daily
!7 mg oral semaglutide once daily 
!14 mg oral semaglutide once daily 
!Placebo once daily
The randomisation will be stratified based on descent (Japanese subjects/non-Japanese subjects). 
The total trial duration for the individual subject will be approximately 33 weeks, including a 2-
week screening period followed by a 26-week randomised treatment period and a 5-week follow-up 
period. The trial design is illustrated in Figure 5–1 .
Figure 5–[ADDRESS_153741] to ensure acceptable glycaemic control during the trial 
for all treatment arms, including the placebo arm (see Section 6.4).
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 28 of 110
The treatment duration of 26 weeks is considered adequate to evaluate the efficacy of semaglutide 
versus placebo, and furthermore, for the assessment of safety and tolerability. 
The follow-up period is 5 weeks to allow for wash-out of semaglutide and to prevent interference in 
the antibody assay.
5.3 Treatment of subjects
Subjects will be randomised to oral semaglutide or placebo. Subjects randomised to oral 
semaglutide will initiate treatment with 3 mg once daily. Subjects randomised to a treatment dose of 
7 or 14 mg, will follow a fixed 4-week dose-escalation regimen until reaching the maximum 
randomised dose, as illustrated in Table 5–1 . All dose levels, including the dose-escalation, will be 
blinded. To mitigate the risk of gastrointestinal AEs, it is important to follow the fixed 4-week dose 
escalation intervals. 
Table 5–[ADDRESS_153742] visit in each period V1 V2 V4 V5 V9
Duration of each period 2 weeks 4 weeks 4 weeks 18 weeks 5 weeks
Treatment arm N
Oral semaglutide (3 mg) 176 Screening 3 mg 3 mg 3 mg Follow-up
Oral semaglutide (7 mg) 176 Screening 3 mg 7 mg 7 mg Follow-up
Oral semaglutide (14 mg) [ADDRESS_153743] can be taken with up to half a glass of water (approximately 120 
mL/4 fluid oz). The tablet must be swallowed whole by [CONTACT_135535] (see Table 9–2 ). Furthermore, other oral medication can be taken [ADDRESS_153744].
5.3.2 Background medication
As the present trial is a monotherapy trial no anti-diabetic medications are allowed 90 days before 
visit 1 and during the trial. Please see Section 6.4with regards to rescue medication.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153745]
When discontinuing trial products, either at the scheduled end-of-treatment visit (see Section 8.1.4 )
or if trial product is discontinued prematurely (see Section 8.1.5 ), the subject should be switched to 
a suitable marketed product at the discretion of the investigator. After discontinuation of trial 
product, GLP-[ADDRESS_153746] (to avoid interference with the antibody assay for oral semaglutide).
Throughout the protocol, last date on trial product is defined as date of the subject’s last dosage of 
trial product. 
Oral semaglutide will not be available for prescription until after marketing authorisation.
5.5 Rationale for treatment
For oral semaglutide, the three dose levels (3, 7 and 14 mg), treatment initiation with the lowest 
dose and 4-week dose escalation step have been chosen based on the data from the phase [ADDRESS_153747] sufficient data on efficacy 
and safety in accordance with the trial objectives.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 30 of 110
6 Trial population
6.1 Number of subjects 
Number of subjects planned to be screened (number of subjects providing informed consent): 1050
Number of subjects planned to be randomised: [ADDRESS_153748]: 634
For Japan only: 100 Japanese subjects are planned to be randomised with an approximate equal 
distribution across the 4 treatment arms.For Mexico only: 45 subjects are planned to be randomised/started on trial product in Mexico
6.[ADDRESS_153749] be answered “yes”. 
1. Informed consent obtained before any trial-related activities. Trial-related activities are any 
procedures that are carried out as part of the trial, including activities to determine suitability for the trial. 
2. Male or female, age above or equal to 18 years at the time of signing informed consent.
For Japan only: Male or female, age ≥ 20 years at the time of signing informed consent.
For Algeria only: Male or female, age ≥ 19 years at the time of signing informed consent.
3. Diagnosed with type 2 diabetes mellitus ≥ 30 days prior to day of screening.
4. HbA 1cbetween 7.0-9.5% (53-80 mmol/mol) (both inclusive).
5. Treatment with diet and exercise for ≥[ADDRESS_153750] be answered "no".
1. Known or suspected hypersensitivity to trial product(s) or related products. 
2. Previous participation in this trial. Participation is defined as signed informed consent.
3. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing 
potential and not using an adequate contraceptive method (adequate contraceptive measure as 
required by [CONTACT_17993]).
For Japan only: Adequate contraceptive measures are abstinence (not having sex), diaphragm, 
condom (by [CONTACT_3969]), intrauterine device, sponge, spermicide or oral contraceptives.
4. Receipt of any investigational medicinal product within 90 days before screening.
5. Any disorder, which in the investigator’s opi[INVESTIGATOR_36174]’s safety or 
compliance with the protocol.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 31 of 110
6. Family or personal history of multiple endocrine neoplasia type 2 (MEN 2) or medullary thyroid 
carcinomas (MTC).
7. History of pancreatitis (acute or chronic).
8. History of major surgical procedures involving the stomach potentially affecting absorption of 
trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric by[CONTACT_4897]).
9. Any of the following: myocardial infarction, stroke or hospi[INVESTIGATOR_135513] 180 days prior to the day of screening and 
randomisation.
10. Subjects presently classified as being in [LOCATION_001] Heart Association (NYHA) Class IV.
11. Planned coronary, carotid or peripheral artery revascularisation known on the day of screening.
12. Subjects with alanine aminotransferase (ALT) > 2.5 x upper normal limit (UNL).
13. Renal impairment defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2
as per Chronic Kidney Disease Epi[INVESTIGATOR_36176] (CKD-EPI). 
14. Treatment with any medication for the indication of diabetes or obesity in a period of 90 days 
before the day of screening. An exception is short-term insulin treatment for acute illness for a 
total of ≤ [ADDRESS_153751] 5 years (except basal and squamous 
cell skin cancer and in-situ carcinomas).
6.[ADDRESS_153752] of treatment on 
glycaemic parameters, rescue criteria will be applied from week 8 and onwards. If any of the FPG 
values (including fasting SMPG) exceed the limits outlined below and no intercurrent cause of the 
hyperglycaemia can be identified, a confirmatory FPG (at the central laboratory) should be obtained 
by [CONTACT_36282] a re-test. If the confirmatory FPG also exceeds the values described below, 
the subject should be offered rescue medication (i.e. initiation of anti-diabetic medication):
!13.3 mmol/L (240 mg/dL) from week 8 to the end of week 13
!11.1 mmol/L (200 mg/dL) from week 14 to the end-of-treatment
It is important for the integrity of the trial that only subjects actually needing treatment 
intensification (as defined above) are started on rescue medication. Subjects who are started on 
rescue medication should continue to follow the protocol-specified visit schedule. Rescue 
medication should be prescribed at investigator’s discretion as add-on to randomised treatment and 
according to ADA/European Association for the Study of Diabetes guidelines25, 26(excluding GLP-
RAs, DPP-4 inhibitors and amylin analogues).  
Rescue medication and any changes hereto should be captured on the concomitant medication form 
in the electronic case report form (eCRF), see Section 8.2.4 . CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153753] (NIMP) and will not 
be provided by [CONTACT_3454].
6.[ADDRESS_153754] if the following applies:
!Safety concern related to the trial product or unacceptable intolerability
!Included in the trial in violation of the inclusion and/or exclusion criteria
!Pregnancy
!Intention of becoming pregnant
!Simultaneous participation in another clinical trial of an approved or non-approved 
investigational medicinal product (IMP)
!Calcitonin ≥ 100 ng/L
If a criterion for premature discontinuation of trial product is met, trial product should not be re-
initiated but subjects should continue with the scheduled site contacts.
See Section 8.1.[ADDRESS_153755]’s request to withdraw from the 
trial must always be respected. Only subjects who withdraw consent should be considered 
withdrawn from trial.
See Section 8.1.6 for procedures to be performed for subjects withdrawing consent. 
For Mexico only: should the subject, his/her family members, parents or legal representative decide 
to withdraw the consent for participation in the trial, the subject will be entitled to receive 
appropriate, free of charge medical care and/or trial drug during the follow-up period of the 
protocol when it will be established with certainty that no untoward medical consequences of the 
subject´s participation in the research occurred.
6.[ADDRESS_153756] prematurely will not be replaced.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153757] the data interpretation. The upper HbA 1climit of 9.5% (80 mmol/mol) has been chosen as 
this is a placebo-controlled trial. FPG will be monitored throughout the trial and rescue medication 
should be initiated in subjects with persistent, unacceptable hyperglycaemia. Subjects with liver test 
abnormalities (ALT > 2.5 x UNL) will be excluded to avoid potential confounding of liver safety 
assessments. Overall, the eligibility criteria will allow for enrolment of a relatively broad trial 
population resembling the target population in common clinical practice.
7 Milestones
Planned duration of recruitment period FSFV-LSFV: 28 weeks
Planned FSFV: 20-Sep-2016
Planned LSLV: 27-Nov-2017
End of trial is defined as LSLV.
Recruitment:
The screening and randomisation rate will be followed closely via the IWRS in order to estimate 
when to stop screening. All investigators will be notified immediately when the recruitment period 
ends, after which no further subjects may be screened and the IWRS will be closed for further 
screening.
Trial registration:
Information of the trial will be disclosed at clinicaltrials.gov, novonordisk-trials.com and the 
Clinical Trials Information Japi[INVESTIGATOR_36187].jp. According to the Novo Nordisk Code of 
Conduct for Clinical Trial Disclosure27, it will also be disclosed according to other applicable 
requirements such as those of the International Committee of Medical Journal Editors (ICMJE)28,
the Food and Drug Administration Amendment Act (FDAAA)29, European Commission 
Requirements30, 31and other relevant recommendations or regulations. If a subject requests to be 
included in the trial via the Novo Nordisk e-mail contact [CONTACT_36283], Novo Nordisk may 
disclose the investigator’s contact [CONTACT_18026]. As a result of increasing requirements for 
transparency, some countries require public disclosure of investigator names and their affiliations.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 34 of 110
8 Methods and assessments
8.1 Visit procedures
The following sections describe the assessments and procedures. These are also included in the flow 
chart (see Section 2). Informed consent must be obtained before any trial-related activity, see 
Section 18.2.
Refer to flowchart (Section 2) for number and timing of visits and specific assessments to be 
performed.
Each subject will attend [ADDRESS_153758] (within the visit window) and entered into the eCRF. Subjects will be invited for the next scheduled visit according to the visit schedule.
The investigator must keep a subject screening log, a subject identification code list and a subject 
enrolment log. Only subjects who have signed the informed consent form should be included on the 
logs. The subject screening log and subject enrolment log may be combined in one log. 
The investigator must keep a log of staff and a delegation of task(s) list at site. Investigator must 
sign the log of staff and the delegation of task(s) at site prior to the delegation of tasks.
8.1.[ADDRESS_153759] address(es) and telephone number(s) of relevant trial site staff. Subjects should be 
instructed to return the card to the investigator at the last trial visit or to destroy the card after the 
last visit.
A screening session must be made in the IWRS. Each subject will be assigned a unique 6-digit 
subject number which will remain the same throughout the trial.
Once all data relating to visit [ADDRESS_153760] be reviewed, dated and signed by [CONTACT_36284]/or documented in medical records to assess that the subject is eligible to continue 
in the trial.
Screening failures: For screening failures the screening failure form in the eCRF must be 
completed with the reason for not continuing in the trial. Serious adverse events (SAEs) from 
screening failures must be transcribed by [CONTACT_941] i nvestigator into the eCRF. Follow-up on SAEs must 
be carried out according to Section 12.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153761] has failed one of the inclusion or exclusion criteria; this 
includes re-sampling if the subject has failed one of the inclusion or exclusion criteria related to 
laboratory parameters. However, in case laboratory samples are lost (e.g. haemolysed or 
misplaced), re-sampling is allowed.
8.1.[ADDRESS_153762] attend several visits in a fasting state (see Section 2).
Fasting for blood sampling is defined as no food or liquid within the last [ADDRESS_153763] be taken after blood sampling (see Section 5.3.1 for dosing instructions). Other 
oral medication can be taken [ADDRESS_153764] blood samples are taken. Note 
that for all subjects, the required fasting period is longer at visits with PK sampling and lactate 
assessments (see Section 8.6).
In case a subject attends a fasting visit in a non-fasting state, all non-fasting measurements should 
be performed. The subject should return to the site in a fasting state to have fasting blood samples
done within the visit window for the relevant visit.
Fasting samples:
!FPG
!Fasting C-peptide
!Fasting insulin and proinsulin
!Fasting glucagon
!Fasting lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides)
!Lactate
!SNAC PK
8.1.[ADDRESS_153765]
be performed in the IWRS which will allocate the dispensing unit number (DUN) of trial product to 
be dispensed to the subject. It is important to dispense the exact allocated DUNs to the subject. 
When DUNs are dispensed, please confirm the dispensed date in the IWRS.
All visit [ADDRESS_153766].CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 36 of 110
Trial products (see Section 9) will be dispensed to the subject by [CONTACT_779], hospi[INVESTIGATOR_135514]-of-
treatment visit (see Section 2). The investigator must document that subjects are trained in the 
dosing instructions at every dosing instruction visit, please see Section 2and5.3.[ADDRESS_153767] will be captured in the eCRF.
8.1.4 End-of-treatment (visit 8) and Follow-up (visit 9)
Subjects, who stay on trial product throughout the trial, must attend the end-of-treatment visit (V8) 
26 weeks after randomisation (±3 days visit wi ndow) and the Follow-up visit (V9) [ADDRESS_153768] (+3 days visit window). A completion call must be performed in the 
IWRS after completion of visit 8 (see Section 10).
In case the subject cannot be reached (by [CONTACT_135536]) at the scheduled visit 9, the site 
should consult the contacts provided by [CONTACT_423] (e.g. close relatives), relevant physicians, 
medical records and locator agencies (if allowed according to local law) to collect health status. If 
no health status can be collected, the subject should be considered lost to follow-up and this should 
be specified in the end-of-trial form.
8.1.[ADDRESS_153769] and follow-up (visits 8A and 9A)
Subjects, who discontinue trial product prematurely, should attend visit 8A, scheduled to take place 
on the day of discontinuation of trial product (+ 3 days visit window). Visit 9A should be scheduled
5 weeks (+3 days visit window) after the last date on trial product. The primary reason for 
premature discontinuation of trial product must be specified in the end-of-trial form in the eCRF, 
and final drug accountability must be performed. A treatment discontinuation session must be made
in the IWRS at visit 8A (see Section 10).
If premature discontinuation of trial product is decided during a scheduled visit, the visit will be 
converted into a V8A and trial procedures must be performed accordingly.
Subjects should continue with the originally scheduled site contacts after visit 9A and up to and 
including visit 8. After visit 9A, samples for antibodies, PK and lactate assessment should not be 
taken. If necessary, in order to retain the subject in the trial, site visits can be replaced by [CONTACT_135537] 9A. However, as a minimum, these subjects should be asked to attend the 
scheduled end-of-treatment visit (V8) at week 26 as these visits should be performed for all 
subjects, if at all possible (except subjects who withdraw informed consent, see Section 8.1.6 ).
Subjects, who only agree to attend or provide health status at the scheduled V8, should not be 
considered withdrawn from the trial. In case the subject cannot be reached (by [CONTACT_135538]) at the scheduled V8, the site should consult the contacts provided by [CONTACT_423] (e.g. close 
relatives), relevant physicians, medical records and locator agencies (if allowed according to local CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 37 of 110
law) to collect health status. If no health status can be collected, the subject should be considered 
lost to follow-up up and this should be specified in the end-of-trial form. 
In summary, subjects should stay in the trial irrespective of lack of adherence to randomised 
treatment, lack of adherence to visit schedule, missing assessments or trial product discontinuation 
for any reason. Only subjects who decline any further contact [CONTACT_36289].
8.1.[ADDRESS_153770] aim to undertake procedures 
for visit 8A as soon as possible and visit 9A should be scheduled 5 weeks (+3 days visit window) 
after the last date on trial product, if the subject agrees to it.
Subjects who agree to attend or provide health status at the planned V8 should not be considered 
withdrawn from the trial.
Subjects should stay in the trial irrespective of lack of adherence to randomised treatment, lack of 
adherence to visit schedule, missing assessments or trial product discontinuation for any reason. 
Only subjects who decline any further contact [CONTACT_135539].
The end-of-trial form must be completed and final drug accountability must be performed even if 
the subject is not able to come to the trial site. A treatment discontinuation session must be made in 
the IWRS (see Section 10). The case book must be signed. 
Although a subject is not obliged to give his/her reason(s) for withdrawing consent, the investigator 
must make a reasonable effort to ascertain the reason(s), while fully respecting the subject’s rights. 
Where the reasons are obtained, the primary reason for withdrawing consent must be specified in
the end-of-trial form in the eCRF.
8.1.7 Investigator assessments
Review of diaries, PROs, laboratory reports, ECGs and fundus photography/dilated fundoscopy
must be documented either on the documents or in the subject’s medical record.
If clarification of entries or discrepancies in the diary or PROs is needed, the subject must be 
questioned and a conclusion made in the subject’s medical record. Care must be taken not to bias 
the subject.
The documents must be retained at the site as source documentation.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153771] follow the categories:
!Normal
!Abnormal
– Was the result clinically significant? (yes/no)
The evaluation should be based on investigator’s judgement.
For laboratory report values outside the reference range, the investigator must specify whether the 
value is clinically significant or not clinically significant. All laboratory printouts must be signed 
and dated by [CONTACT_36290]. The signed laboratory report is retained at 
the site as source documentation.
In case of abnormal clinically significant findings found as a result of screening procedures 
conducted at visit [ADDRESS_153772]’s medical record and record this in the concomitant illness and 
medical history form in the eCRF. 
The investigator or his/her delegate must collect and review the PROs and diaries for completeness 
and to ensure that AEs are reported.
8.[ADDRESS_153773] related information/assessments
8.2.1 Demography
Demography will be recorded in the eCRF at screening and consists of:
!Date of birth (according to local regulation)
!Sex
!Ethnicity (according to local regulation)
!Race (according to local regulation)
8.2.2 Diabetes history and diabetes complications
Diabetes history and diabetes complications will be recorded on a disease specific form at screening 
and consists of:
!Date of diagnosis of T2DM
!Information regarding diabetes complications including date of onset
– Diabetic retinopathy– Diabetic neuropathy
– Diabetic nephropathy
Please note that macroangiopathy (including peripheral arterial disease) should be reported on 
disease specific form History of cardiovascular disease (see Section 8.2.3 ).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 39 of 110
8.2.3 Concomitant illness and medical history
A concomitant illness is any illness that is present at the start of the trial (V1) or found as a result 
of a screening procedure or other trial procedures performed before exposure to trial product .
Medical history is a medical event that the subject has experienced in the past. Only relevant 
medical history as judged by [CONTACT_41150].
The information collected for concomitant illness and medical history should include diagnosis, 
date of onset and date of resolution or continuation, as applicable.
The following must be recorded in the eCRF (at visit 1) on the disease specific forms only, i.e. not 
on the concomitant illness and medical history form:
!History of cardiovascular disease (e.g. ischaemic heart disease, myocardial infarction, 
heart failure incl. NYHA class, hypertension, stroke, peripheral arterial disease)
!History of gallbladder disease (e.g. gallstone, cholecystitis, cholecystectomy)
!History of gastrointestinal disease (e.g. gastroesophageal reflux disease, ulcer disease, 
chronic gastritis)
Any change to a concomitant illness should be recorded during the trial. A clinically significant 
worsening of a concomitant illness must be reported as an AE (see Section 12).
It must be possible to verify the subject’s medical history and a valid fundus photography/dilated 
fundoscopy if previous assessment is used in source documents such as subject’s medical record. If 
a subject is not from the investigators own practice, the investigator must make reasonable effort to 
obtain a copy of subject’s medical record from relevant party e.g. primary physician. The 
investigator must document any attempt to obtain external medical information by [CONTACT_135540](s) when information was requested and who has been contact[INVESTIGATOR_530].
8.2.[ADDRESS_153774] be recorded at each visit as they occur. 
The information collected for each concomitant medication includes:
!Trade name [CONTACT_18058]
!Indication
!Start date and stop date or continuation
!Only applicable for anti-diabetic medication: start date of current dose and total daily doseCONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153775]’s eligibility to continue in the trial, the monitor must be informed.
8.2.[ADDRESS_153776] be performed on female subjects of childbearing potential as described in
Section 8.4.7 (pregnancy testing). Female subjects of childbearing potential must be instructed to 
use an adequate contraceptive method throughout the trial and until 5 weeks after end-of-treatment.
Female of non-childbearing potential is defined as:
!Female who has undergone a hysterectomy, bilateral oophorectomy or bilateral tubal 
ligation 
!Postmenopausal defined as no menses for 12 months without an alternative medical cause
!Other medical reasons preventing childbearing potential
Contraceptive methods
For Japan only: Adequate contraceptive measures are abstinence (not having sex), diaphragm, 
condom (by [CONTACT_3969]), intrauterine device, sponge, spermicide or oral contraceptives.
8.2.[ADDRESS_153777] one 
cigarette or equivalent daily. 
Smoking status:
!Never smoked
!Previous smoker, smoking stop date
!Current smoker
8.3 Efficacy assessments
8.3.1 Blood samples for efficacy
Blood samples will be drawn according to flow chart (see Section 2) and will be analysed at the 
central laboratory to determine levels of the following efficacy laboratory parameters (for fasting 
see Section 8.1.2 ):CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 41 of 110
Glucose metabolism:
!HbA 1c
!FPG
!Fasting C-peptide
!Fasting insulin and proinsulin
!Fasting glucagon
Fasting lipi[INVESTIGATOR_130925]:
!Total cholesterol
!LDL cholesterol
!HDL cholesterol
!Triglycerides
Other parameters:
!Semaglutide PK (please refer to Section 8.6.2 )
!SNAC PK (please refer to Section 8.6.2 )
!CRP
8.3.2 Self-measured plasma glucose (SMPG)
At visit 1, subjects will be provided with a BG meter including auxiliaries as well as instructions for 
use. The subjects will be instructed in how to use the device, and the instruction will be repeated as 
necessary during the trial. In case a hypoglycaemic epi[INVESTIGATOR_41102], the provided BG meter 
should be used for SMPG measurement.
The BG meters use test strips calibrated to plasma values. Therefore, all measurements performed 
with capi[INVESTIGATOR_36191], which will be 
shown on the display. Only the BG meters provided by [CONTACT_135541].
For Japan only: The trial sites are allowed to purchase and supply themselves with BG meters, if 
possible. BG meters must be the same model as supplied by [CONTACT_3454].Subjects should be instructed in how to record the results of the SMPG values in the diaries. The 
record of each SMPG value should include date, time and value. All data from the diary must be 
transcribed into the eCRF during or following the contact. If obtained via phone and a discrepancy 
is later detected between the diary and the SMPG data obtained at the phone contact, the values in 
the eCRF must be corrected.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153778] will be instructed to perform a 7-point SMPG profile two times during the trial period 
(see Section 2) using the BG meter provided for the trial. The 7-point SMPG profile should be 
performed on a day where the subject does not anticipate unusual strenuous exercise. The 7-point 
profile should preferably be taken within a week prior to the visit.
The record of each  SMPG measurement should include the following seven time points:
!Before breakfast
![ADDRESS_153779]
!Before lunch
!90 minutes after start of lunch
!Before dinner
!90 minutes after start of dinner
!At bedtime
8.3.[ADDRESS_153780] be measured and recorded in the eCRF in kilogram or pound (kg or lb), with one 
decimal (with an empty bladder, without shoes and only wearing light clothing). The body weight 
should be assessed on the same calibrated weighing scale equipment throughout the trial, if 
possible.
Height is measured without shoes in centimetres or inches and recorded in the eCRF to nearest 
½ cm or ¼ inch.
8.3.[ADDRESS_153781] is breathing out gently.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 43 of 110
8.3.5 Patient reported outcomes questionnaires
PRO will be assessed using the questionnaires:
!SF-36v2™ (acute version) health survey32-34
!IWQOL-Lite Clinical Trial Version35, 36
!PGI-S items
!PGI-C items
The questionnaires SF-36v2™ and IWQOL-Lite Clinical Trial Version are commonly used 
instruments to evaluate the PROs, also in the T2DM area. The PGI-S items are designed to assess 
patients’ impression of their health status and the PGI-C items are designed to assess patients’ 
impression of change of their health. 
The questionnaires must be completed by [CONTACT_135542], see Section 2, 
preferably before any other trial-related activit ies for that visit. It takes approximately fifteen 
minutes to complete the four questionnaires. Subjects should be given the opportunity to complete 
the questionnaires by [CONTACT_135543]. The completed questionnaires must be 
reviewed for potential adverse events and missing data while the subject is still at the site. All 
results from the PRO questionnaires must be transferred into the eCRF.
All the questionnaires will be translated to local languages, and also be linguistically validated 
before being handed out to the subjects participating in the trial.
SF-36 acute version
SF-36v2™ acute version measures the individual overall health-related quality of life on 8 domains; 
physical functioning, role physical, bodily pain, general health, vitality, social functioning, role 
emotional and mental health. The acute version’s questions are based on a recall period of one 
week. SF-36v2™ contains [ADDRESS_153782] of Weight on Quality of Life Clinical Trial Version
The IWQOL-Lite for Clinical Trials was adapted from the IWQOL-Lite and measures the health-
related quality of life. The IQWOL-Lite Clinical Trial Version contains 22 items.
Patients Global Impression of Status Items
The PGI-S assesses patients’ impression of physical functioning and mental health status during the 
clinical trial. The PGI-S contains two items.
Patients Global Impression of Change items
The PGI-C assesses patients’ impression of change in physical functioning and mental health during 
the clinical trial compared to when they entered the trial. Hence, the PGI-C should not be answered 
at V2. The PGI-C contains two items.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 44 of 110
8.4 Safety assessments
8.4.1 Adverse events
Adverse events (AEs) must be reported at each visit in accordance with the procedures outlined in 
Section 12and appendix B . 
[IP_ADDRESS] Medication error 
If a medication error is observed during the trial, the following information is required and a 
specific event form must be completed in the eCRF in addition to the AE form (see Section [IP_ADDRESS]
and appendix B ): 
!Trial product(s) involved 
!Classification of medication error
!Whether the subject experienced any hypoglycaemic epi[INVESTIGATOR_36192]/or adverse event(s) as a 
result of the medication error 
!Suspected primary reason for the medication error 
For definition of medication errors, see Section 12.1.4 and appendix B .
[IP_ADDRESS] Adverse events requiring additional data collection 
For the following AEs additional data collection is required and specific event forms must be 
completed in the eCRF in addition to the AE form (see Section 12.1.5 ):
!Acute coronary syndrome (myocardial infarction or hospi[INVESTIGATOR_36193])
!Cerebrovascular event (stroke or transient ischaemic attack)
!Heart failure 
!Pancreatitis
!Neoplasm (excluding thyroid neoplasm)
!Thyroid disease (including thyroid neoplasm)
!Renal event
!Hypersensitivity reaction
!Acute gallstone disease
!Medication error
!Lactic acidosis
!Creatine kinase (CK) > 10x UNL
!Hepatic events defined as:
– ALT or aspartate aminotransferase (AST) > 5x UNL and total bilirubin ≤ 2x UNL
– ALT or AST > 3x UNL and total bilirubin > 2x UNL*
– Hepatic events leading to trial product discontinuationCONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 45 of 110
*Please note that in case of a hepatic event defined as ALT or AST > 3x UNL and total bilirubin >
2x UNL, where no alternative aetiology exists (Hy's law), this must be reported as an SAE using the 
important medical event criteria if no other seriousness criteria are applicable.
See Section 12andappendix B for details about the additional information to report. 
Note that additional assessments will be required according to appendix B in case of: 
!Suspi[INVESTIGATOR_36194]
!Suspi[INVESTIGATOR_36195]
!Increased levels of creatine kinase
!Increased levels of aminotransferase
In case any of these events fulfil the criteria for a serious adverse event, please report accordingly, 
see Section 12.
8.4.2 Physical examination
A physical examination will be performed by [CONTACT_36291] (see 
flow chart, Section 2and 8.1.7 ). A physical examination must include:
!General appearance
!Head, ears, eyes, nose, throat, neck
!Thyroid gland
!Respi[INVESTIGATOR_2133]
!Cardiovascular system
!Gastrointestinal system including mouth
!Musculoskeletal system
!Central and peripheral nervous system
!Skin
!Lymph node palpation
8.4.[ADDRESS_153783] be recorded in the eCRF. The actual value of the blood pressure measurement should be 
recorded in the eCRF (without rounding). The same equipment should be used throughout the trial.
Pulse
Pulse (beats per minute) must be recorded in the eCRF at site visits after resting for 5 minutes in a 
sitting position.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 46 of 110
8.4.4 Eye examination 
Fundus photography/dilated fundoscopy will be performed as per flow chart (see Section 2) by [CONTACT_36369]. Results of the fundus photography/dilated fundoscopy
will be interpreted by [CONTACT_093] (see Section 8.1.7 ).
If fundus photography/dilated fundoscopy has been performed within [ADDRESS_153784] be available prior to randomisation.
If the fundus photography/dilated fundoscopy is performed before the subject has signed the 
informed consent form, it must be documented in the medical records that the reason for performing 
the procedure was not related to this trial.
8.4.5 Electrocardiogram (12–lead)
12-lead ECG will be performed as per flow chart (see Section 2) and the assessment must be 
reviewed as described in Section 8.1.[ADDRESS_153785] the ECGs to the central ECG reader as soon as 
possible.
If the central ECG evaluation of a baseline ECG is suggestive of a prior myocardial infarction (MI), 
the investigator will be notified. The investigator should consider if an update of the History of 
cardiovascular disease form is required.
If the central ECG evaluation of a post-baseline ECG is suggestive of new MI, the investigator will 
be notified and a confirmatory ECG should be performed. Unless already done, the investigator 
should report this as an AE or a SAE at investigator’s discretion in according to Section 12.
Additional ECG recordings can be performed at the investigator’s site at investigator’s discretion at 
other visits than the planned ECG visits. All these ECGs will undergo central assessment. The 
reason for additional ECG assessments should be documented and an AE should be reported if 
applicable.
All findings suggestive of new MI detected by [CONTACT_135544] (EAC) (see Section 12.7.2 ).
8.4.6 Blood samples for safety
Blood samples will be drawn according to flow chart (see Section 2) and will be analysed at the 
central laboratory to determine levels of the following safety laboratory parameters:
Haematology:
!HaemoglobinCONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 47 of 110
!Haematocrit
!Leucocytes
!Thrombocytes
!Differential count (eosinophils, neutrophils, basophils, lymphocytes and monocytes)
Biochemistry: 
!Alanine aminotransferase (ALT)
!Albumin
!Alkaline phosphatase
!Amylase
!Aspartate aminotransferase (AST)
!Bilirubin, total
!Calcium, total
!Creatinine
!eGFR per CKD-EPI37
!Creatine kinase (CK)
!Lipase
!Potassium
!Sodium
!Urea
Hormones:
!Calcitonin
Other parameters:
!Lactate (please refer to Section 8.6.1 )
!Anti-semaglutide antibodies (please refer to Section 8.4.8 )
In case any calcitonin value at any time during the trial is ≥10 ng/L, the algorithm in appendix A 
must be followed.
8.4.[ADDRESS_153786] the site CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153787] semaglutide at selected 
visits (see Section 2). Positive anti-semaglutide binding antibody samples will be further 
characterised for cross reactivity to native GLP-1. Samples which are positive for anti-semaglutide 
binding antibodies will be further characterised for in vitro neutralising effect towards semaglutide.
In addition, samples which are positive for antibodies cross reacting with native GLP-[ADDRESS_153788] be done pre-dose. 
Antibody samples will be stored as described in Section 24.2.
8.4.9 Hypoglycaemic epi[INVESTIGATOR_36196] (PG) should always be measured and recorded when a hypoglycaemic epi[INVESTIGATOR_36190].
All PG values:
!≤ 3.9 mmol/L (70 mg/dL) or 
!> 3.9 mmol/L (70 mg/dL) occurring in conjunction with hypoglycaemic symptoms
should be reported in the diary according to the instructions below throughout the trial from visit [ADDRESS_153789] is recommended to measure PG every 15 
minutes until the SMPG value is > 3.9 mmol/L (70 mg/dL) and/or symptoms have been resolved in 
accordance to current guidelines38.
A SMPG value ≤ 3.9 mmol/L (70 mg/dL) or hypoglyc aemic symptoms must trigger a 
hypoglycaemic epi[INVESTIGATOR_36197]. Repeated SMPG measurements and/or 
symptoms will per default be considered as  one hypoglycaemic epi[INVESTIGATOR_135515] a succeeding SMPG 
value is > 3.9 mmol/L (70 mg/dL) and/or symptoms have been resolved. One hypoglycaemic 
epi[INVESTIGATOR_36198]/or symptoms. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153790] SMPG value and/or symptom.
The record should include the following information: 
!Start date and time of the hypoglycaemic epi[INVESTIGATOR_1865].
!Stop date and time of the hypoglycaemic epi[INVESTIGATOR_1865] (stop time is the first time the PG value is 
> 3.9 mmol/L (70 mg/dL) and/or symptoms have been resolved).
If a stop date and time is not reported, a h ypoglycaemic epi[INVESTIGATOR_36200] a period of 60 
minutes.
!The PG level before treating the epi[INVESTIGATOR_1865] (if available) and any follow-up measurements. 
The lowest value measured during the hypoglycaemic epi[INVESTIGATOR_135516], the remaining values will be kept as source data in the diary.
!Whether the epi[INVESTIGATOR_36202] (Yes/No).
A hypoglycaemic epi[INVESTIGATOR_135517]. 
!Whether the subject was able to treat him/herself.
If the severity of a hypoglycaemic epi[INVESTIGATOR_135518], only one hypoglycaemic epi[INVESTIGATOR_135519].
!Date and time of last trial product administration and date, time and dose of other anti-
diabetic medication prior to the epi[INVESTIGATOR_1865].
!Date and time of last main meal (not including snacks) prior to the epi[INVESTIGATOR_1865].
!Whether the epi[INVESTIGATOR_36205].
!Change in any concomitant illness.
!Any sign of fever and/or other acute disease.
!Whether the subject was asleep when the epi[INVESTIGATOR_36206].
– If yes, whether the symptoms of the epi[INVESTIGATOR_36207].
The answer to the question: "Was the subject able to treat him/herself?" must be answered "No" for 
an epi[INVESTIGATOR_36208], glucagon, or 
take other corrective actions. PG concentrations may not be available during an event, but 
neurological recovery following the return of PG to normal is considered sufficient evidence that 
the event was induced by a low PG concentration38.
Oral carbohydrates must not be given if the subject is unconscious.
If the question "Was the subject able to treat him/herself?" is answered "No", the following 
information should be recorded by [CONTACT_423]:
!Who assisted in the treatment of the hypoglycaemic epi[INVESTIGATOR_1865] (i.e. medical person or non-
medical person)CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 50 of 110
!Where the treatment was administered (in clinic/emergency room/hospi[INVESTIGATOR_36209]. If the 
subject was treated in clinic/emergency room/hospi[INVESTIGATOR_307], whether they were transported in an ambulance or not)
!Type of treatment provided by [CONTACT_19015] (i.e. oral carbohydrates, glucagon, 
intravenous glucose or other)
!Were symptoms alleviated after administration of treatment?
!Factors contributing to the epi[INVESTIGATOR_1865] (i.e. physical activity, missed meal, diet changed, 
medication error (i.e. overdose, mix-up between products, incorrect use of device), other 
factors not listed or unknown)
!Did the subject experience seizure?
!Was the subject unconscious/comatose?
!
Did the subject experience any of the following symptoms39
– Autonomic: sweating, trembling, hunger or palpi[INVESTIGATOR_814] (rapid or irregular heart beat)
– Neuroglycopenic: confusion, drowsiness, speech difficulty, visual disturbances, odd 
behaviour, impaired balance or incoordination (reduced ability to coordinate movement)
– General malaise: headache or malaise (feeling discomfort/unease)
!Other symptoms
The investigator must review the diary for low SMPG values not reported as hypoglycaemic 
epi[INVESTIGATOR_1841] (see Section 2for relevant visits). The subject must be questioned whether any of the low 
values were severe i.e. whether the subject was able to self-treat or not. If the subject was not able 
to self-treat it has to be reported as a severe hypoglycaemic epi[INVESTIGATOR_36210] a hypoglycaemic epi[INVESTIGATOR_36211].
Low SMPG values for non-severe hypoglycaemic epi[INVESTIGATOR_36212] a hypoglycaemic epi[INVESTIGATOR_36213] [ADDRESS_153791] be re-trained in how to report  hypoglycaemic epi[INVESTIGATOR_36214] e investigator identifies 
low SMPG values not reported as hypoglycaemic epi[INVESTIGATOR_1841].
If the hypoglycaemic epi[INVESTIGATOR_135520] a safety 
information form (SIF) must also be filled in, see Section 12.
8.[ADDRESS_153792] to semaglutide and GLP-1, IgE anti-semaglutide antibodies 
and PK samples (semaglutide and SNAC) will be analysed by a special laboratory and Novo CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 51 of 110
Nordisk A/S (see Sections 8.4.8 and 8.6.2 ). For some of the analyses related to suspi[INVESTIGATOR_135521], a local laboratory must be used (see appendix B ).
The handling, transportation and storage of biological samples are described in the laboratory 
manual (for central and special laboratory details see attachment I ).
For Mexico only: Descriptions of assay methods, laboratory supplies and procedures for obtaining 
samples, handling, transportation and storage of biological samples and information regarding 
who will perform the assessments, will be described in a trial specific laboratory manual, provided 
by [CONTACT_2237] (for central laboratory details, see attachment 1 ). 
Samples will be coded in order to keep subject identity anonymous.
Laboratory samples not drawn on the day of the actual visit should preferably be drawn on another 
day within the visit window stated in the flow chart (see Section 2). Please note that a laboratory 
sample pertaining to a specific visit must always be reported to that visit.
The central laboratory will provide laboratory results to the investigator on an on-going basis. 
However, anti-semaglutide antibody, semaglutide and SNAC plasma concentration results will not 
be available to the investigator during the trial. These results will be provided to the investigator 
upon request after the completion of the clinical trial report.
The laboratory provides results to the trial sites in the units preferred by [CONTACT_135545].
The laboratory equipment may provide analyses not requested in the protocol but produced 
automatically in connection with the requested analyses according to specifications in the laboratory 
standard operating procedures. Such data will not be transferred to the trial database, but abnormal 
values will be reported to the investigator. The investigator must review all laboratory results for 
concomitant illnesses and AEs and report these according to Section 8.2.[ADDRESS_153793] 
attend these visits fasting (see Section 8.1.2 ).
A central FPG result ≤3.9 mmol/L (70 mg/dL) in relation to planned fasting visits should not be 
reported as a hypoglycaemic epi[INVESTIGATOR_36189] a clinical laboratory adverse event (CLAE) at the 
discretion of the investigator (see Section 12.1.1 ).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 52 of 110
8.6 Other assessments
8.6.1 Lactate
Assessment of lactate levels will be included in this trial as a biomarker for impaired cellular 
respi[INVESTIGATOR_1516] (see Section 18). At selected visits (see flow chart, Section 2) three samples should be 
drawn for lactate assessment at the following time points in relation to dosing of trial product:
!Pre-dose
!25 (+/- 5) minutes post-dosing
!40 (+/- 5) minutes post-dosing
At visits with lactate sampling trial product must be taken at site. The subject must be fasting and 
not take any other oral medication until last sample has been taken, that is, at least 40 minutes after 
dosing (see Section 8.1.[ADDRESS_153794] attends the visit in a non-fasting state). Also, the 
subject should have rested for at least 30 minutes in a sitting position prior to sampling. During 
sampling, use of tourniquet should be avoided (if possible) and if blood pressure measurement has 
been performed prior to sampling, blood should preferably be drawn from the opposite arm.
Correct pre-analytical handling of these samples is extremely important to ensure valid results. The 
blood samples must be kept on ice and centrifuged within [ADDRESS_153795] be recorded at the laboratory 
requisition form.
8.6.2 Pharmacokinetics
Blood samples for the semaglutide and SNAC PK will be drawn at selected visits (see flow chart, 
Section 2) and must be collected, handled and shipped according to the description in the laboratory 
manual. 
The PK responsible laboratory will be provided with the randomisation list and only samples from 
subjects treated with oral semaglutide will be analysed for semaglutide and SNAC plasma 
concentrations. 
Semaglutide PK and SNAC PK samples will be stored at the specialised laboratory until final
clinical trial report in case Novo Nordisk request further analysis of the PK samples.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 53 of 110
[IP_ADDRESS] SNAC PK sampling
Samples for SNAC PK should be drawn at the following time points in relation to dosing of trial 
product:
!25 (+/- 5) minutes post-dosing
!40 (+/- 5) minutes post-dosing
At visits with sampling of SNAC PK trial product must be taken at site. The subject must be fasting 
and not take any other oral medication until last sample has been taken (see section 8.1.[ADDRESS_153796] attends the visit in a non-fasting state).
The date and exact time of dosing of trial product must be recorded in the medical record and 
entered into the eCRF. The date and exact time of sampling must be recorded at the laboratory 
requisition form.
[IP_ADDRESS] Semaglutide PK sampling
Samples for semaglutide PK can be drawn at any time during the visit. For simplicity it is 
recommended to take the sample for semaglutide PK together with biochemistry samples at all 
visits requiring semaglutide PK. 
The date and exact time of the latest trial product administration prior to semaglutide PK sampling 
must be recorded in the diary and entered into the eCRF. The date and time of sampling must be 
recorded at the laboratory requisition form.
8.6.[ADDRESS_153797] diary
The diaries should be handed out at the visits described in the flow chart (see Section 2). The 
recordings must be reviewed as described in Section 8.1.[ADDRESS_153798] in recording the following data in the diary:
!Date of first trial product administration
!Date and exact time of last trial product administration on the day prior to sampling of 
semaglutide PK 
!Hypoglycaemic epi[INVESTIGATOR_1841]
!Changes in concomitant medication
!AEs
!SMPG 7-point profileCONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153799] compliance.
Treatment compliance: will be assessed by [CONTACT_36295]. Prior to visits 
where drug accountability is performed, the subject will be asked to return all used, partly used and 
unused trial products and dosepacks. The investigator must assess the amount of trial products 
returned compared to what was dispensed at the last dispensing visit and, in case of discrepancies, 
question the subject.
If a subject is found to be non-compliant, the investigator will remind the subject of the importance 
of following the instructions given including taking the trial products as prescribed and should 
document this discussion in the subject’s medical record.
[ADDRESS_153800] not be dispensed to any person not included in the trial. 
9.1 Trial products
The following trial products are considered as investigational medicinal products (IMPs) and will 
be provided by [CONTACT_3454] A/S, Denmark:
Table 9–[ADDRESS_153801] Strength Dosage form Route of 
administrationContainer/ 
packaging 
materials
Semaglutide 3 mg tablet 3 mg
Tablet Oral Dosepacka Semaglutide 7 mg tablet 7 mg
Semaglutide 14 mg tablet 14 mg
Placebo tablet N/A
aOne dosepack contains one blister card with 7 tablets
Rescue medication is considered NIMP and will not be supplied by [CONTACT_3454]. 
For Japan only: During the treatment period, all anti-diabetic medication including rescue 
medication will be reimbursed by [CONTACT_36297].CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153802] for the trial on an on-going basis 
controlled by [CONTACT_8784]. Trial products will be distributed to the trial sites according to enrolment 
and randomisation.
9.3 Storage 
Storage conditions of the trial products are outlined in Table 9–2 .
Table 9–[ADDRESS_153803] Storage conditions
(not-in-use)In-use conditions
Semaglutide 3 mg tabletDo not store above 30ºC
(86ºF)
Do not freeze
Do not refrigerateStore in the original packageTake the tablet immediately 
after dispensation from blister 
card
Take the tablets whole: Do not 
break or chewSemaglutide [ADDRESS_153804] has been stored outside specified conditions (e.g. outside temperature range). Additional 
details regarding handling of temperature deviations can be found in the Trial Materials Manual.
Trial product that has been stored improperly must not be dispensed to any subject before it has 
been evaluated and approved for further use by [CONTACT_3454]. The investigator must take 
appropriate action to ensure correct storage.
For Japan only: The head of the study site or the trial product storage manager if assigned by [CONTACT_36298], record and evaluate 
the temperature.
9.4 Drug accountability and destruction
Drug accountability of all trial products received at site is the responsibility of the investigator.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 56 of 110
For Japan only: Drug accountability is the responsibility of the head of the study site or the trial 
product storage manager if assigned by [CONTACT_36299].
Subjects must be instructed to return all used, partly used and unused trial products including empty 
packaging material at each dispensing visit.
Returned trial product (used/partly used and/or unused), expi[INVESTIGATOR_135522]-allocated trial product. Non-
allocated trial product including expi[INVESTIGATOR_135523].
Drug accountability is performed by [CONTACT_36300]. Drug accountability must be done on tablet 
level.
Destruction of trial products can be performed on an on-going basis and will be done according to 
local procedures after accountability is finalised and reconciled by [CONTACT_2037]. Destruction of 
products must be documented in the IWRS.
9.5 Auxiliary supply
The following will be provided by [CONTACT_135546]:
• BG meters and BG meter auxiliaries 
For Japan only: The trial sites are allowed to purchase and supply themselves with auxiliary 
supplies, if possible. BG meters must be the same model as supplied by [CONTACT_3454].
10 Interactive web/voice response system
A trial-specific IWRS will be set up which can be accessed at any time via the internet or telephone. 
Access to the IWRS must be restricted to and controlled by [CONTACT_36301]. 
IWRS is used for: 
!Screening
!Screening failure
!Randomisation
!Medication arrival
!Dispensing
!Treatment discontinuation
!Completion
!Code break
!Drug accountability
!Data changeCONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 57 of 110
IWRS user manuals will be provided to each trial site.
11 Randomisation procedure and breaking of blinded codes
The trial is a double-blinded trial. A randomisation session will be carried out for all subjects using 
the IWRS. The randomisation will be stratified based on descent (Japanese subjects/non-Japanese 
subjects) to ensure an even distribution of the four treatment arms (see Section 17).
At the randomisation visit (V2) subjects meeting all eligibility criteria will be randomised to one of 
four parallel treatment arms as described in Section 5.1.
11.1 Breaking of blinded codes
The IWRS will notify Novo Nordisk (monitor and the Global Safety department) immediately after 
the code is broken.
The code for a particular subject may be broken in a medical emergency if knowing the actual 
treatment would influence the treatment of the subject. Whenever a code is broken the person breaking the code must print the Code Break Confirmation Notification generated by [CONTACT_8784], 
record the reason and sign and date the document.
When the code is broken, the treatment allocation will be accessible to the investigator and the 
Novo Nordisk Global Safety department. If IWRS is not accessible at the time of code break the 
IWRS helpdesk should be contact[INVESTIGATOR_530]. Contact [CONTACT_135547] I . If the code has been 
broken the subject must discontinue treatment with trial product but be asked to continue in the trial 
(see Section 8.1.5 ). A treatment discontinuation session must be completed in the IWRS.
The laboratory responsible for antibody and PK (semaglutide and SNAC) analysis and the 
responsible development bioanalysis scientist in Novo Nordisk will have access to the unblinding 
report in the IWRS.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 58 of 110
12 Adverse events, technical complaints and pregnancies
12.1 Definitions
12.1.1 Adverse event 
An adverse event (AE) is any untoward medical occurrence in a subject administered a medicinal 
product and which does not necessarily have a causal relationship with this treatment.
An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory 
finding), symptom or disease temporally associated with the use of a product, whether or not 
considered related to the product.
An AE includes:
!A clinically significant worsening of a concomitant illness.
!A clinical laboratory adverse event (CLAE): a clinical laboratory abnormality which is 
clinically significant, i.e. an abnormality that suggests a disease and/or organ toxicity and is 
of a severity that requires active management. Active management includes active treatment 
or further investigations, for example change of medicine dose or more frequent follow-up 
due to the abnormality.
The following should notbe reported as AEs:
!Pre-existing conditions, including those found as a result of screening or other trial 
procedures performed before exposure to trial product (pre-existing conditions should be 
reported as medical history or concomitant illness).
!Pre-planned procedures unless the condition for which the procedure was planned has 
worsened from the first trial-related activity after the subject has signed the informed consent.
!Non-serious hypoglycaemia is an AE, but is reported on a hypoglycaemic epi[INVESTIGATOR_135524], see Section 8.4.9 .
The following three definitions are used when assessing an AE:
!Severity 
–Mild - no or transient symptoms, no interference with the subject's daily activities.
–Moderate - marked symptoms, moderate interference with the subject's daily activities.
–Severe - considerable interference with the subject's daily activities; unacceptable.
!Causality 
Relationship between an AE and the relevant trial product(s): 
–Probable - Good reason and sufficient documentation to assume a causal relationship.
–Possible - A causal relationship is conceivable and cannot be dismissed.
–Unlikely - The event is most likely related to aetiology other than the trial product.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 59 of 110
!Final outcome
–Recovered/resolved - The subject has fully recovered, or by [CONTACT_135548]-related activity 
after the subject signed the informed consent.
–Recovering/resolving - The condition is improving and the subject is expected to 
recover from the event. This term is only applicable if the subject has completed the trial 
or has died from another AE.
–Recovered/resolved with sequelae - The subject has recovered from the condition, but 
with lasting effect due to a disease, injury, treatment or procedure. If a sequela meets an 
SAE criterion, the AE must be reported as an SAE.
–Not recovered/not resolved - The condition of the subject has not improved and the 
symptoms are unchanged, or the outcome is not known.
–Fatal - This term is only applicable if the subject died from a condition related to the 
reported AE. Outcomes of other reported AEs in a subject before he/she died should be assessed as "recovered/resolved", "recovering/resolving", "recovered/resolved with 
sequelae" or "not recovered/not resolved". An AE with fatal outcome must be reported 
as an SAE.
–Unknown - This term is only applicable if the subject is lost to follow-up.
12.1.2 Serious adverse event
A SAE is an experience that at any dose results in any of the following:
!Death.
!A life-threatening
aexperience.
!In-patient hospi[INVESTIGATOR_36220].
!A persistent or significant disability or incapacityc.
!A congenital anomaly or birth defect.
!Important medical events that may not result in death, be life threateninga or require 
hospi[INVESTIGATOR_36221] - based on appropriate medical judgement 
- they may jeopardise the subject and may require medical or surgical intervention to 
prevent one of the outcomes listed in the definition of SAEd. 
aThe term "life threatening" in the definition of SAE refers to an event in which the subject was at risk of death at the time of the event. It does not refer to an event which 
hypothetically might have caused death if it was more severe.
bThe term "hospi[INVESTIGATOR_11956]" is used when a subject: 
– Is admitted to a hospi[INVESTIGATOR_36222]-patient, irrespective of the duration of physical stay, or 
– Stays at the hospi[INVESTIGATOR_36223] [ADDRESS_153805] 
should be regarded as a hospi[INVESTIGATOR_11956]. Hospi[INVESTIGATOR_17957], trial-related and CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153806]'s ability to conduct normal life functions (e.g. following the event or clinical investigation the subject has significant, persistent or permanent change, 
impairment, damage or disruption in his/her body function or structure, physical activity 
and/or quality of life).
dFor example intensive treatment in an emergency room or at home of allergic bronchospasm, blood dyscrasia or convulsions that do not result in hospi[INVESTIGATOR_11956], or 
development of drug dependency or drug abuse.
The following adverse events must always be reported as an SAE using the important medical event 
criterion if no other seriousness criteria are applicable:
!suspi[INVESTIGATOR_36225]
!risk of liver injury defined as ALT or AST >3 x UNL and total bilirubin >2 x UNL, where 
no alternative aetiology exists (Hy's law).
Additional assessments should be made for events meeting the criterion of Hy’s law as stated above 
(see appendix B ). 
12.1.3 Non-serious adverse event
A non-serious AE is any AE which does not fulfil the definition of an SAE.
12.1.4 Medication errors
A medication error concerning trial products is defined as:
!Administration of wrong drug. 
!Note: Use of wrong DUN is not considered a medication error.
!Wrong route of administration.
!Administration of an overdose with the intention to cause harm (e.g. suicide attempt), 
misuse or abuse of trial product.
!Accidental administration of a higher dose than intended. A higher dose is a dose of at least 
one tablet more than the intended dose; however, the administered dose must deviate from 
the intended dose to an extent where clinical consequences for the trial subject were likely to 
happen as judged by [CONTACT_093], although they did not necessarily occur.
Medication errors must be reported on an AE form and a specific event form, see Section [IP_ADDRESS] ,
12.1.5 and appendix B .CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153807] been pre-specified. See appendix B for details about these events and the additional 
information to report.
Some events in this trial will be adjudicated by [CONTACT_36304] 12.7.2 .
Table 12–1 lists AEs that require completion of specific event forms in the eCRFs and/or are 
subject to event adjudication.
Table 12–1 Adverse events requiring completion of specific event forms and/or are subject 
to event adjudication
Event Specific event form Event adjudication
Death No Yes
Acute coronary syndrome (myocardial infarction or 
hospi[INVESTIGATOR_36193])Yes Yes
Cerebrovascular event (stroke or transient ischaemic 
attack)Yes Yes
Heart failure YesYes (only if requiring 
hospi[INVESTIGATOR_11956])
Pancreatitis Yes Yes (only if acute pancreatitis)
Neoplasm (excluding thyroid neoplasm) Yes Yes (only if malignant)
Thyroid disease (including thyroid neoplasm) YesYes (only if malignant thyroid 
neoplasm or C-cell hyperplasia)
Renal event Yes Yes (only if acute kidney injury)
Hypersensitivity reactions Yes No
Acute gallstone disease Yes No
Medication error Yes No
Lactic acidosis Yes Yes
CK > 10x UNL Yes No
Hepatic events defined as:
ALT or AST > 5x UNL and total bilirubin ≤ 2x UNL
ALT or AST > 3x UNL and total bilirubin > 2x UNL*Hepatic events leading to trial product discontinuation.Yes No
*Please note that in case of a hepatic event defined as ALT or AST > 3x UNL and total bilirubin > 2 x UNL, where no 
alternative aetiology exists (Hy's law), this must be reported as an SAE using the important medical event criterion if no 
other seriousness criteria are applicable.
For details about specific event forms, see Section [IP_ADDRESS] , 12.2 and appendix B .CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153808] 
(medicine) defects. The technical complaint may be associated with an AE, but does not concern 
the AE itself.
Examples of technical complaints:
!The physical or chemical appearance of trial products (e.g. discoloration, particles or 
contamination)
!All packaging material including labelling
Only technical complaints related to adverse events will be reported in the clinical trial report.
12.[ADDRESS_153809]-treatment follow-up period (V9) for subjects on trial product, or until the end of 
trial (V8 or V9A, whichever comes last) for the subjects who have discontinued trial product 
prematurely. Events for withdrawn subjects will be collected and reported until last trial-related 
contact [CONTACT_1155]. The events must be recorded in the applicable eCRF forms in a timely 
manner, see timelines below and Figure 12–[ADDRESS_153810] be asked about AEs and technical 
complaints, for example by [CONTACT_7939]: "Have you experienced any problems since the last contact?"
All AEs, either observed by [CONTACT_36305], must be reported by [CONTACT_36306].
All AEs must be recorded by [CONTACT_49738]. The investigator should report the 
diagnosis, if available. If no diagnosis is available, the investigator should record each sign and 
symptom as individual AEs using separate AE forms.
For SAEs, a SIF must be completed in addition to the AE form. A SIF is a form to collect 
supplementary clinical information. If several symptoms or diagnoses occur as part of the same 
clinical pi[INVESTIGATOR_1103], one SIF can be used to describe all the SAEs.
AEs requiring additional data collection must be reported using both the AE form and the specific 
event form. A specific event form is a form tailored to collect specific information related to the 
individual event. See appendix B for details about the events and the additional information to 
report. In case any of these events fulfil the criteria for seriousness in Section 12.1, then the event 
should be reported as serious.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 63 of 110
Some events will undergo event adjudication by [CONTACT_135549] (EAC), please 
refer to Section 12.7.[ADDRESS_153811]. 
Timelines for initial reporting of AEs:
The investigator must complete the following forms in the eCRF within the specified timelines:
!SAEs : The AE form within 24 hours and the SIF within 5 calendar days of the 
investigator's first knowledge of the SAE.
Both forms must be signed within 7 calendar days from the date the information was entered 
in the eCRF. 
For SAEs requiring reporting on a specific event form: In addition to the above, the 
specific event form within [ADDRESS_153812] knowledge of the 
AE.
!Events for adjudication: adjudication form should be completed within 14 calendar days 
of investigator’s first knowledge of the AE, see Section 12.7.[ADDRESS_153813] details (fax, telephone, e-mail and address) are provided in the investigator trial master file.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 64 of 110
AE identifiedDoes the AE require 
a specific event 
form?Is the AE subject to 
adjudication and/or 
is  the outcome 
fatal?
AE  form < 24 hours
SIF < 5 calendar days
Specific event  form  
For SAEs:
< 14 calendar days
Is the AE serious or 
non-serious?
AE  form
Adjudication form
< 14 calendar days
Source data < 4 weeks
Non-seriousSerious
NoYes Yes
Queries and follow-up 
requests to be resolved 
< 14 calendar days
Timelines are for the completion of forms from the time of investigator’s awareness.
AEs requiring specific event forms are described in Section 12.1.4, 12.1.5 and appendix B.
AEs  for adjudica tion are de scribed in Section 12.7.2
AE: Adverse event  SAE: Serious adverse event  SIF: Safety Information form 
No additional action
 No additional actionNo
Figure 12–1 Reporting of adverse events
Novo Nordisk assessment of AE expectedness: 
Novo Nordisk assessment of expectedness is performed according to the following reference 
documents: IB for oral administration of semaglutide (NN9924) edition 624or any updates hereof.
Reporting of trial product-related S[LOCATION_003]Rs by [CONTACT_3454]:
Novo Nordisk will notify the investigator of trial product-related suspected unexpected serious 
adverse reactions (S[LOCATION_003]Rs) in accordance with local requirements and ICH GCP1. In addition, the 
investigator will be informed of any trial-related SAEs that may warrant a change in any trial procedure.
In accordance with regulatory requirements, Novo Nordisk will inform the regulatory authorities, 
including European Medicines Agency (EMA), of trial product-related S[LOCATION_003]Rs. In addition, Novo 
Nordisk will inform the IRBs/IECs of trial product-related S[LOCATION_003]Rs in accordance with local 
requirement and ICH GCP
1, unless locally this is an obligation of the investigator.
Novo Nordisk products used as concomitant medication or non-investigational medicinal product:
If an AE is considered to have a causal relationship with a Novo Nordisk marketed product used as 
non-investigational medicinal product or concomitant medication in the trial, it is important that the CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153814] be reported to Novo Nordisk according to the following:
!SAEs : All SAEs must be followed until the outcome of the event is “recovered/resolved”, 
“recovered/resolved with sequelae” or “fatal”, and until all queries have been resolved. Cases of chronic conditions, cancer or AEs on-going at time of death (where death is due to 
another AE) may be closed with the outcome “recovering/resolving” or “not recovered/not 
resolved”. Cases can be closed with the outcome of “recovering/resolving” when the subject 
has completed the follow-up period and is expected by [CONTACT_36308].
The SAE follow-up information should only include new (e.g. corrections or additional) 
information and must be reported within 24 hours of the investigator's first knowledge of 
the information. This is also the case for previously non-serious AEs which subsequently 
become SAEs.
!Non-serious AEs: Non-serious AEs must be followed until the outcome of the event is 
“recovering/resolving”, “recovered/resolved” or “recovered/resolved with sequelae” or until the end of the follow-up period stated in the protocol, whichever comes first, and until all 
queries related to these AEs have been resolved. Cases of chronic conditions, cancer or AEs 
on-going at time of death (where death is due to another AE) may be closed with the 
outcome “recovering/resolving” or “not recovered/not resolved”. Cases can be closed with 
the outcome of “recovering/resolving” when the subject has completed the follow-up period 
and is expected by [CONTACT_36308].
The investigator must ensure that the recording of the worst case severity and seriousness of an 
event is kept throughout the trial. A worsening of an unresolved AE must be reported as follow-up
with re-assessment of severity and/or seriousness of the event.
Queries or follow-up requests from Novo Nordisk must be responded to within [ADDRESS_153815].
SAEs after end of trial: If the investigator becomes aware of an SAE with a suspected causal 
relationship to the investigational medicinal product occurring to a subject after the subject has 
ended the trial, the investigator should report this SAE within the same timelines as for SAEs 
during the trial.  CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 66 of 110
12.4 Technical complaints and technical complaint samples
12.4.1 Reporting of technical complaints
All technical complaints on any of the following products: 
!Semaglutide 3 mg/7 mg/[ADDRESS_153816] details (fax, e-mail and address) are provided in attachment I to the protocol.
The investigator must assess whether the technical complaint is related to any AEs or SAEs.
Technical complaints must be reported on a separate technical complaint form: 
!One technical complaint form must be completed for each affected DUN
!If DUN is not available, a technical complaint form for each code number must be 
completed. 
The investigator must complete the technical complaint form in the eCRF within the following 
timelines of the trial site obtaining knowledge of the technical complaint:
!Technical complaint assessed as related to an SAE within 24 hours
!All other technical complaints within [ADDRESS_153817] coordinate the shipment to 
Customer Complaint Center, Novo Nordisk (the address is provided in attachment I ) and ensure that 
the sample is sent as soon as possible. A copy of the technical complaint form must be included in 
the shipment of the sample. If several samples are returned in one shipment, the individual sample 
and the corresponding technical complaint form must be clearly separated.
The investigator must ensure that the technical complaint sample contains the code number and, if 
available, the DUN. All parts of the DUN should be returned.
If the technical complaint sample is unobtainable, the investigator must specify on the technical 
complaint form why it is unobtainable.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153818] report information about the pregnancy, pregnancy outcome and health of the 
newborn infant(s), as well as AEs in connection with the pregnancy and AEs in the foetus and 
newborn infant.
The following must be collected and reported by [CONTACT_36309] - electronically 
(e.g. in PDF format), or by [CONTACT_36310]:
1. Reporting of pregnancy information
Information about the pregnancy and pregnancy outcome/health of the newborn infant(s) has to 
be reported on Maternal Form 1A and 1B, respectively. 
When the pregnancy outcome is abnormal (i.e. congenital anomalies, foetal death including 
spontaneous abortion and/or any anomalies of the foetus observed at gross examination or 
during autopsy) and/or when a congenital anomaly is diagnosed within the first month, further 
information has to be reported for the female subject on Maternal Form 2. In addition, 
information from the male partner has to be reported on the Paternal Form, after an informed 
consent has been obtained from the male partner. 
Initial reporting and follow-up information must be reported within 14 calendar days of the 
investigator's first knowledge of initial or follow-up information. 
2. Reporting of AE information
The investigator has to report AEs in connection with the pregnancy as well as in the foetus and 
newborn infant(s). The SAEs that must be reported include abnormal outcome, such as foetal 
death (including spontaneous abortion), congenital anomalies (including those observed at gross 
examination or during autopsy of the foetus), as well as other pregnancy complications fulfilling 
the criteria of an SAE.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 68 of 110
Forms and timelines for reporting AEs:
Non-serious AEs: 
!AE formawithin 14 calendar days of the investigator's first knowledge of the initial or 
follow-up information to the non-serious AE.
SAEs: 
!AE formawithin 24 hours of the investigator's first knowledge of the SAE. 
!SIF within 5 calendar days of the investigator's first knowledge of the SAE.
!SAE follow-up information to the AE form and/or SIF within 24 hours of the 
investigator's first knowledge of the follow-up information.
aIt must be clearly stated in the AE diagnosis field on the AE form if the event occurred in 
the subject, foetus or newborn infant. If the AE occurred in the foetus or newborn infant, the AE 
can only be reported on paper AE and SIF.
Any queries or follow-up requests from Novo Nordisk to non-serious AEs, SAEs and pregnancy 
forms must be responded to by [CONTACT_19452] [ADDRESS_153819].
12.6 Precautions and/or overdose
There are no specific antidotes to semaglutide. Treatment of an overdose should be symptomatic.
There is a potential risk of hypoglycaemia during dosing with semaglutide. The typi[INVESTIGATOR_36226] a non-severe hypoglycaemia include: hunger, slight headache, nausea, light-
headedness, palpi[INVESTIGATOR_36227]. Symptoms of non-severe hypoglycaemia should be treated 
by [CONTACT_36311]. 
Severe hypoglycaemia resulting in loss of consciousness should be treated according to best 
available medical practise. 
One case of accidental overdose of oral semaglutide was reported in the NN9924-[ADDRESS_153820] 
wished to continue in the trial. No symptoms  of hypoglycaemia or  any other symptoms or signs 
were noted.  CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 69 of 110
For further details please see the current edition of the IB for oral administration of semaglutide 
(NN9924), edition 624, and any updates hereof.
12.7 Committees related to safety
12.7.1 Novo Nordisk safety committee
Novo Nordisk will constitute an internal oral semaglutide safety committee to perform on-going 
safety surveillance. The oral semaglutide safety committee may recommend unblinding of any data 
for further analysis and in this case an independent ad hoc group will be established in order to 
maintain the blinding of the trial personnel.
12.7.2 Event adjudication committee
An independent external event adjudication committee (EAC) is established to perform validation 
of selected AEs according to pre-defined diagnostic criteria. The validation is based on review of 
pre-defined clinical source data related to the specific AE. Pre-defined clinical data consist of 
copi[INVESTIGATOR_135525].
The EAC is composed of permanent members covering required medical specialities. EAC 
members must disclose any potential conflicts of interest and must be independent of Novo 
Nordisk. 
The events are reviewed by [CONTACT_36312] a blinded manner. The EAC will have no authorisations to 
impact on trial conduct, trial protocol or amendments.
The EAC works in accordance with written guidelines included in the EAC Charter describing in 
details the composition, tasks, responsibilities and work processes of the committee.
The events outlined in Table 12–[ADDRESS_153821] been selected for adjudication in order to obtain an external 
independent validation of the diagnosis. In addition, cardiovascular events are being adjudicated 
according to FDA requirements43.
The EAC will review copi[INVESTIGATOR_36229] (translated if necessary) of medical documentation received in the adjudication packages (e.g. x-ray, ECGs, ultrasound images, discharge summaries, pathology 
reports and death certificates). The investigator must provide medical documentation as soon as 
possible, when they receive the request from Novo Nordisk or the event adjudication vendor. The 
AEs for adjudication are listed in Table 12–2 :CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 70 of 110
Table 12–2 Adverse events for adjudication
Events Description Adjudication outcome
Death* !All-cause death !Cardiovascular death 
(including 
undetermined cause 
of death)
!Non-Cardiovascular 
death
Acute Coronary Syndrome Acute Coronary Syndrome conditions include: 
!ST-elevation acute myocardial infarction 
(STEMI)
!Non-ST elevation acute myocardial 
infarction (NSTEMI)
!Silent MI 
!Unstable angina pectoris (UAP)!Acute myocardial 
infarction (STEMI or 
NSTEMI), silent MI
!Unstable angina 
pectoris requiring 
hospi[INVESTIGATOR_36230] !Epi[INVESTIGATOR_36231], spi[INVESTIGATOR_1831], 
or retinal vascular injury as a result of 
haemorrhage or infarction
!Transient Ischaemic Attack is defined as 
a transient epi[INVESTIGATOR_1865] (< 24 hours) of focal 
neurological dysfunction caused by [CONTACT_36313], 
spi[INVESTIGATOR_1831], or retinal ischaemia, without acute infarction!Ischaemic stroke
!Haemorrhagic stroke
!Undetermined stroke
!Transient Ischaemic 
Attack 
Heart failure requiring hospi[INVESTIGATOR_11956]!Hospi[INVESTIGATOR_36233] a primary diagnosis 
of heart failure (new epi[INVESTIGATOR_135526])!Heart failure 
requiring 
hospi[INVESTIGATOR_36235]:
!Abdominal pain consistent with acute 
pancreatitis (acute onset of a persistent, 
severe, epi[INVESTIGATOR_135527])
!Serum lipase activity (and/or amylase 
activity) at least three times greater the 
UNL
!Characteristic findings of acute 
pancreatitis on imagingAcute pancreatitis
!Mild
!Moderately severe
!SevereCONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 71 of 110
Events Description Adjudication outcome
Malignant neoplasm Malignant neoplasms are defined as:
!Neoplasms in which abnormal cells 
divide without control and can invade 
nearby [CONTACT_36315]/or spread to other parts 
of the body through the blood and lymph 
systems
Thyroid neoplasms are excluded in this event 
category!Malignant neoplasm
Thyroid disease, if malignant 
thyroid neoplasm or C-cell 
hyperplasiaMalignant thyroid neoplasms are defined as:
!Thyroid neoplasms in which abnormal 
cells divide without control and can 
invade nearby [CONTACT_36315]/or spread to 
other parts of the body through the blood 
and lymph systems
!C-cell hyperplasia, defined as hyperplasia 
of the parafollicular C-cells of the thyroid 
gland!Malignant thyroid 
neoplasm:
!C-cell hyperplasia
Acute kidney injury Acute kidney injury44is defined as any of the 
following (not graded):
!Increase in serum creatinine by ≥ 0.3 
mg/dL (≥26.5 μmol/L) within 48 hours, 
or
!Increase in serum creatinine to ≥ 1.[ADDRESS_153822] occurred within the 
prior 7 days, or
!Urine volume < 0.5 mL/kg/h for 6 hours!Acute kidney injury
Lactic acidosis !Lactic acidosis is characterized by 
[CONTACT_135550]!Lactic acidosis
*Death is not a separate event, but an outcome
There are different processes for capturing events for adjudication:
!Direct reporting by [CONTACT_1697]:
– All AEs need to be assessed by [CONTACT_36317]. If the 
AE category selected is in scope for adjudication, the event specific adjudication form 
will be populated for sites to complete
– AEs with fatal outcome
!Screening: 
– All AEs will be screened by [CONTACT_135551], the investigator will be asked to provide additional information such as an 
alternative aetiology, underlying cause(s) and/or clinical details.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 72 of 110
– All ECGs will be centrally read. If the central reading conclusion is suggestive of new 
MI, the ECG adjudication form will be populated for sites to complete for all post-
baseline ECGs.
!EAC identified events:
– The EAC can decide to have an AE adjudicated even if not initially reported as an event 
for adjudication by [CONTACT_093].
Event adjudication will be performed for AEs in randomised subjects including AEs with an onset 
date during the screening period. Event adjudication will not be performed for AEs in screening 
failures.
The assessments made by [CONTACT_135552]. However, the adjudication made by [CONTACT_36320], given its independent 
analysis of each event, will be attributed with greater importance of the two. The outcome of 
adjudication will be kept in the clinical trial database.
[ADDRESS_153823] or an 
assessment has not been done and will not be available, or if the question is irrelevant (e.g. is not 
applicable), indicate this according to the data entry instructions.
The following will be provided as paper case report forms (CRF):
!Pregnancy forms
The following will be provided as paper CRFs to be used when access to the eCRF is revoked of if 
the eCRF is unavailable:
!AE forms 
!SIFs
!Technical complaint forms (also to be used to report complaints that are not subject related
(e.g. discovered at trial site before allocation)).
On the paper CRF forms print legibly, using a ballpoint pen. Ensure that all questions are answered
and that no empty data blocks exist. Ensure that no information is recorded outside the data blocks. 
If a test/assessment has not been done and will not be available, indicate this by [CONTACT_565] "ND" (not 
done) in the appropriate answer field in the CRF. If the question is irrelevant (e.g. is not applicable) 
indicate this by [CONTACT_565] "NA" (not applicable) in the appropriate answer field. Further guidance can 
be obtained from the instructions in the CRF.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153824].
13.1 Corrections to case report forms 
Corrections to the eCRF data may be made by [CONTACT_36322]'s delegated staff.
An audit trail will be maintained in the eCRF application containing as a minimum: the old and the 
new data, identification of the person entering the data, date and time of the entry and reason for the 
correction.
If corrections are made by [CONTACT_093]'s delegated staff after the date the investigator has signed 
the case book, the case book must be signed and dated again by [CONTACT_093].
13.[ADDRESS_153825] been entered into 
the eCRF no later than 3 days after LSLV at the site in order to ensure the planned lock of the 
database.
Site specific eCRF data (in an electronic readable format) will be provided to the trial site before 
access to the eCRF is revoked. This data must be retained at the trial site. When the final clinical 
trial report is available, the data will be archived by [CONTACT_3454].
[ADDRESS_153826] monitoring visit will be performed as soon as possible after FSFV at 
the trial site and no later than 4 weeks after. The monitoring visit intervals will depend on the 
outcome of the remote monitoring of the eCRFs, the trial site's recruitment rate and the compliance 
of the trial site to the protocol and GCP, but will not exceed 12 weeks until LSLV at the trial site
(for trial sites with active subjects (defined as subjects in screening, treatment and follow-up)).
The monitor must be given direct access to all source documents (original documents, data and 
records). Direct access includes permission to examine, analyse, verify and reproduce any record(s) 
and report(s) that are important to the evaluation of the trial. If the electronic medical record does 
not have a visible audit trail, the investigator must provide the monitor with signed and dated CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 74 of 110
printouts. In addition the relevant trial site staff should be available for discussions at monitoring 
visits and between monitoring visits (e.g. by [CONTACT_756]).
All data must be verifiable in source documentation other than the eCRF.
For all data recorded the source document must be defined in a source document agreement at each 
trial site. There must only be one source defined at any time for any data element.
Source data generated by [CONTACT_36323]; any correction must be explained, signed and dated 
by [CONTACT_36324].
The original diaries and/or PROs must not be removed from the trial site, unless they form part of 
the CRF and a copy is kept at the site.
The monitor will ensure that the eCRFs are completed and that paper CRFs are collected.
The following data will be source data verified for screening failures:
!Date for obtaining informed consent.
!Reason for screening failure
Monitors will review the subject's medical records and other source data (e.g. the diaries and PROs) 
to ensure consistency and/or identify omissions compared to the eCRF. If discrepancies are found, 
the investigator must be questioned about these.
A follow-up letter (paper or electronic) will be sent to the investigator following each monitoring 
visit. This should address any action to be taken.
[ADDRESS_153827] 
number and trial ID. Appropriate measures such as encryption or leaving out certain identifiers will CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153828] Operating Procedures and IT architecture documentation. The use and 
control of these systems are documented.
Investigators working on the trial may use their own electronic systems to capture source data.
17 Statistical considerations
General considerations
If necessary, a statistical analysis plan may be written in addition to the protocol, including a more 
technical and detailed elaboration of the statistical analyses. The statistical analysis plan will be 
finalised before database lock.
The blinding of the randomised treatments will be maintained until the database has been released 
for statistical analysis.
Data from all sites will be analysed and reported together.
The randomisation is stratified based on descent (Japanese subjects/non-Japanese subjects). The 
information regarding descent will be included based on country details from the IWRS. Descent
(Japanese subjects/non-Japanese subjects) will be included in the statistical analyses as part of 
region.
The latest available measurement, at or prior to the randomisation visit, will be used as the baseline
measurement. If no measurement(s) have been obtained, at or prior to randomisation, the baseline
value will be left missing.
Laboratory values below the lower limit of quantification (LLoQ) will be set to ½LLoQ. Number of 
values below LLoQ by [CONTACT_36326].
Results from a statistical analysis will as a minimum be presented by [CONTACT_135553]-sided 95% confidence intervals and 
p-values corresponding to two-sided tests of no difference:
!Oral semaglutide 14 mg vs. placebo
!Oral semaglutide 7 mg vs. placebo
!Oral semaglutide 3 mg vs. placebo
If no statistical analysis is specified, data will be presented using relevant summary statistics.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 76 of 110
Primary and secondary estimands
Two estimands addressing different aspects of the trial objective will be defined; a primary de-facto 
(effectiveness) estimand and a secondary de-jure (efficacy) estimand: 
!Primary estimand
– de-facto treatment difference (oral semaglutide versus placebo) at week 26 for all 
randomised subjects regardless of adherence to randomised treatment and initiation of 
rescue medication
The primary de-facto estimand assesses the expected glycaemic benefit in a future population that 
results from subjects initiating treatment with oral semaglutide including potential rescue
medication(s). Generalisation of this estimand depends among other things on the extent to which 
the use of rescue medication in this trial reflects clinical practice and the treatment adherence 
reflects the behaviour of the target population. Accordingly, data collected regardless of 
discontinuation of trial product or initiation of rescue medication(s) will be used to draw inference.
!Secondary estimand
– de-jure treatment difference (oral semaglutide versus placebo) at week [ADDRESS_153829] 
even though subjects are intended to stay in the trial regardless of treatment status and initiation of 
rescue medication, is expected to be maximum 10% based on the oral semaglutide phase 2 trial 
(NN9924-3790). Thus, missing data will mainly be due to withdrawal from trial or lost to follow-up.
When estimating the secondary estimand, the proportion of missing data is expected to be higher 
(20%) since data collected after discontinuation of trial product or initiation of rescue medication(s)
will be set to missing. The 20% of missing data is based on the oral semaglutide phase 2 trial 
(NN9924-3790), that indicates that a low starting dose with gradual dose escalation diminishes 
gastrointestinal AEs compared with more aggressive dosing regimens. Across treatment arms the CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153830] dose levels of oral semaglutide. A higher proportion of subjects are expected to 
discontinue treatment due to AEs in the oral semaglutide 14 mg arm, compared to the other 
treatment arms. So overall the frequency of missing data is expected to be similar across treatment 
arms.
Descriptive summaries and graphical representation of extent, reason(s) for and pattern of missing 
data will be presented by [CONTACT_2939].
17.1 Sample size calculation
Both the primary endpoint, change from baseline to week 26 in HbA 1cand the confirmatory 
secondary endpoint, change from baseline to week 26 in body weight are planned to be tested for 
superiority of oral semaglutide vs. placebo at each dose level (3 mg, 7 mg, and 14 mg).
The sample size calculation is made to ensure a power of at least 90% to jointly confirm HbA 1c
superiority of oral semaglutide vs. placebo at each dose level out of the six pre-specified 
confirmatory hypotheses shown in Figure 17–1 . The closed testing procedure described in Bretz et 
al.45is used to control the overall type I error at a nominal two-sided 5% level. The statistical testing 
strategy is built on the following two principles:
!Within a dose level, glycaemic effect must be established in terms of HbA 1csuperiority 
before testing for added benefits in terms of body weight superiority.
!Glycaemic effect in terms of HbA 1csuperiority must be established on all higher dose levels 
before continuing testing hypotheses on lower dose levels.
The sample size is calculated using the calcPower function in the R package, gMCP46using [ZIP_CODE] 
simulations. All of the six pre-specified confirmatory tests are assumed to be independent. Since 
some of the tests are positively correlated, the assumption of independence is viewed as 
conservative.
The sample size assumptions for treatment effects (TE), adjusted treatment effects and the common 
standard deviations used across dose levels are given in Table 17–1 . These are primarily based on 
the oral semaglutide phase 2 results (NN9924-3790) and supported by [CONTACT_135554] s.c. 
semaglutide phase 2 trial (NN9535-1821).
Since the equalising effect of rescue medication will be included in the primary analysis as well as a 
conservative approach for handling of missing data will be performed, an adjustment in treatment 
effect will be implemented for the 10% of subjects who are expected to discontinue trial product or 
initiate rescue medication and for the 10% of subjects who are expected to have actual missing data. 
The treatment effects used in the sample size calculation will be adjusted according to a 75% CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153831] in these subjects. The adjusted treatment effects for testing superiority are defined as 
0.8×TE + 0.2×TE×0.25.
Table 17–1 Assumptions used in the sample size calculation
Oral semaglutide vs. placebo HbA 1c(%-point) Body weight (kg)
Treatment dose [ADDRESS_153832] (TE) -1.[ADDRESS_153833] deviation 1.1 1.1 1.1 4.0 4.0 4.0
With the above assumptions, allocating 176 subjects to each of the oral semaglutide arms and the 
placebo arm provides 90% power to confirm HbA 1csuperiority of oral semaglutide vs. placebo at 
all dose levels. Calculated powers for individual hypotheses are presented in Table 17–2 . In total 
4×176 = 704 subjects are planned to be randomised.
Table 17–[ADDRESS_153834] HbA 1csuperiority Body weight superiority
Treatment dose 14 mg 7 mg 3 mg 14 mg 7 mg 3 mg
Power (%) > 99% > 99% 90% > 99% 96% 46%CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 79 of 110
Figure 17–1 Graphical illustration of the closed testing procedure
The overall significance level of α = 0.05 (two-sided) is initially allocated to the HbA 1csuperiority test on the highest 
dose level. The local significance level ( α-local) will be reallocated if a hypothesis is confirmed according to the weight 
given by [CONTACT_135555] (hypotheses). The sample size is based on the hypotheses in the dark boxes.
17.2 Definition of analysis sets
The following analysis sets will be defined:       =0 . 0 5HbA 1c(%-point)
Superiority
       =0Body weight (kg)
Superiority
       =0HbA 1c(%-point)
Superiority12⁄12⁄
1
       =0Body weight (kg)
Superiority
       =0HbA 1c(%-point)
Superiority12⁄12⁄
1
       = Body weight (kg)
Superiority1Oral semaglutide 7 mg
vs. placebo
Oral semaglutide 3 mgvs. 
placeboOral semaglutide 14 mg
vs. placeboCONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 80 of 110
Full analysis set (FAS): Includes all randomised subjects. Subjects in the FAS will contribute to 
the evaluation “as randomised”.
Safety analysis set (SAS): Includes all subjects exposed to at least one dose of trial product. 
Subjects in the SAS will contribute to the evaluation based on the trial product received for the 
majority of the period where they were on treatment. This will be referred to as contributing to the 
evaluation “as treated”.
Data selections and observation periods
Unless subjects withdraw their informed consent, data collection will continue for the full duration 
of the trial. The full duration of the trial is defined as up to and including:
!The follow-up visit (V9) for subjects on trial product
!The latest occurring visit of the end-of-treatment visit (V8) or the follow-up premature 
discontinuation visit (V9A), for subjects who have discontinued trial product prematurely
Subjects and data to be used in an analysis will be selected in a two-step manner:
!Firstly, subjects will be selected based on the specified analysis set
!Secondly, data points on the selected subjects from first step will be selected based on the 
specified observation period
Definition of the observation periods:In-trial: This observation period represents the time period where subjects are considered to be in 
the trial, regardless of discontinuation of trial product or initiation of rescue medication. The in-trial 
observation period starts at randomisation (as registered in IWRS) and ends at the date of:
!The last direct subject-site contact, which is scheduled to take place [ADDRESS_153835] at a follow-up visit
!Withdrawal for subjects who withdraw their informed consent
!The last subject-investigator contact [CONTACT_135556]-up
!Death for subjects who dies before any of the above
On-treatment: This observation period represents the time period where subjects are considered 
treated with the trial product. The observation period is a subset of the in-trial observation period. It 
starts at the date of first dose of trial product. Two slightly different end dates will be needed to 
cover all assessments appropriately. For adjudicated events, ECGs, anti-semaglutide antibodies, and 
AEs including hypoglycaemic ep isodes, the observation period ends at the first date of any of the 
following:
!The follow-up visit (V9)
!The follow-up prematurely discontinuation visit (V9A)
!The last date on trial product + 38 daysCONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 81 of 110
!The end-date for the in-trial observation period
The follow-up visit is scheduled to take place [ADDRESS_153836] 
corresponding to approximately five half-lives of oral semaglutide. The visit window for the follow-
up visit is + 3 days.
For efficacy and other safety assessments (laboratory assessments, physical examination and vital 
signs) the observation period ends at the last date on trial product + 3 days. This will be used in 
order to ensure specificity to reversible effects of treatment.
On-treatment without rescue medication: This observation period is a subset of the on-treatment 
observation period, where subjects are considered treated with trial product, but have not initiated 
any rescue medications. Specifically it starts at date of first dose of trial product and the end date is 
the first date of any of the following:
!The last dose of trial product + 3 days
!Initiation of rescue medication
The in-trial observation period will be the primary observation period for estimating the primary 
estimand. The on-treatment without rescue medication observation period will be the primary 
observation period when estimating the secondary estimand. The on-treatment observation period 
will be considered supportive for evaluating efficacy. Safety will be evaluated based on the in-trial 
and the on-treatment observation periods.
Data points collected outside an observation period will be treated as missing in the analysis. 
Baseline data will always be included in an observation period. For adjudicated events, the onset 
date will be the EAC adjudicated onset date.
Before data are locked for statistical analysis and the randomisation code is broken, a review of all 
data will take place. Any decision to exclude either a subject or single observations from the 
statistical analysis is the joint responsibility of the members of the Novo Nordisk study group. 
Exclusion of data from analyses should be used restrictively and normally no data should be 
excluded from the FAS. The subjects or observations to be excluded, and the reasons for their 
exclusion must be documented and signed by [CONTACT_36331]. The subjects 
and observations excluded from analysis sets, and the reason for this, will be described in the 
clinical trial report.
Confirmatory hypotheses
For the primary HbA 1cendpoint and the confirmatory sec ondary body weight  endpoint the 
following confirmatory one-sided hypotheses are planned to be tested at each dose level of oral 
semaglutide versus placebo. Let the mean treatment difference be defined as μ = (oral semaglutide 
minus placebo):CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 82 of 110
!HbA 1csuperiority
–H 0: μ≥0.0 %-point against H A: μ< 0.0 %-point
!Body weight superiority
–H 0: μ≥0.[ADDRESS_153837] H A: μ< 0.0 kg
Operationally the hypotheses will be evaluated by [CONTACT_1192]-sided tests at the 5% significance level.
Multiplicity and criteria for confirming hypotheses
The type I error for testing the six confirmatory hypotheses related to the HbA 1cand body weight 
endpoints will be preserved in the strong sense at 5% (two-sided) using the weighted Bonferroni-
based closed testing procedure described in Bretz et al.45and outlined in Figure 17–[ADDRESS_153838] dose level. It will be tested at 
the overall significance level (5%) while allocating 0% local significance level to the remaining of 
the hypotheses. For this hypothesis, and in general, if a hypothesis is confirmed, then the 
significance level will be reallocated according to the weight and the direction of the edges going 
from the confirmed hypothesis to the next hypotheses as specified in Figure 17–1 . Each of the 
following hypotheses will be tested at their updated local significance level ( α-local). This process 
will be repeated until no further hypotheses can be confirmed.
Superiority will be considered confirmed if the mean treatment difference is supporting the 
corresponding alternative hypothesis and the two-sided p-value from the primary analysis of the 
primary estimand is strictly below its local two-sided significance level as defined by [CONTACT_135557] 17–1 . This is equivalent to using a one-sided p-value (nominal α = 
0.025) and a one-sided 2.5% overall significance level in the closed testing procedure.
17.3 Primary endpoint
The primary endpoint is change from baseline to week 26 in HbA 1c.
17.3.1 Primary analysis for the primary estimand
The primary estimand will be estimated based on the FAS using week 26 measurements from the 
in-trial observation period. The primary statistical analysis will be a pattern mixture model using 
multiple imputation to handle missing data assuming that the missing data mechanism is missing at 
random (MAR) within the groups used for imputation. Imputation of missing data at week 26 will
be done within 8 groups of subjects defined by [CONTACT_36333], and whether subjects at 
week 26; (i) have discontinued treatment or initiated rescue medication or (ii) are still on treatment and have not initiated rescue medication. It is hereby [CONTACT_135558] 26 are similar in terms of randomised treatment arm and treatment adherence/rescue
medication status.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 83 of 110
Missing values for each group will be imputed as follows:
!An analysis of covariance (ANCOVA) with region as a categorical fixed effect and baseline 
HbA 1cmeasurement as a covariate will be fitted to observed values of the change from 
baseline in HbA 1cat week 26.
!The estimated parameters for location and dispersion will be used to impute [ADDRESS_153839] with missing week 26 data based on region and baseline HbA 1c. Thus, 100 
complete data sets will be generated including observed and imputed values.
Analysis used for confirming superiority versus placebo at week 26:
For each of the 100 (now complete) imputed data sets the change from baseline to week 26 in 
HbA 1cwill be analysed using an ANCOVA with treatment and region as categorical fixed effects 
and baseline HbA 1cas covariate. The results obtained from analysing the datasets will be combined 
using Rubin’s rule47to draw inference.
From this analysis the estimated treatment differences between each of the oral semaglutide dose levels and placebo together with associated two-sided 95% confidence intervals and unadjusted 
two-sided p-values for testing no difference from zero will be presented.
17.3.[ADDRESS_153840]-baseline measurements up 
to and including week 26 from the on-treatment without rescue medication observation period. The 
primary analysis for the secondary estimand will be a Mixed Model for Repeated Measurements 
(MMRM). A restricted maximum likelihood will be used. The model will include all post-baseline 
HbA
1cmeasurements collected at scheduled visits up to and including week [ADDRESS_153841] will be employed, assuming measurements 
from different subjects are independent.
The MMRM is a well-established method that accounts for the uncertainty pertaining to missing 
data. This analysis assumes that the missing data mechanism is MAR. Under this assumption the 
statistical behaviour of the missing data (given the observed responses and model fixed effects and 
covariates) is assumed to be same as the observed data. 
17.3.[ADDRESS_153842] of missing data. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 84 of 110
The evaluation of the robustness of the primary analysis results will primarily be based on a pattern 
mixture model approach using multiple imputation. An overview of the sensitivity analyses for each 
of the estimands are specified below followed by a more detailed description of the three different 
pattern mixture models used. Finally, one additional sensitivity analysis for the primary analysis 
will be described that is not based on the pattern mixture model approach, see Section [IP_ADDRESS] .
Sensitivity analyses for the primary estimand
The estimation of the primary estimand will be repeated using the following sensitivity analyses:
!A comparator multiple imputation analysis based on FAS using the in-trial observation
period
!A comparator multiple imputation analysis differentiating between reasons for discontinuing 
treatment prematurely based on FAS using the in-trial observation period
!A tippi[INVESTIGATOR_007]-point multiple imputation analysis based on FAS using the in-trial observation
period
!An MMRM analysis (the primary analysis for the secondary estimand) based on FAS using 
the in-trial observation period
Sensitivity analyses for the secondary estimand
The estimation of the secondary estimand will be repeated using the following sensitivity analyses:
!A comparator multiple imputation analysis based on FAS using the on-treatment without 
rescue medication observation period.
!A comparator multiple imputation analysis based on FAS using the on-treatment 
observation period. This sensitivity analysis aims to compare oral semaglutide versus 
placebo for subjects who adhere to treatment regardless of whether or not rescue medication 
has been initiated.
!A comparator multiple imputation analysis differentiating between reasons for discontinuing 
treatment prematurely based on FAS using the on-treatment without rescue medication 
observation period.
!A tippi[INVESTIGATOR_007]-point multiple imputation analysis based on FAS using the on-treatment without 
rescue medication observation period.
[IP_ADDRESS] Pattern mixture models
Common for the three pattern mixture model sensitivity analyses is that they all aim to stress-test 
the primary HbA 1cresults by [CONTACT_135559], while maintaining the missing at random data assumption for the 
placebo arm:
!Comparator multiple imputation analysis: In this sensitivity analysis missing data at week 
[ADDRESS_153843] this imputation approach removes the CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 85 of 110
treatment difference between oral semaglutide and placebo for all subjects randomised to 
oral semaglutide, given that oral semaglutide is better than placebo.
!Comparator multiple imputation analysis differentiating between reasons for discontinuing 
treatment prematurely: In this sensitivity analysis only missing data at week [ADDRESS_153844] this imputation approach removes the 
treatment difference between oral semaglutide and placebo for this selected group of 
subjects randomised to oral semaglutide.
!Tippi[INVESTIGATOR_007]-point multiple imputation analysis: In this sensitivity analysis, missing data will 
first be imputed according to the primary analysis. Secondly, for all oral semaglutide 
treatment arms a penalty will be added to the imputed values at week 26. The approach is to 
gradually increase this penalty until all confirmed HbA 1cconclusions from the primary 
analysis are changed. For each hypothesis tested the specific value of the penalty that 
reverses the conclusion will be used to evaluate the robustness of the primary analysis 
results. 
[IP_ADDRESS] Other sensitivity analyses
The following additional sensitivity analysis will be specified:
!Last observation carried forward analysis: This sensitivity analysis will be based on the 
FAS using the on-treatment without rescue medication observation period. The change from 
baseline to week 26 in HbA 1cwill be analysed by a linear normal model (ANCOVA) with 
treatment and region as categorical fixed effects and baseline HbA 1cas a covariate. 
[IP_ADDRESS] Assessment of sensitivity analyses
The results from the sensitivity analyses will be collectively used to interpret the robustness of the
trial results for HbA 1c. Due to the sensitivity analyses inherent conservative nature, it will not be a 
requirement that all confirmatory hypotheses are consistently confirmed across the sensitivity 
analyses. Thus, no absolute success criteria will be pre-defined for each sensitivity analysis. The 
sensitivity results in totality will be used to substantiate the credibility of the trial results.
17.4 Secondary endpoints
17.4.1 Confirmatory secondary endpoints
Change from baseline to week 26 in body weight (kg) will be a confirmatory secondary endpoint.
The primary and secondary estimands will be estimated using the same approaches as described for 
the primary HbA 1cendpoint. Baseline body weight will be used as a covariate instead of baseline 
HbA 1cin both the multiple imputation and MMRM analysis models.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 86 of 110
Superiority will be considered confirmed if the mean treatment difference is supporting the 
corresponding hypothesis and the two-sided p-value from the analysis of the primary estimand is 
strictly below its local two-sided significance level resulting from the closed testing procedure in
Figure 17–1 . Sensitivity analyses similar to the ones pre-specified for the primary HbA 1cendpoint 
will be made to evaluate the robustness of the body weight results.
17.4.2 Supportive secondary endpoints
[IP_ADDRESS] Efficacy endpoints
The below supportive secondary efficacy endpoints will be evaluated for:
!The primary estimand based on FAS using the in-trial observation period
!The secondary estimand based on FAS using the on-treatment without rescue medication 
observation period
No sensitivity analyses are planned for these.
Continuous efficacy endpoints
Change from baseline to week 26 in:
!FPG
!Fasting C-peptide
!Fasting insulin and proinsulin 
!Fasting glucagon
!Insulin resistance (homeostatic model assessment index of insulin resistance (HOMA-IR)) 
and beta-cell function (homeostatic model assessment index of beta-cell function (HOMA-
B))
!CRP
!Body weight (%)
!BMI
!Waist circumference
!Fasting lipid profiles (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides)
BMI will be calculated based on body weight and height based on the formulae:
BMI kg/m2= body weight (kg)/(height (m) × height (m)) or (kg/m2= [lb/in2× 703])
Change from baseline to week 26 in the below derived endpoints from the SMPG 7-point profile:
!Mean 7-point profile. Defined as the area under the profile, calculated using the trapezoidal 
method, divided by [CONTACT_36336]
!Mean postprandial increment (over all meals)
The above continuous endpoints will be analysed separately using similar model approaches as for 
the primary endpoint with the associated baseline response as a covariate. Fasting lipid profile CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153845]-baseline measurement up to and including week 26. From this model the estimated 
treatment differences (ratios) will be presented at week 26 with 95% confidence intervals and two-
sided p-values for test of no difference.
Binary efficacy endpoints
If a subject after week 26 achieves (yes/no): 
!HbA 1c< 7.0 % (53 mmol/mol) (ADA target)
!HbA 1c≤ 6.5 % (48 mmol/mol) (AACE target)
!HbA 1creduction ≥ 1 %-point (10.9 mmol/mol)
!Body weight loss ≥ 3 %
!Body weight loss ≥ 5 %
!Body weight loss ≥ 10 %
!HbA 1c< 7.0 % (53 mmol/mol) without hypoglycaemia (treatment-emergent severe or BG-
confirmed symptomatic hypoglycaemic epi[INVESTIGATOR_1841]) and no weight gain
!HbA 1creduction ≥ 1 %-point (10.9 mmol/mol) and weight loss ≥ 3 %
The above eight binary endpoints will be analysed using a logistic regression model with treatment 
and region as fixed effects and baseline response as covariate (i.e. baseline HbA 1cfor binary HbA 1c
endpoints, baseline weight for weight endpoints and both baseline HbA 1cand baseline weight for 
the binary endpoints that combines both parameters). To account for missing data, the analysis will 
be made using a sequential multiple imputation approach as described below:
!Multiple imputed data sets (100) will be created in which missing values for the underlying 
continuous assessments are imputed by [CONTACT_36337]/rescue 
status assuming MAR and as described in section 17.3.1 for the primary estimand and by 
[CONTACT_36338] 17.3.2 for the secondary 
estimand.
!The binary endpoint will be created for each of the 100 complete data sets
!Each of the created complete data set will be analysed with the logistic model and inference 
will be drawn using Rubin’s rule47.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 88 of 110
Time to event endpoint
!Time to rescue medication
The endpoint will be analysed based on FAS using both the on-treatment observation period and the 
in-trial observation period. For the analysis based on the on-treatment observation period, subject 
without need for rescue medication during the on-treatment observation period will be censored at 
the time point of the date of last trial product. For the in-trial period subject without need for 
addition of glucose-lowering medication during the in-trial observation period, will be censored at 
the time point of the date of end of the in-trial observation period. For this analysis, the follow-up 
period will be excluded from the in-trial observation period, since subjects will have to stop 
treatment at the end-of-treatment visit and therefore might need addition of glucose-lowering 
medication during the follow-up period.
The endpoint will be described and compared for oral semaglutide versus placebo using likelihood 
ratio tests obtained from a Cox proportional hazards model with treatment, stratification factors, the 
interaction between the two stratification factors and region as categorical fixed effects and baseline HbA
1cas a covariate. From this analysis the estimated Hazard ratios between oral semaglutide 
versus placebo will be presented together with 95% confidence intervals and two sided p values for 
test of no difference.
[IP_ADDRESS] Safety endpoints
The safety endpoints will be evaluated based on SAS using the on-treatment observation period and 
based on SAS using the in-trial observation period unless otherwise stated. The following endpoints 
are used to support the safety objectives.
Adverse events 
!Number of TEAEs during exposure to trial product, assessed up to approximately [ADDRESS_153846] recent version of the Medical Dictionary for Regulatory 
Activities (MedDRA) coding. 
A treatment-emergent AE is defined as an AE with onset in the on-treatment observation period 
(see definition of observation periods in Section 17.2).
TEAEs will be summarised in terms of the number of subjects with at least one event (N), the 
percentage of subjects with at least one event (%), the number of events (E) and the event rate per 
100 patient years of observation time (R) for the on-treatment observation period. Supportive 
summaries of AEs will be made for the in-trial observation period. The development over time in gastrointestinal AEs will be presented graphically.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 89 of 110
Other safety endpoints
Change from baseline to week 26 in:
!Amylase
!Lipase
!Pulse
!Systolic blood pressure
!Diastolic blood pressure
The above safety endpoints will be evaluated using the primary analysis for the primary estimand 
based on SAS using the in-trial observation period and using the primary analysis for the secondary 
estimand based on SAS using the on-treatment observation period. Endpoints will be analysed 
separately as described above for continuous efficacy endpoints. Results will be presented at week 
26. Amylase and lipase endpoints will be log-transformed prior to analysis with the associated log-
transformed baseline value as a covariate.
Change from baseline to week 26 in:
!Haematology 
!Biochemistry (except for amylase and lipase)
!Calcitonin
!ECG evaluation
!Physical examination
Change from pre-dose to post-dose (25 and 40 minutes) at week 4 and 26 in:
!Lactate
Any occurrence of anti-semaglutide antibodies (yes/no) up to approximately 31 weeks:
!Anti-semaglutide binding antibodies
!Anti-semaglutide neutralising antibodies
!Anti-semaglutide binding antibodies cross reacting with native GLP-1
!Anti-semaglutide neutralising antibodies cross reacting with native GLP-1
Anti-semaglutide binding antibodies up to approximately 31 weeks:
!Anti-semaglutide binding antibody levels
The above safety endpoints will be summarised descriptively by [CONTACT_31703]. 
Categorical safety endpoints will be summarised as counts and relative frequencies. Calcitonin will 
also be presented by [CONTACT_547]. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 90 of 110
Hypoglycaemia
!Number of treatment-emergent severe or BG-confirmed symptomatic hypoglycaemic 
epi[INVESTIGATOR_36184], assessed up to approximately 31 weeks
!Treatment-emergent severe or BG-confirmed symptomatic hypoglycaemic epi[INVESTIGATOR_36237], assessed up to approximately 31 weeks (yes/no)
Classification of hypoglycaemia
Hypoglycaemic epi[INVESTIGATOR_36238]-treatment observation period 
only.
Treatment-emergent: hypoglycaemic epi[INVESTIGATOR_36239]-emergent if the onset of 
the epi[INVESTIGATOR_36240]-treatment observation period (see definition of observation periods 
in Section 17.2).
Nocturnal hypoglycaemic epi[INVESTIGATOR_1841]: epi[INVESTIGATOR_36241] 00:01 and 05.59 both inclusive.
Hypoglycaemic epi[INVESTIGATOR_36242] (see Figure 17–2 ).
Novo Nordisk classification of hypoglycaemia
In normal physiology, symptoms of hypoglycaemia occur below a PG level of 3.1 mmol/L 
(56 mg/dL)50. Therefore, Novo Nordisk has included hypoglycaemia with PG levels below this cut-
off point in the definition of BG-confirmed hypoglycaemia.
Novo Nordisk uses the following classification in addition to the ADA classification:
!Severe or BG-confirmed symptomatic hypoglycaemia: An epi[INVESTIGATOR_135528]38or BG-confirmed by a PG value < 3.1 mmol/L (56 mg/dL) with
symptoms consistent with hypoglycaemia.
ADA classification38of hypoglycaemia
!Severe hypoglycaemia: An epis ode requiring assistance of another person to actively 
administer carbohydrate, glucagon, or take other corrective actions. PG concentrations may 
not be available during an event, but neurological recovery following the return of PG to 
normal is considered sufficient evidence that the event was induced by a low PG
concentration.
!Asymptomatic hypoglycaemia: An epi[INVESTIGATOR_36245], but with a measured PG concentration ≤ 3.9 mmol/L (70 mg/dL).
!Documented symptomatic hypoglycaemia: An epi[INVESTIGATOR_36246] a measured PG concentration ≤ 3.9 mmol/L 
(70 mg/dL).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 91 of 110
!Pseudo-hypoglycaemia: An epi[INVESTIGATOR_36247] a measured PG concentration > 3.9 mmol/L (70 mg/dL) but approaching that level.
!Probable symptomatic hypoglycaemia: An epi[INVESTIGATOR_135529] a PG determination but that was presumably caused 
by a PG concentration ≤ 3.9 mmol/L (70 mg/dL).
Hypoglycaemic 
epi[INVESTIGATOR_36249] ≤ 3.9 mmol/L 
(70 mg/dL) 
or 
Alleviation of 
symptoms 
or
Seizure, coma or 
fatal 
SMPG
measurementAsymptomatic 
hypoglycaemia
Documented 
symptomatic 
hypoglycaemia
Pseudo-
hypoglycaemia
Probable 
symptomatic 
hypoglycaemiaNo
Yes
No measurement 
with symptomsPG > 3.9 mmol/L 
(70 mg/dL)
with symptomsPG ≤3.9 mmol/L 
(70 mg/dL)
with symptomsPG ≤3.9 mmol/L 
(70 mg/dL)
without symptoms
NoYes
Note: Glucose measurements are performed with capi[INVESTIGATOR_135530]: plasma glucose  SMPG: Self-measured plasma glucose  Subject 
able to 
treat him/
herselfSevere 
hypoglycaemia
(ADA 2013)
Figure 17–[ADDRESS_153847] one epi[INVESTIGATOR_1865] (%), the total 
number of epi[INVESTIGATOR_36252] [ADDRESS_153848]’s on-treatment observation period as 
offset. The model will include treatment and region as fixed factors and baseline HbA 1cas 
covariate.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153849] one treatment-emergent severe or BG-
confirmed symptomatic hypoglycaemic epi[INVESTIGATOR_36253] a logistic regression model 
with treatment and region as fixed factors and baseline HbA 1cas covariate.
[IP_ADDRESS] Pharmacokinetic endpoints
!Semaglutide plasma concentrations for population PK analysis
!SNAC plasma concentrations 
The semaglutide plasma concentrations and SNAC plasma concentrations collected in this trial will 
be evaluated using relevant summary statistics. In addition, the semaglutide plasma concentration 
will be part of a meta-analysis across the oral semaglutide phase 3a trials, see more details in 
Section 17.6.
17.5 Interim analysis
No interim analyses or other analyses of unblinded data will be performed before the database is 
locked.
17.6 Pharmacokinetic and/or pharmacodynamic modelling
Data from this trial will be evaluated using population pharmacokinetic analysis and exposure-
response for semaglutide. The purpose of the population pharmacokinetic analysis will be: 
!To describe the covariate factors (such as weight, age, gender, race and ethnicity) that 
influence semaglutide exposure
!To estimate a steady-state exposure level for each subject with pharmacokinetic data, in 
order to facilitate subsequent exposure-response analyses
The purpose of the exposure-response analyses will be to support the recommended dose, by 
[CONTACT_135560]. 
The population pharmacokinetic and exposure-response analyses will be conducted as a meta-
analysis, including all relevant oral semaglutide phase 3a trials with PK assessments. A separate 
modelling analysis plan will be prepared before first database lock in the oral semaglutide phase 3a 
programme, outlining details of the analyses. The modelling will be performed by [CONTACT_135561] A/S and will be reported separately from the clinical trial 
report.
17.7 Health economics and/or patient reported outcomes
PRO endpoints
Change from baseline to week 26 in:
!SF-36v2™ (acute version) health survey: Scores from the 8 domains and summary of the 
physical component score and the mental component scoreCONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 93 of 110
!IWQOL-Lite Clinical Trial Version: Total score of the 22 items
!PGI-S Items: Scores of the two individual items
!PGI-C Items: Scores of the two individual items
The PRO questionnaire endpoints will be evaluated using the primary analysis for the primary 
estimand based on FAS using the in-trial observation period and using the primary analysis for the 
secondary estimand based on FAS using the on-treatment without rescue medication period. Scores 
will be analysed separately as the other continuous efficacy endpoints with the associated baseline 
response as a covariate.
[ADDRESS_153850] been gastrointestinal disorders (nausea, vomiting, diarrhoea, dyspepsia 
and constipation). Clinical trials have indicated that a low starting dose and gradual dose escalation 
mitigates the risk of gastrointestinal AEs. Consequently, a low starting dose and dose escalation 
with [ADDRESS_153851] that rodents are more sensitive to the mode of action of GLP-1 RAs 
for induction of C-cell tumours. However, as a precaution, subjects with a family or personal 
history of MEN 2 or MTC will not be enrolled in the trial. During the trial, calcitonin will be 
measured on a regular basis, and the guidance for investigators on further evaluation and action on 
elevated calcitonin concentrations is included in appendix A .CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153852](s) or related products 
will not be enrolled in the trial. In addition, subjects will be instructed to contact [CONTACT_36339][INVESTIGATOR_1884] a hypersensitivity reaction to the trial product 
occurs.
Hypoglycaemia
Based on current knowledge about the GLP-[ADDRESS_153853] mainly been observed when a GLP-1 RA is combined with 
sulphonylurea or insulin. The risk for development of hypoglycaemia with oral semaglutide in 
combination with sulphonylurea and insulin is currently unknown. 
Acute renal impairment
In subjects treated with GLP-1 RAs including oral semaglutide, gastrointestinal AEs such as 
nausea, vomiting and diarrhoea may lead to significant dehydration and secondary acute renal 
impairment. Subjects with gastrointestinal AEs are recommended to drink plenty of fluids to avoid 
volume depletion. Also, serum creatinine and other markers of kidney function will be monitored 
throughout the trial.
The use of the background medication should be in accordance with the current approved labels.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 95 of 110
Other safety considerations
Teratogenicity (embryo-foetal development toxicity)
Semaglutide caused embryo-foetal malformations in the rat through a GLP-[ADDRESS_153854] to ensure acceptable glycaemic control 
during the trial. If rescue medication is required, it should be in accordance with ADA/European 
Association for the Study of Diabetes 25, 26(excluding GLP-1 RAs, DPP-4 inhibitors and amylin 
analogues).
It is the responsibility of the investigator to ensure the best possible care according to the principles 
outlined in Diabetes Care [ADDRESS_153855] are described in the current edition of the IB for oral administration of semaglutide (NN9924)
24, or any updates thereto.
18.1.[ADDRESS_153856] with the study site, with close follow-up of their T2DM and a 
careful medical examination; all of which will most likely result in an intensified management of 
their T2DM.
All subjects in this trial will receive trial products and auxiliary supplies free of charge. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153857] comply with applicable 
regulatory requirement(s) and adhere to ICH GCP1and the requirements in the Declaration of 
Helsinki2.
Before any trial-related activity, the investigator must give the subject verbal and written 
information about the trial and the procedures involved in a form that the subject can read and 
understand.
The subjects must be fully informed of their rights and responsibilities while participating in the 
trial as well as possible disadvantages of being treated with the trial products.
The investigator must ensure the subject ample time to come to a decision whether or not to 
participate in the trial.
A voluntary, signed and personally dated informed consent must be obtained from the subject 
before any trial-related activity.
The responsibility for seeking informed consent must remain with the investigator, but the 
investigator may delegate the task to a medically qualified person, in accordance with local 
requirements. The written informed consent must be signed and personally dated by [CONTACT_135562]-related activity.
If information becomes available that may be relevant to the subject’s willingness to continue 
participating in the trial, the investigator must inform the subject in a timely manner and a revised 
written subject information must be provided and a new informed consent must be obtained.
In order to avoid missing data, the subjects will be informed about the importance of completing the 
trial also if the subjects discontinue from trial product.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153858]’s data will be handled 
as follows:
!Data already collected and any data collected at the end-of-trial visit including follow-up 
visit will be retained by [CONTACT_3454], entered into the database and used for the clinical
trial report. 
!Safety events will be reported to Novo Nordisk and regulatory authorities according to 
local/national requirements.
If data is used, it will always be in accordance with local regulations and IRBs/IECs.
18.[ADDRESS_153859] be sent to IRB/IEC for approval/favourable opi[INVESTIGATOR_17950].
18.5 Premature termination of the trial and/or trial site
Novo Nordisk, the IRBs/IECs or a regulatory authority may decide to stop the trial, part of the trial 
or a trial site at any time, but agreement on procedures to be followed must be obtained.
If the trial is suspended or prematurely terminated, the investigator must inform the subjects 
promptly and ensure appropriate therapy and follow-up. The investigator and/or Novo Nordisk must 
also promptly inform the regulatory authorities and IRBs/IECs and provide a detailed written 
explanation. 
If, after the termination of the trial, the benefit-risk analysis changes, the new evaluation must be 
provided to the IRBs/IECs in case it has an impact on the planned follow-up of subjects who have 
participated in the trial. If it has an impact, the actions needed to inform and protect the subjects 
should be described.
[ADDRESS_153860] be documented and explained in a protocol deviation by [CONTACT_18030], date
and the action(s) taken. Some deviations, for which corrections are not possible, can be 
acknowledged and confirmed via edit checks in the eCRF or via listings from the trial database .CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153861] be kept in the investigator's trial master file and 
sponsor trial master file.
19.[ADDRESS_153862] or withdrawal of consent to secure 
early mitigations in collaboration with the trial sites. 
The investigator will make every effort to ensure that all assessments are performed and data is 
collected. If missing data does occur the reason will be collected via the protocol deviation process, 
see Section 19.1. Novo Nordisk will monitor protocol deviations on an on-going basis throughout 
the trial followed by [CONTACT_36340] (e.g. re-training of site staff).
[ADDRESS_153863] to audits conducted by [CONTACT_36341]/IECs. Audits and inspections may 
take place during or after the trial. The investigator and the site staff as well as Novo Nordisk staff 
have an obligation to cooperate and assist in audits and inspections. This includes giving auditors 
and inspectors direct access to all source documents and other documents at the trial site relevant to 
the clinical trial. This includes permission to examine, analyse, verify and reproduce any record(s) 
and report(s) that are relevant to the evaluation of the trial.
[ADDRESS_153864] be available to Novo Nordisk:
!Regulatory approval and/or acknowledgement of notification as required 
!Approval/favourable opi[INVESTIGATOR_36254]/IECs clearly identifying the documents reviewed as 
follows: protocol, any protocol amendments, subject information/informed consent form, 
any other written information to be provided to the subject and subject recruitment materials
!List of IRB/IEC members and/or constitution (or a general assurance number/statement of 
compliance)
!Curricula vitae of investigator and sub-investigator(s) (current, dated and signed - must 
include documented GCP training or a certificate)
!Signed receipt of IBCONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 99 of 110
!Signed and dated Agreement on Protocol
!Signed and dated Agreement on Protocol Amendment, if applicable
!Contract, signed by [CONTACT_1755]/or appropriate parties on behalf of the investigator’s 
site and Novo Nordisk
!Source document agreement
!Central laboratory certification and normal ranges
!Insurance statement, if applicable
!Financial disclosure form from investigator and sub-investigator(s)
Only applicable for US trial sites: 
!For US trial sites: verification under disclosures per Code of Federal Regulations of 
Financial Conflict of Interest
!For US trial sites: FDA form [ADDRESS_153865] be completed and signed by [CONTACT_135563]: A seal is accepted as signature.
FDA form 1572:
For US sites:
!Intended for US sites
!Conducted under the Investigational New Drug (IND)
!All US investigators, as described above, will sign FDA Form 1572
For sites outside the US:
!Intended for participating sites outside of the US
!Not conducted under the IND
!All investigators outside of the US will not sign FDA form 1572
Novo Nordisk will analyse and report data from all sites together if more than one site is involved in 
the trial.
By [CONTACT_36343], each investigator agrees to comply fully with ICH GCP1,
applicable regulatory requirements and the Declaration of Helsinki2.
By [CONTACT_36343], each investigator also agrees to allow Novo Nordisk to make
investigator's name [CONTACT_36374] [CONTACT_36344].CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153866] of the trial at his/her site and must ensure adequate 
supervision of the conduct of the trial at the trial site. If any tasks are delegated, the investigator 
must maintain a log of appropriately qualified persons to whom he/she has delegated specified trial-
related duties. The investigator must ensure that there is adequate and documented training for all 
staff participating in the conduct of the trial. It is the investigator's responsibility to supervise the 
conduct of the trial and to protect the rights, safety and well-being of the subjects.
A qualified physician, who is an investigator or a sub-investigator for the trial, must be responsible 
for all trial-related medical decisions.
The investigator will follow instructions from Novo Nordisk when processing data.
The investigator is responsible for filing essential documents (i.e. those documents which 
individually and collectively permit evaluation of the conduct of a trial and the quality of the dataproduced) in the investigator trial master file. The documents including the subject identification 
code list must be kept in a secure locked facility, so no unauthorized persons can get access to the 
data. 
The investigator will take all necessary technical and organisational safety measures to prevent 
accidental or wrongful destruction, loss or deterioration of data. The investigator will prevent any 
unauthorised access to data or any other processing of data against applicable law. The investigator 
must be able to provide the necessary information or otherwise demonstrate to Novo Nordisk that 
such technical and organisational safety measures have been taken.
During any period of unavailability, the investigator must delegate responsibility for medical care of 
subjects to a specific qualified physician who will be readily available to subjects during that time.
If the investigator is no longer able to fulfil the role as investigator (e.g. if he/she moves or retires), 
a new investigator will be appointed in consultation with Novo Nordisk. 
The investigator and other site personnel must have sufficient English skills according to their 
assigned task(s).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153867], if deemed necessary by [CONTACT_3454]. Provided that certain 
conditions are fulfilled, Novo Nordisk may grant access to information obtained during this trial to 
researchers who require access for research projects studying the same disease and/or trial product 
studied in this trial.
Novo Nordisk may publish on its clinical trials website a redacted clinical trial report for this trial.
Two investigators will be appointed by [CONTACT_41170] 
(signatory investigator) on behalf of all participating investigators. The signatory investigators will 
be appointed based upon the criteria defined by [CONTACT_36346]52.
23.[ADDRESS_153868] for 
Clinical Trial Disclosure27.
Novo Nordisk reserves the right to defer the release of data until specified milestones are reached, for example when the clinical trial report is available. This includes the right not to release the 
results of interim analyses, because the release of such information may influence the results of the 
entire trial.
At the end of the trial, one or more scientific publications may be prepared collaboratively by [CONTACT_1275](s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or 
communication for up to [ADDRESS_153869] intellectual property.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 102 of 110
In all cases the trial results will be reported in an objective, accurate, balanced and complete 
manner, with a discussion of the strengths and limitations. All authors will be given the relevant 
statistical tables, figures and reports needed to evaluate the planned publication. In the event of any 
disagreement on the content of any publication, both the investigators' and Novo Nordisk opi[INVESTIGATOR_36255].
Where required by [CONTACT_18038], the investigator from each trial site will be named in an 
acknowledgement or in the supplementary material, as specified by [CONTACT_18038].
Novo Nordisk maintains the right to be informed of plans by [CONTACT_36347], presentation, communication or other information concerning the 
investigation described in this protocol. Any such communication must be submitted in writing to 
Novo Nordisk before submission for comments. Comments will be given within four weeks from 
receipt of the planned communication.
23.1.1 Authorship
Authorship of publications should be in accordance with the Uniform Requirements of the 
International Committee of Medical Journal Editors52(sometimes referred to as the Vancouver 
Criteria). Novo Nordisk will appoint investigator(s) to prepare publications in collaboration with Novo Nordisk.
23.1.2 Site-specific publication(s) by [CONTACT_1697](s)
For a multi-centre clinical trial, analyses based on single-site data usually have significant statistical 
limitations and frequently do not provide meaningful information for healthcare professionals or 
subjects and therefore may not be supported by [CONTACT_3454]. It is a Novo Nordisk policy that such 
individual reports do not precede the primary manuscript and should always reference the primary 
manuscript of the trial.
Novo Nordisk reserves the right to prior review of such publications. Further to allow for the 
primary manuscript to be published as the first, Novo Nordisk asks for deferment of publication of 
individual site results until the primary manuscript is accepted for publication. As Novo Nordisk 
wants to live up to the industry publication policy, submission of a primary publication will take 
place no later than [ADDRESS_153870] their own research subjects' data, and will be provided with the 
randomisation code after results are available.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153871]'s medical records must be kept for the maximum period permitted by [CONTACT_5035][INVESTIGATOR_307], 
institution or private practice.
The investigator must agree to archive the documentation (this includes both electronic and paper-
based records) pertaining to the trial in an archive after completion or discontinuation of the trial if 
not otherwise notified. The investigator should not destroy any documents without prior permission 
from Novo Nordisk. If the investigator cannot archive the documents at the trial site, Novo Nordisk 
can refer the investigator to an independent archive provider that has a system in place to allow only 
the investigator to access the files.
The investigator must be able to access his/her trial documents without involving Novo Nordisk in 
any way. Site-specific CRFs and other subject data (in an electronic readable format or as paper copi[INVESTIGATOR_17951]) will be provided to the investigator before access is revoked to the systems and/or 
electronic devices supplied by [CONTACT_3454]. These data must be retained by [CONTACT_21655]. If the 
provided data (e.g. the CD-ROM) is not readable during the entire storage period, the investigator 
can request a new copy. A copy of all data will be stored by [CONTACT_3454].
Novo Nordisk will maintain Novo Nordisk documentation pertaining to the trial for at least [ADDRESS_153872].
The files from the trial site/institution must be retained for 15 years after end of trial as defined in 
Section 7, or longer if required by [CONTACT_36348]. In any case trial files cannot 
be destroyed until the trial site/institution is notified by [CONTACT_3454]. The deletion process must 
ensure confidentiality of data and must be done in accordance with local regulatory requirements.
24.[ADDRESS_153873]’s identity will remain confidential and the antibody samples will be identified only by 
[CONTACT_18022], visit number and trial identification number. No direct identification of the subject 
will be stored together with the samples.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153874] the investigator if they wish to be informed about results derived from stored 
antibody samples obtained from their own body.
25 Institutional Review Boards/Independent Ethics Committees and 
regulatory authorities
IRB/IEC:
Written approval or favourable opi[INVESTIGATOR_135531]/IEC prior to commencement of 
the trial.
During the trial, the investigator or Novo Nordisk, as applicable, must promptly report the 
following to the IRB/IEC, in accordance with local requirements: updates to IB, unexpected SAEs 
where a causal relationship cannot be ruled out, protocol amendments according to local 
requirements, deviations to the protocol implemented to eliminate immediate hazards to the 
subjects, new information that may affect adversely the safety of the subjects or the conduct of the 
trial (including new benefit-risk analysis in case it will have an impact on the planned follow-up of 
the subjects), annually written summaries of the trial status and other documents as required by [CONTACT_36349]/IEC.
The investigator must ensure submission of the clinical trial report synopsis to the IRB/IEC.
Protocol amendments must not be implemented before approval or favourable opi[INVESTIGATOR_36257], unless necessary to eliminate immediate hazards to the subjects.
The investigator must maintain an accurate and complete record of all submissions made to the 
IRB/IEC. The records must be filed in the investigator trial master file and copi[INVESTIGATOR_36258].
Regulatory Authorities:
Regulatory authorities will receive the clinical trial application, protocol amendments, reports on 
SAEs and the clinical trial report according to national requirements.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153875] liability for its products and liability as assumed under the special 
laws, acts and/or guidelines for conducting clinical trials in any country, unless others have shown 
negligence.
Novo Nordisk assumes no liability in the event of negligence, or any other liability of the sites or 
investigators conducting the trial, or by [CONTACT_18033].
Novo Nordisk accepts liability in accordance with:
For Russia only: Federal law of 12 April 2010 No. 61-FZ ‘On Medicinal Drugs’ Circulation.
For Mexico only: 
a) Novo Nordisk carries product liability for its products, and liability as assumed under the 
special laws, acts and/or guidelines for conducting clinical trials in any country, including those applicable provisions on the Mexican [LOCATION_002]. If the subject feels that something 
goes wrong during the course of this trial, the subject should contact [CONTACT_135564]. 
b) If during their participation in the trial the subject experiences a disease or injury that, 
according to the trial doctor and the sponsor, is directly caused by [CONTACT_135565]/or a study procedure that otherwise would not have been part of his/her regular 
medical care, the subject will receive from the Institution or Medical Care Establishment 
and free of charge, the appropriate medical treatment as required. In this case, the costs 
resulting from such treatment as well as the costs of any indemnification established by [CONTACT_135566]; even if the subject discontinues his/her participation in the study by [CONTACT_135567] a decision from the investigator. 
c) By [CONTACT_79844], the subject will not renounce to any compensation or 
indemnification he/she may be entitled to by [CONTACT_2371], nor will he/she will incur any additional 
expense as a result of his/her participation in the trial; any additional expense resulting 
from the subject’s participation in the trial will be covered by [CONTACT_135568]. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 106 of 110
27 References
1. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. 
Guideline for Good Clinical Practice E6(R1), Step 4. [ADDRESS_153876] amended by [CONTACT_941] 64th WMA General Assembly, Fortaleza, Brazil. October 2013.
3. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 
2004;88(4):787-835, ix.
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional 
treatment and risk of complications in patients with type 2 diabetes ([LOCATION_006]PDS 33). [LOCATION_006] Prospective Diabetes Study ([LOCATION_006]PDS) Group. Lancet. 1998;352(9131):837-53.
5. Chuang LM, Tsai ST, Huang BY, Tai TY, Diabcare-Asia Study G. The status of diabetes 
control in Asia--a cross-sectional survey of 24 317 patients with diabetes mellitus in 1998. Diabet Med. 2002;19(12):978-85.
6. Ford ES, Li C, Little RR, Mokdad AH. Trends in A1C concentrations among U.S. adults 
with diagnosed diabetes from 1999 to 2004. Diabetes Care. 2008;31(1):102-4.
7. Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. 
Mol Cell Endocrinol. 2009;297(1-2):127-36.
8. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev. 1999;20(6):876-913.9. Bagger JI, Knop FK, Lund A, Vestergaard H, Holst JJ, Vilsboll T. Impaired regulation of 
the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(3):737-45.
10. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in 
normal and diabetic sujbjects. J Clin Invest. 1967;46(12):1954-62.
11. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-
insulin-dependent) diabetes. Diabetologia. 1986;29(1):46-52.
12. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 
(GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia. 2011;54:10-8.
13. Hojberg PV, Vilsboll T, Rabol R, Knop FK, Bache M, Krarup T, et al. Four weeks of near-
normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia. 2009;52(2):199-207.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 107 of 110
14. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. 
Nat Rev Endocrinol. 2012;8(12):728-42.
15. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide [ADDRESS_153877]. 1998;101(3):515-20.
16. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, et al. Glucagon-like 
peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273(5 Pt 1):E981-8.
17. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of 
fasting hyperglycaemia by [CONTACT_36353]-lik e peptide 1 (7-36 amide) in type 2 (non-
insulin-dependent) diabetic patients. Diabetologia. 1993;36(8):741-4.
18. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, et al. 
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86(8):3717-23.
19. Toft-Nielsen MB, Madsbad S, Holst JJ. Determinants of the effectiveness of glucagon-like 
peptide-1 in type 2 diabetes. J Clin Endocrinol Metab. 2001;86(8):3853-60.
20. Nauck MA, Petrie JR, Sesti G, Mannucci E, Courreges JP, Atkin S, et al. The once-weekly 
human GLP-[ADDRESS_153878]. 2012.
21. European Medicines Agency. ICH Topic M 3 (R2): Non-Clinical Safety Studies for the 
Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, Step 3. July 2008.
22. Waser B, Blank A, Karamitopoulou E, Perren A, Reubi JC. Glucagon-like-peptide-1 
receptor expression in normal and diseased human thyroid and pancreas. Mod Pathol. 2015;28(3):391-402.
23. Novo Nordisk A/S. Investigators Brochure for s.c. Semaglutide (NN9535), Edition 10 or 
any updates hereof. 2015.
24. Novo Nordisk A/S. Investigators Brochure for oral Semaglutide (NN9924), Edition 6 or any 
updates hereof. 2015.
25. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. 
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-79.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 108 of 110
26. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. 
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58(3):429-42.
27. Novo Nordisk Code of Conduct for Clinical Trial Disclosure http:/novonordisk-
trial.com/website/content/how-we-disclose-trial-information.aspx. 1/11/2015 2015.
28. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial 
registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med. 2004;351(12):1250-1.
29. U.S. Department of Health and Human Services, Food and Drug Administration. Food and 
Drug Administration Amendments Act of 2007.
30. The European Parliament and the Council of the European Council. Directive 2001/20/EC 
of the European Parliament and of the Councill of [ADDRESS_153879] of clinical trials on medicinal products for human use, article 11. Official Journal of the European Communities. 1 May 2001.
31. Council TEPatCotE. Regulation (EC) No 726/2004 of the European Parliament and of the 
Council of 31 March laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, article 57. Official Journal of the European Communities. April 2001.
32. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. 
Conceptual framework and item selection. Med Care. 1992;30(6):473-83.
33. Ware JE, Kosinski M, Dewey JE. How to Score Version Two of the SF-36 Health Survey. 
Edition 3 ed: Lincoln RI: QualityMetric, Incorporated. 2000.
34. Turner-Bowker DM, Bartley PJ, Ware JE. SF-36® Health Survey & "SF" Bibliography. 
Lincoln, RI: QualityMetric Incorporated; [ADDRESS_153880] Edition (1988-2000). 2002.
35. Kolotkin RL, Crosby [CONTACT_135569], Kosloski KD, Williams GR. Development of a brief measure to 
assess quality of life in obesity. Obesity Research. 2001;9(2):102-11.
36. RTI Health Solutions. Adaptation of the Impact of Weight on Quality of Life-Lite for Use in 
Clinical Trials - Draft Instrument Adaptation Report. 22 May 2015.
37. National Kidney F. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 
Update. Am J Kidney Dis. 2012;60(5):850-86.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: [ADDRESS_153881] ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia 
and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36(5):1384-95.
39. McAulay V, Deary IJ, Frier BM. Symptoms of hypoglycaemia in people with diabetes. 
Diabet Med. 2001;18(9):690-705.
40. U.S. Department of Health and Human Services, Food and Drug Administration. Guidance 
for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. December 2009.
41. Stull DE, Leidy NK, Parasuraman B, Chassany O. Optimal recall periods for patient-
reported outcomes: challenges and potential solutions. Curr Med Res Opin. 2009;25(4):929-42.
42. Commission E. The Rules Governing Medicinal Products in the European Union, Volume 4, 
Annex 13, Investigational Medicinal Products. Brussels, February 2010.
43. Hicks KA, Hung HMJ, Mahaffey KW, Mehran R, Nissen SE, Strockbridge NL, et al. 
Standardized Definitions for Cardiovascular and Stroke End Point Events in Clinical Trials (Draft). 20 Aug 2014.
44. KDIGO. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney international 
supplements. 2012;2(1):1-138.
45. Bretz F, Posch M, Glimm E, Klinglmueller F, Maurer W, Rohmeyer K. Graphical 
approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests. Biometrical Journal. 2011;53(6):894-913.
46. Rohmeyer K, Klinglmueller F. gMCP: Graph Based Multiple Test Procedures. R package 
version 0.8-8. [ADDRESS_153882] 2014.
47. Little RJA, Rubin DB. Statistical analysis with missing data: [LOCATION_001]: John Wiley & 
Sons. 1987.
48. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). 
Guideline on Missing Data in Confirmatory Clinical Trials (EMA/CPMP/EWP/1776/99 Rev. 1). 2 Jul 2010.
49. National Academy of Sciences (NAS). The Prevention and Treatment of Missing Data in 
Clinical Trials. Washington D.C.: The National Academies Press. 2010.
50. Schwartz NS, Clutter WE, Shah SD, Cryer PE. Glycemic thresholds for activation of 
glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest. 1987;79(3):777-81.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT no.2015-005622-19 Page: 110 of 110
51. Association AD. Standards of medical care in diabetes -2016. Diabetes Care. 2016;[ADDRESS_153883]. 
1:S13-S22.
52. International Committee of Medical Journal Editors. Recommendations for the Conduct, 
Reporting, Editing and Publication of Scholarly Work in Medical Journals; current version 
available at www.icmje.org.CONFIDENTIAL
Protocol - Appendix A
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.: 2015-005622-19 Page: [ADDRESS_153884] be restricted to relevant 
parties.
Protocol - Appendix A
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.: 2015-005622-19 Page: 2 of 5
1 Background
Treatment with GLP-1 receptor agonists has shown to be associated with thyroid C-cell changes in 
rodents but not in non-human primates. The human relevance of this finding is unknown. However, 
based on the findings in rodents, monitoring of serum calcitonin (a sensitive biomarker for C-cell 
activation) is currently being performed in clinical trials with semaglutide.
While there is general agreement on the clinical interpretation of substantially elevated calcitonin 
levels (greater than 100 ng/L) as likely indicative of C-cell neoplasia, the interpretation of values 
between upper normal range (5.0 and 8.4 ng/L for women and men, respectively) and 100 ng/L is 
less clear with regards to indication of disease.
There are several known confounding factors affecting calcitonin levels, e.g.:
!Renal dysfunction
!Smoking
!Autoimmune thyroiditis
!Several drug classes (e.g. proton pump inhibitors, beta-blockers, H 2-blockers and 
glucocorticoids)
Physiology of C-cell activation in various clinical conditions and in different patient populations 
(i.e. with various co-morbidities) is poorly understood. There may be various clinical conditions not 
identified so far which mildly or moderately affect calcitonin secretion by C-cells.CONFIDENTIAL
Protocol - Appendix A
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.: 2015-005622-19 Page: [ADDRESS_153885] has a calcitonin value ≥ 10 ng/L the algorithm outlined in Figure 1 and described 
below should be followed. The algorithm applies for all calcitonin values in the trial.
Calcitonin < 10ng/L
Calcitonin  ≥ 10 ng/L and 
< 50 ng/L
Calcitonin  ≥ 50 ng/L and 
< 100 ng/L
Calcitonin  ≥ 100 ng/LEvaluation of 
calcitonin results
Calcitonin  ≥ 10 ng/L and 
last measurement in the 
trialNo action
●Investigate potential confounding 
factors
●Continue sampling of calcitonin 
according to protocol
●Refer to thyroid specialist
●Discontinue trial product
●Refer to thyroid specialist
●Refer to thyroid specialist
Figure 1 Flow of calcitonin monitoring
2.1 Calcitonin ≥ 100 ng/L  
Action: The subject must immediately be referred to a thyroid specialist for further evaluation and 
the trial product must be discontinued (see protocol Section 6.5premature discontinuation of trial CONFIDENTIAL
Protocol - Appendix A
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.: 2015-005622-19 Page: [ADDRESS_153886]). The subject should remain in the trial, however, all medications suspected to relate to this 
condition must be discontinued until diagnosis has been established.
Background: These values were found in 9 (0.15%) of a population of 5817 patients with thyroid 
nodular disease1. All of these patients were diagnosed with MTC resulting in a positive predictive 
value of 100 %.
Diagnostic evaluation should include:
!Thyroid ultrasound examination
!Fine needle aspi[INVESTIGATOR_36260] > 1 cm 
!Potentially surgery with neck dissection
In case a subject is diagnosed with MTC, it is common clinical practice to explore the family 
history of MTC or MEN2 and perform a genetic test for RET (re-arranged during transfection) 
proto-oncogene mutation.
2.2 Calcitonin ≥ 50 and < 100 ng/L
Action: The subject should be referred to a thyroid specialist for further evaluation. The subject 
should remain in the trial and continuation on trial product should be based on the evaluation done 
by [CONTACT_36354]. 
Background: These values were found in 8 (0.14%) of the population of 5817 patients with thyroid 
nodular disease1. Two of these subjects were diagnosed with MTC and two were diagnosed with 
C-cell hyperplasia, resulting in a positive predictive value of a C-cell anomaly of 50%.
Diagnostic evaluation should include: 
!Thyroid ultrasound examination 
!If available and there are no contraindication, a pentagastrin stimulation test should be done. For 
subjects with positive pentagastrin stimulation test, surgery should be considered
!If pentagastrin stimulation test is not available, thyroid ultrasound and fine needle aspi[INVESTIGATOR_36261]
2.3 Calcitonin ≥ 10 and < 50 ng/L
Action: The subject can continue in the trial on trial product. Continue sampling of calcitonin 
according to the protocol.
If the value is from the last sample taken in the trial, the subject should be referred to a thyroid 
specialist for further evaluation.CONFIDENTIAL
Protocol - Appendix A
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.: 2015-005622-19 Page: 5 of 5
Background: Calcitonin values from 20-50 ng/L were found in up to 1% of subjects of the 
population of 5817 patients with thyroid nodular disease1. The predictive value of a C-cell anomaly 
for this calcitonin level was 8.3%. However, the likelihood of having a medullary carcinoma >1 cm with calcitonin in this range is extremely low.
For calcitonin values between 10-20 ng/L Costante et al
1identified 216 (3.7%) patients. One patient 
out of the 216 had a subsequent basal (unstimulated) calcitonin of 33 ng/L, and had C-cell 
hyperplasia at surgery. Two other studies used a cut-off of CT > 10 ng/L to screen for C-cell 
disease, but they do not provide sufficient information on patients with basal CT > 10 and < 20 ng/L 
to allow conclusions2,3.
3 References
1 Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S et al. Predictive value of serum calcitonin 
levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with 
thyroid nodules. J Clin Endocrinol Metab 2007; 92(2):450-455.
2 Scheuba C, Kaserer K, moritz A, drosten R. Sporadic hypercalcitoninemia: clinica and therapeutic consequences. 
Endocrine Related Cancer 2009; 16(1):243-253.
3 Verga U, Ferrero S, Vicentini L, Brambilla T, Cirello V, Muzza M et al. Histopathological and molecular studies in 
patients with goiter and hypercalcitoninemia: reactive or neoplastic C-cell hyperplasia? Endocr Relat Cancer 2007; 14(2):393-403.CONFIDENTIAL
Protocol - Appendix B
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.: 2015-005622-19 Page: [ADDRESS_153887] be restricted to relevant 
parties.
Protocol - Appendix B
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.: 2015-005622-19 Page: [ADDRESS_153888] be 
completed in the eCRF in addition to the AE form:
!Acute coronary syndrome (myocardial infarction or hospi[INVESTIGATOR_36193])
!Cerebrovascular event (stroke or TIA)
!Heart failure 
!Pancreatitis
!Neoplasm (excluding thyroid neoplasm)
!Thyroid disease (including thyroid neoplasm)
!Renal event
!Hypersensitivity reaction
!Acute gallstone disease
!Medication error (concerning trial products):
!Administration of wrong drug
!Note: Use of wrong DUN is not considered a medication error
!Wrong route of administration
!Administration of an overdose with the intention to cause harm (e.g. suicide attempt), 
misuse or abuse of trial product
!Accidental administration of a higher dose than intended. A higher dose is a dose of at least 
one tablet more than the intended dose; however the administered dose must deviate from 
the intended dose to an extent where clinical consequences for the trial subject were likely 
to happen as judged by [CONTACT_093], although they did not necessarily occur
!Lactic acidosis
!Creatine kinase (CK) > 10x upper normal limit (UNL)
!Hepatic events:
!ALT or AST > 5x UNL and total bilirubin ≤ 2x UNL
!ALT or AST > 3x UNL and total bilirubin > 2x UNL*
!Hepatic events leading to trial product discontinuation 
*Please note that in case of a hepatic event defined as aminotransferase (ALT) or aspartate 
aminotransferase (AST) >3 x UNL and total bilirubin >2 x UNL, where no alternative aetiology 
exists (Hy's law), this must be reported as an SAE using the important medical event criteria if no 
other seriousness criteria are applicable.
In case any of these events fulfil the criteria for an SAE, please report accordingly, see protocol
Section 12.1.2 .
Some of these events will undergo event adjudication by [CONTACT_36355] (EAC), 
please see protocol Section 12.7.2 and Table 12-1.CONFIDENTIAL
Protocol - Appendix B
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.: 2015-005622-19 Page: 3 of 8
1.1 Acute coronary syndrome
If an event of acute coronary syndrome (ranging from unstable angina pectoris to myocardial 
infarction) is observed during the trial, the following additional information must be reported if 
available: 
!Duration of symptoms
!Changes in ECG
!Collection of cardiac biomarkers
!Cardiac imaging
!Cardiac stress testing
!Angiography
!Use of thrombolytic drugs
!Revascularisation procedures 
1.2 Cerebrovascular event
If a cerebrovascular event (e.g. TIA, stroke) is observed during the trial, the following additional 
information must be reported if available: 
!Type of event (e.g. TIA, Stroke)
!Contributing condition
!Neurologic signs and symptoms
!History of neurologic disease
!Imaging supporting the condition
!Treatment given for the condition
1.[ADDRESS_153889] be 
reported if available: 
!Signs and symptoms of heart failure
!NYHA Class
!Supportive imaging
!Supportive laboratory measurements
!Initiation or intensification of treatment for this condition
1.[ADDRESS_153890] be reported if 
available:
!Signs and symptoms of pancreatitis
!Specific laboratory test supporting a diagnosis of pancreatitis
!Imaging performed and consistency with pancreatic diseaseCONFIDENTIAL
Protocol - Appendix B
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.: 2015-005622-19 Page: 4 of 8
!Treatment for and complications of the event
!Relevant risk factors for pancreatic disease
!Family history of pancreatic disease
1.4.[ADDRESS_153891] patients with acute pancreatitis experience severe abdominal pain that is located generally in 
the epi[INVESTIGATOR_135532]. The onset of the pain may be swift reaching maximum 
intensity within 30 min, it is frequently unbearable and characteristically persists for more than 24 
hours without relief1. The pain is often associated with nausea and vomiting. Physical examination 
usually reveals severe upper abdominal tenderness at times associated with guarding. 
In general, both amylase and lipase are elevated during the course of acute pancreatitis. The serum 
lipase may remain elevated slightly longer than amylase. The level of the serum amylase and/or 
lipase does not correlate with the severity of acute pancreatitis1. In general, serum lipase is thought 
to be more sensitive and specific than serum amylase in the diagnosis of acute pancreatitis. 
In case of suspi[INVESTIGATOR_36194], the trial product should promptly be interrupted (no 
treatment discontinuation call should be made in IWRS before diagnosis of acute pancreatitis is 
confirmed). Appropriate additional examinations must be performed, including local measurement 
of amylase and lipase. 
The diagnosis of acute pancreatitis requires two of the following three features2: 
!abdominal pain consistent with acute pancreatitis (acute onset of a persistent, severe, epi[INVESTIGATOR_17961])
!serum lipase activity (and/or amylase activity) at least three times greater than the UNL
!characteristic findings of acute pancreatitis on imaging
If acute pancreatitis is ruled out, trial product should be re-initiated.
If acute pancreatitis is confirmed, appropriate treatment and careful monitoring of the subject 
should be initiated. The subject must be discontinued from trial product (treatment discontinuation 
call), but should remain in the trial (see protocol Section 6.5and8.1.5 ). 
1.5 Neoplasm
All events of neoplasms (excluding thyroid neoplasms, which will be reported under thyroid 
disease) must be reported during the trial and the following additional information must be reported 
if available:
!Type of neoplasm
!Symptoms leading to identification of event
!Diagnostic imagingCONFIDENTIAL
Protocol - Appendix B
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.: 2015-005622-19 Page: 5 of 8
!Pathological examination results
!Treatment for the event
!Participation in screening programs
!Risk factors associated to the event
1.[ADDRESS_153892] be reported if available:
!History of thyroid disease
!Signs and symptoms leading to investigations of thyroid disease
!Specific laboratory tests describing thyroid function
!Diagnostic imaging performed and any prior imaging supporting the disease history 
!Pathologic examinations
!Treatment given for the condition
!Risk factors identified
!Family history of thyroid disease
1.[ADDRESS_153893] be reported if 
available:
!Signs and symptoms of renal failure
!Specific laboratory tests supporting the diagnosis 
!Imaging performed supporting the diagnosis
!Kidney biopsy results
!Risk or confounding factors identified including exposure to nephrotoxic agents
1.[ADDRESS_153894] be reported if available:
!Signs and symptoms associated to the event
!Time of appearance after administration of trial drug
!Relevant immunological tests performed
!Treatment given for the reaction
!Previous history of similar reactions
!Risk or confounding factors identifiedCONFIDENTIAL
Protocol - Appendix B
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.: 2015-005622-19 Page: [ADDRESS_153895] but should remain in the trial (see protocol
Section 6.5and8.1.5 ).
To assist in the diagnostic evaluation it is recommended to draw a blood sample for measurement of 
tryptase (total and/or mature tryptase, local assessment) within [ADDRESS_153896] but should remain in the trial (see protocol Section 6.5and8.1.5 ). It is recommended to 
draw a blood sample for local assessment of complement levels (C3 and C4) to assist in the 
diagnostic evaluation. Complement level results should be included in the specific event form when 
reporting the AE.
1.[ADDRESS_153897] be reported if available: 
!Signs and symptoms of acute gallstone disease
!Specific laboratory tests supporting a diagnosis of gallstone
!Imaging performed and consistency with gallstone disease
!Treatment given for the condition
!Relevant risk factors for acute gallstone disease
!Family history of gallstones
1.[ADDRESS_153898] be reported: 
!Trial product involved 
!Classification of medication error
!Wrong drug administered
!Administration of an overdose
!Whether the subject experienced any hypoglycaemic epi[INVESTIGATOR_36192]/or AE(s) as a result of the 
medication error 
!Suspected primary reason for the medication error CONFIDENTIAL
Protocol - Appendix B
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.: 2015-005622-19 Page: [ADDRESS_153899] 
be reported if available:
!Signs and symptoms of lactic acidosis
!Specific laboratory tests describing the event 
!Possible cause(s) of the event
1.12 Creatine kinase (CK) > 10x UNL
If an event of CK > 10x UNL is observed during the trial, the following additional information must 
be reported if available:
!Signs and symptoms associated to the event 
!Recent physical activity
!Possible cause(s) of the event
1.12.1 Assessments in case of increased levels of creatine kinase
In case of CK > 10x UNL, prompt repeat testing (at central laboratory) of CK should be done. 
Repeat testing (at central laboratory) should be done regularly until CK levels return to normal or 
baseline state. Additional clinical information should be gathered to seek the possible cause of the 
observed CK elevation. 
1.13 Hepatic events
!ALT or AST > 5x UNL and total bilirubin ≤ 2x UNL
!ALT or AST > 3x UNL and total bilirubin > 2x UNL*
!Hepatic events leading to trial product discontinuation 
If one of the above events is observed during the trial, the following additional information must be 
reported if available:
!Signs and symptoms associated to the event 
!Risk factors
!Relevant laboratory test results 
!Diagnostic imaging performed 
!Possible cause(s) of the event 
1.13.1 Assessments in case of increased levels of aminotransferases
Both events should prompt repeat testing (at central laboratory) including ALT, AST, alkaline 
phosphatase (ALP) and total bilirubin and discontinuation of trial product should be considered. CONFIDENTIAL
Protocol - Appendix B
CONFIDENTIALDate: 20 April 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 2.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.: 2015-005622-19 Page: 8 of 8
Thereafter, repeat testing (at central laboratory) of ALT, AST, ALP and total bilirubin should be 
done regularly until the abnormalities return to normal or baseline state. Additional clinical 
information such as related symptoms, risk factors and contributing conditions (e.g. viral hepatitis, 
autoimmune hepatitis, alcoholic hepatitis, hepatobiliary or pancreatic disorders) should be gathered 
to seek a possible cause of the observed laboratory test abnormalities.
*Please note that risk of liver injury defined as ALT or AST > 3x UNL and total bilirubin > 2x 
UNL, where no alternative aetiology exits (Hy’s law), should also be reported as a SAE (important 
medical event, according to protocol Section 12.1.2 ). 
2 References
1. Banks PA, Freeman ML, Practice Parameters Committee of the American College of G. 
Practice guidelines in acute pancreatitis. Am J Gastroenterol. 2006;101(10):2379-400.
2. Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Classification 
of acute pancreatitis-2012: revision of the Atlanta classification and definitions by [CONTACT_5757]. Gut. 2013;62(1):102-11.
3. Food and Drug Administration. Guidance for Industry: Immunogenicity Assessment for 
Therapeutic Protein Products. August 2015.CONFIDENTIAL
Global and country key Novo Nordisk staff
Attachments I and II (if applicable) to the protocol are located in the Trial Master File.
Content: Global key staff and Country key staffCONFIDENTIALDate: Novo Nordisk
Version:
Status:Oral semaglutide
Trial ID: NN9924-4233Clinical Trial Report
Appendix 16.1.120 June 2018
1.0
FinalCONFIDENTIAL
Protocol Amendment 
CONFIDENTIALDate: [ADDRESS_153900] 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 1
UTN: U1111-1177-5112 Status: Final
EudraCT No.: 2015-005622-19 Page: 1 of 4
Protocol Amendment
no 1
to Protocol, final version 2.0
dated 20 April 2016
Trial ID: NN9924-4233
Efficacy and safety of oral semaglutide versus placebo in 
subjects with type 2 diabetes mellitus treated with
diet and exercise only
Trial phase: 3a
Applicable to Czech Republic
Amendment originator:
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol Amendment 
CONFIDENTIALDate: [ADDRESS_153901] 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 1
UTN: U1111-1177-5112 Status: Final
EudraCT No.: 2015-005622-19 Page: 2 of 4
Table of Contents   
Page
Table of Contents.............................................................................................................. ................................2
1 Introduction including rationale for the protocol  amendment .............................................................3
2 Changes ....................................................................................................................... ...............................3
2.1 Changes to sec tion 1 Summary................................................................................................ ......3
2.2 Changes to section 6.3 Exclusion criteria................................................................................... ...3
2.3 Changes to section 8.2.5 Childbearing potential............................................................................4CONFIDENTIAL
Protocol Amendment 
CONFIDENTIALDate: [ADDRESS_153902] 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 1
UTN: U1111-1177-5112 Status: Final
EudraCT No.: 2015-005622-19 Page: 3 of 4
1 Introduction including rationale for the protocol amendment
This protocol amendment was issued to incorporate changes requested by [CONTACT_135570] 2.0 dated 20 April 2016. 
In this protocol amendment:
!Any new text is written in italics.
!Any text deleted from the protocol is written using strike through.
2 Changes
2.1 Changes to section 1 Summary
Key exclusion criteria
!Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing 
potential and not using an adequate contraceptive method (adequate contraceptive measure as required by [CONTACT_17993]). 
For Japan only: Adequate contraceptive measures are abstinence (not having sex), diaphragm, 
condom (by [CONTACT_3969]), intrauterine device, sponge, spermicide or oral contraceptives.
For Czech Republic only: Adequate contraceptive measures are always one highly reliable method 
(such as intrauterine device, sterilisation of one of the partners, hormonal birth control methods) 
plus one supplementary barrier method (such as condom, diaphragm) with a spermicide. In 
justified cases, this combination may be replaced with a double-barrier method with a spermicide. 
Total sexual abstinence may also be considered contraception. (Please note: hormonal 
contraception should always be discussed with a gynaecologist).
2.[ADDRESS_153903]-feeding or intends to become pregnant or is of child-bearing 
potential and not using an adequate contraceptive method (adequate contraceptive measure as 
required by [CONTACT_17993]). 
For Japan only: Adequate contraceptive measures are abstinence (not having sex), diaphragm, 
condom (by [CONTACT_3969]), intrauterine device, sponge, spermicide or oral contraceptives.CONFIDENTIAL
Protocol Amendment 
CONFIDENTIALDate: [ADDRESS_153904] 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 1
UTN: U1111-1177-5112 Status: Final
EudraCT No.: 2015-005622-19 Page: 4 of 4
For Czech Republic only: Adequate contraceptive measures are always one highly reliable method 
(such as intrauterine device, sterilisation of one of the partners, hormonal birth control methods) 
plus one supplementary barrier method (such as condom, diaphragm) with a spermicide. In 
justified cases, this combination may be replaced with a double-barrier method with a spermicide. 
Total sexual abstinence may also be considered contraception. (Please note: hormonal 
contraception should always be discussed with a gynaecologist).
2.3 Changes to section 8.2.5 Childbearing potential
8.2.5 Childbearing potential
Contraceptive methods
For Japan only: Adequate contraceptive measures are abstinence (not having sex), diaphragm, 
condom (by [CONTACT_3969]), intrauterine device, sponge, spermicide or oral contraceptives.
For Czech Republic only: Adequate contraceptive measures are always one highly reliable method 
(such as intrauterine device, sterilisation of one of the partners, hormonal birth control methods) 
plus one supplementary barrier method (such as condom, diaphragm) with a spermicide. In 
justified cases, this combination may be replaced with a double-barrier method with a spermicide. 
Total sexual abstinence may also be considered contraception. (Please note: hormonal 
contraception should always be discussed with a gynaecologist).CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 18 November 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 1.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.:2015-005622-19 Page: 1 of 15
Protocol Amendment
no 2
to Protocol, final version 2
dated 20 April 2016
Trial ID:NN9924-4233
PI[INVESTIGATOR_15597] 1 – Monotherapy
Efficacy and safety of oral semaglutide versus placebo in
subjects with type 2 diabetes mellitus treated with
diet and exercise only
Trial phase: 3a
Applicable to all countries
 
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol Amendment
CONFIDENTIALDate: 18 November 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 1.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.:2015-005622-19 Page: 2 of 15
Table of Contents   
Page
Table of Contents.............................................................................................................. ................................2
1 Introduction including rationale for the protocol  amendment .............................................................3
1.1 Additional eye examinations and additional data collection on diabetic retinopathy....................3
1.2 Investigator’s responsibility in ensuring evaluation and management of certain risk factors 
and complications .............................................................................................................. ............[ADDRESS_153905] to follow-up..............................4
1.4 Other minor adjustments, clarifications and correction of typogr aphical errors............................4
Adverse events for Adjudication ................................................................................................ ...4
2 Changes ....................................................................................................................... ...............................6
2.1 Section 2 Flow Chart ........................................................................................................ .............6
2.2 Section [IP_ADDRESS]  Supportive s econdary endpoints ..........................................................................7
2.3 Section 6.6 Withdrawal from trial ........................................................................................... ......7
2.4 Section 8.1.4  End-of-treatment (visit 8) and Follow-up (visit 9)..................................................[ADDRESS_153906] and follow-up (visits 8A and 9A)........8
2.6 [IP_ADDRESS] Lost to follow-up ................................................................................................................9
2.7 Section [IP_ADDRESS] Adverse events requi ring additional data collection.............................................9
2.8 Section 8.4.2 Physical examination .......................................................................................... ...10
2.9 Section 8.4.4 Eye examination............................................................................................... ......10
2.10 Section 8.4.8 Anti-semaglutide antibodies .................................................................................. 10
2.11 Section 12.1.5  Adverse events re quiring additional data collection...........................................10
2.12 Section 12.7.2 Event ad judication committee..............................................................................11
2.13 Section 17.2 Definition of analysis sets................................................................................... ....11
2.14 Section 17.3.1 Primary analysis for the primary estimand ..........................................................12
2.15 Section [IP_ADDRESS] Efficacy endpoints (Binary efficacy endpoints)................................................12
2.16 Section [IP_ADDRESS]  Safety endpoints......................................................................................... ......12
2.17 Section 18.1  Benefit-risk assessment of the trial ........................................................................1 3
2.18 Section 18.1  General precautions .......................................................................................... .....13
2.19 Section 27 References...................................................................................................... ............13
2.20 Reference Numbers.......................................................................................................... ............14
2.21 Appendix B, Section 1 Adverse Events  requiring additional data collection..............................14
2.21.1 Appendix B, new section 1.14 Diabetic retinopathy .................................................15CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 18 November 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 1.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.:2015-005622-19 Page: 3 of 15
1 Introduction including rationale for the protocol amendment
This protocol amendment introduces:
1. Additional eye examinations and additional data collection on diabetic retinopathy 
2. Investigator’s responsibility in ensuring evaluation and management of certain risk factors and 
complications
3. Clarification of the criteria for completion, withdrawal and lost to follow-up
4. Other minor corrections and clarifications 
1.1 Additional eye examinations and additional data collection on diabetic retinopathy
Updated sections in the protocol: 2, [IP_ADDRESS], [IP_ADDRESS], 8.4.4, 12.1.5, [IP_ADDRESS], 18.1, Appendix B; 
section 1, 1.[ADDRESS_153907] been implemented in all trials in the PI[INVESTIGATOR_36181]. Also, to further understand this 
safety signal, additional information will be collected  for all diabetic retinopathy events reported 
during the trial. The information will be collected not only from new subjects enrolled by [CONTACT_135571], but also from already enrolled subjects to the extent that the information is 
available. Furthermore, information to the investigators and subjects related to diabetic retinopathy 
has been added to the protocol (see Section 18) and the subject information. 
                                                
1Dahl-Jørgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O. Rapid tightening of blood glucose 
control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. Br Med J 
(Clin Res Ed). 1985;290(6471):811-5.
2The Diabetes Control and Complications Trial Research Group. Early worsening of diabetic retinopathy in the 
Diabetes Control and Complications Trial. Arch Ophthalmol. 1998;116(7):874-86.
3Varadhan L, Humphreys T, Walker AB, Varughese GI. The impact of improved glycaemic control with GLP-[ADDRESS_153908]. 2014;103(3):e37-9.
4Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes 
in Patients with Type 2 Diabetes. N Engl J Med. 2016.CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 18 November 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 1.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.:2015-005622-19 Page: 4 of 15
1.2 Investigator’s responsibility in ensuring evaluation and management of certain risk 
factors and complications
Updated sections in the protocol: 8.4.2, 18.1
, text is added to highlight the investigators responsibility in relation 
to further evaluation of potential incidental thyroid nodules discovered at the physical examination.
In addition, text is added to highlight the investigator’s responsibility in ensuring evaluation and 
management of cardiovascular risk factors and microvascular complications such as diabetic kidney 
disease and diabetic retinopathy.
1.[ADDRESS_153909] to follow-up
Updated sections in the protocol: 6.6, 8.1.4, 8.1.5, [IP_ADDRESS] 
The criteria for subject completion, -withdrawal and -lost to follow-up respectively are clarified and 
have been made consistent across sections. Lost to follow-up is considered a subcategory to 
withdrawal from trial. In addition, it is emphasised that as soon as contact [CONTACT_1639] a subject is lost, efforts 
must be made to regain contact [CONTACT_36358]. 
Only if contact [CONTACT_36359]. 
Because this trial is not an outcome trial the terminology ‘health status’ is replaced with “relevant 
safety information” - the purpose of which is to follow up on any adverse events or pregnancy, and 
not to determine if a subject completes the trial or not.
1.4 Other minor adjustments, clarifications and correction of typographical errors
Updated sections in the protocol: 8.4.8, 12.7.2, 17.2, 17.3.1, [IP_ADDRESS]
Laboratory analysis
The protocol currently specifies that the in vitro neutralising antibody assays will be performed by 
[CONTACT_3454], however, it may be decided by [CONTACT_135572] (Celerion) will perform the assay. 
Adverse events for Adjudication
Table 12-2 has been aligned with Table 12-1 reflecting that unstable angina pectoris (UAP) require 
hospi[INVESTIGATOR_36265].
Statistical considerations
The eye examination category has been added to the list of assessments where the follow-up period 
is included in the “on-treatment” observation period. This is due to the inclusion of the fundus CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 18 November 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 1.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.:2015-005622-19 Page: 5 of 15
photography or dilated fundoscopy at the end of trial visit or within 5 weeks thereafter for subjects 
completing treatment.
For the pattern mixture model using multiple imputation, the number of imputations will be 
increased from 100 to 1000 data sets, to ensure a greater precision of the estimates. In addition, an 
error in the number of groups used for imputation is corrected.
In the section “Time to event endpoint” stratification factors have been added in error and will be 
deleted. CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 18 November 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 1.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.:2015-005622-19 Page: 6 of 15
2 Changes
In this protocol amendment:
!Any new text is written in italics.
!Any text deleted from the protocol is written using strike through.
2.1 Section 2 Flow Chart 
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 18 November 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 1.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.:2015-005622-19 Page: [ADDRESS_153910] be performed again:
!at V8 or within 5 weeks thereafter for subjects completing treatment
!at V8A or within [ADDRESS_153911]
2.2 Section [IP_ADDRESS] Supportive secondary endpoints
Change from baseline to week 26 in:
!Haematology 
!Biochemistry 
!Calcitonin
!Pulse
!Systolic blood pressure
!Diastolic blood pressure
!Electrocardiogram (ECG) category
!Physical examination
!Eye examination category
2.[ADDRESS_153912]’s request to withdraw from the 
trial must always be respected. Only subjects who withdraw consent should be considered 
withdrawn from trial. A subject who does not complete the trial is also considered withdrawn from 
the trial. Hence a subject is considered withdrawn if the following applies: 
!Subject withdrew consent 
!Subject is lost to follow up (only to be used if there is no contact [CONTACT_36360]’s last scheduled visit, see sections 8.1.4 - [IP_ADDRESS])
!Other (subject deceased or closure of trial site)CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 18 November 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 1.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.:2015-005622-19 Page: 8 of 15
2.4 Section 8.1.4 End-of-treatment (visit 8) and Follow-up (visit 9)
At V8 the subject should be reminded about the importance of attending the follow-up visit (V9). If
the subject, nonetheless, does not attend V9, the site should make efforts to obtain contact [CONTACT_135573]. 
A trial completer is defined as a subject who attends, or is in contact [CONTACT_36362], at the subject’s 
last scheduled visit. For subjects who complete treatment, the last scheduled visit is V9. (For 
subjects who discontinue trial product, see Section 8.1.5) 
In case the subject cannot be reached (by [CONTACT_135536]) at the scheduled visit 9, the site 
should consult the contacts provided by [CONTACT_423] (e.g. close relatives), relevant physicians, 
medical records and locator agencies (if allowed according to local law) to collect health status. If 
no health status can be collected, the subject should be considered lost to follow-up and this should 
be specified in the end-of-trial form. 
2.[ADDRESS_153913] and follow-up (visits 8A 
and 9A)
Subjects should continue with the originally scheduled site contacts after visit V9A and up to and 
including visit V8. After visit V9A, samples for antibodies, PK and lactate assessment should not be 
taken. If necessary, in order to retain the subject in the trial, site visits can be replaced by [CONTACT_135537] V9A. However, as a minimum, these subjects should be asked to attend the 
scheduled end-of-treatment visit (V8) at week 26 as these visits should be performed for all 
subjects, if at all possible (except subjects who withdraw informed consent, see Section 8.1.6)
Subjects, who only agree to attend or provide health status at the scheduled V8, should not be 
considered withdrawn from the trial. In case the subject cannot be reached (by [CONTACT_135538]) at the scheduled V8, the site should consult the contacts provided by [CONTACT_423] (e.g. close 
relatives), relevant physicians, medical records and locator agencies (if allowed according to local 
law) to collect health status. If no health status can be collected, the subject should be considered 
lost to follow-up up and this should be specified in the end-of-trial form.
A subject who prematurely discontinued trial product is still considered a trial completer if the subject attends or is in contact [CONTACT_36362], at the subject’s last scheduled visit. For subjects who 
prematurely discontinue trial product, the last scheduled visit is V8 (or V9A if it is scheduled after 
V8). The site should in due time prepare for establishing contact [CONTACT_135574] V8 if the subject has agreed to attend these visits. 
In summary, subjects should stay in the trial irrespective of lack of adherence to randomised 
treatment, lack of adherence to visit schedule, missing assessments or trial product discontinuation CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 18 November 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 1.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.:2015-005622-19 Page: [ADDRESS_153914] with the site in relation to the trial 
should be considered as having withdrawn consent from the trial (for withdrawal procedures, see 
section 8.1.6).
2.6 [IP_ADDRESS] Lost to follow-up
In case contact [CONTACT_36365], the site should immediately undertake efforts to 
re-establish contact. If the subject cannot be reached (by [CONTACT_36286]) and the 
subject has consented to it, the site should consult the contacts provided by [CONTACT_423] (e.g. close 
relatives), relevant physicians, medical records and locator agencies (if allowed according to local 
law) in an attempt to regain contact [CONTACT_36366]. Efforts to regain contact [CONTACT_36367]’s last scheduled 
visit: V9 for subjects who have completed treatment, whereas for subjects who have discontinued 
trial product prematurely the last visit is V8 (or V9A if it is scheduled after V8). Only if contact [CONTACT_135575] (see Section 6.6). 
2.7 Section [IP_ADDRESS] Adverse events requiring additional data collection 
For the following AEs additional data collection is required and specific event forms must be 
completed in the eCRF in addition to the AE form (see Section 12.1.5):
!Acute coronary syndrome (myocardial infarction or hospi[INVESTIGATOR_36193])
!Cerebrovascular event (stroke or transient ischaemic attack)
!Heart failure 
!Pancreatitis
!Neoplasm (excluding thyroid neoplasm)
!Thyroid disease (including thyroid neoplasm)
!Renal event
!Hypersensitivity reaction
!Acute gallstone disease
!Medication error
!Lactic acidosis
!Creatine kinase (CK) > 10x UNL
!Hepatic events defined as:
!ALT or aspartate aminotransferase (AST) > 5x UNL and total bilirubin ≤ 2x UNL
!ALT or AST > 3x UNL and total bilirubin > 2x UNL*
!Hepatic events leading to trial product discontinuation
!Diabetic retinopathy and related complicationsCONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 18 November 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 1.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.:2015-005622-19 Page: 10 of 15
*Please note that in case of a hepatic event defined as ALT or AST > 3x UNL and total bilirubin >
2x UNL, where no alternative aetiology exists (Hy's law), this must be reported as an SAE using the 
important medical event criteria if no other seriousness criteria are applicable.
2.8 Section 8.4.2 Physical examination
A physical examination will be performed by [CONTACT_36291] (see 
flow chart, Section 2 and 8.1.7). A physical examination must include:
!General appearance
!Head, ears, eyes, nose, throat, neck
!Thyroid gland *
!Respi[INVESTIGATOR_2133]
!Cardiovascular system
!Gastrointestinal system including mouth
!Musculoskeletal system
!Central and peripheral nervous system
!Skin
!Lymph node palpation
*Please note that the diagnostic evaluation of thyroid nodules should be in accordance with the 
American Thyroid Association Management Guidelines or any updates hereof 37, and adapted to 
local treatment guidelines if applicable.
2.9 Section 8.4.4 Eye examination 
Fundus photography/dilated fundoscopy will be performed as per flow chart (see Section 2) by [CONTACT_36369]. Fundoscopy requires pharmacological dilation of both 
pupi[INVESTIGATOR_8324] . Results of the fundus photography/dilated fundoscopy will be interpreted by [CONTACT_093] 
(see Section 8.1.7).
2.[ADDRESS_153915] 
in the in vitro neutralising antibody assays. The in vitro neutralising assays will be performed by 
[CONTACT_135576].
2.11 Section 12.1.5 Adverse events requiring additional data collection
Table 12–1 Adverse events requiring completion of specific event forms and/or are subject to 
event adjudication [Note: Only shown is the event with updated event description, all other events 
are unchanged]CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 18 November 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 1.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.:2015-005622-19 Page: 11 of 15
Event Specific event form Event adjudication
Diabeic retinopathy and related complications Yes No
2.12 Section 12.7.2 Event adjudication committee
Table 12–2 Adverse events for adjudication
[Note: Only shown is the event with updated event description, all other events are unchanged ]
Events Description Adjudication outcome
Acute Coronary Syndrome !Acute Coronary Syndrome conditions include: 
!ST-elevation acute myocardial infarction 
(STEMI)
!Non-ST elevation acute myocardial infarction 
(NSTEMI)
!Silent MI 
!Unstable angina pectoris (UAP ) requiring 
hospi[INVESTIGATOR_11956]!Acute myocardial 
infarction (STEMI or 
NSTEMI), silent MI
!Unstable angina pectoris 
requiring hospi[INVESTIGATOR_11956]
2.13 Section 17.2 Definition of analysis sets
On-treatment: This observation period represents the time period where subjects are considered
treated with the trial product. The observation period is a subset of the in-trial observation period. It
starts at the date of first dose of trial product. Two slightly different end dates will be needed to
cover all assessments appropriately. For adjudicated events, ECGs, eye examination category , anti-
semaglutide antibodies, and AEs including hypoglycaemic epi[INVESTIGATOR_1841], the observation period ends at 
the first date of any of the following:
!The follow-up visit (V9)
!The follow-up prematurely discontinuation visit (V9A)
!The last date on trial product + 38 days
!The end-date for the in-trial observation periodCONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 18 November 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 1.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.:2015-005622-19 Page: 12 of 15
2.14 Section 17.3.1 Primary analysis for the primary estimand
Missing values for each group will be imputed as follows:
!An analysis of covariance (ANCOVA) with region as a categorical fixed effect and baseline 
HbA 1cmeasurement as a covariate will be fitted to observed values of the change from 
baseline in HbA 1cat week 26.
!The estimated parameters for location and dispersion will be used to impute [ADDRESS_153916] with missing week 26 data based on region and baseline HbA 1c. Thus, 100
1000 complete data sets will be generated including observed and imputed values.
Analysis used for confirming superiority versus placebo at week 26:
For each of the 100 1000 (now complete) imputed data sets the change from baseline to week 26 in 
HbA 1cwill be analysed using an ANCOVA with treatment and region as categorical fixed effects 
and baseline HbA 1cas covariate. The results obtained from analysing the datasets will be combined 
using Rubin’s rule47to draw inference.
2.15 Section [IP_ADDRESS] Efficacy endpoints (Binary efficacy endpoints)
!Multiple imputed data sets (100 1000 ) will be created in which missing values for the 
underlying continuous assessments are imputed by [CONTACT_36371]/rescue status assuming MAR and as described in section 17.3.1 for the primary 
estimand and by [CONTACT_36338] 17.3.2 for the 
secondary estimand.
!The binary endpoint will be created for each of the 100 1000 complete data sets
!Each of the created complete data set will be analysed with the logistic model and inference 
will be drawn using Rubin’s rule47.
Time to event endpoint
The endpoint will be described and compared for oral semaglutide versus placebo using likelihood 
ratio tests obtained from a Cox proportional hazards model with treatment, stratification factors, the 
interaction between the two stratification factors and region as categorical fixed effects and baseline 
HbA 1cas a covariate. From this analysis the estimated Hazard ratios between oral semaglutide 
versus placebo will be presented together with 95% confidence intervals and two sided p values for 
test of no difference.
2.16 Section [IP_ADDRESS] Safety endpoints
Other safety endpoints
Change from baseline to week 26 in:
!Haematology CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 18 November 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 1.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.:2015-005622-19 Page: 13 of 15
!Biochemistry (except for amylase and lipase)
!Calcitonin
!ECG evaluation
!Physical examination
!Eye examination category
2.[ADDRESS_153917] a fundus photography or 
dilated fundoscopy performed before enrolment into the trial; moreover, subjects with proliferative retinopathy or maculopathy requiring acute treatment will be excluded. As part of good diabetes 
management the investigator is encouraged to ensure adequate monitoring and treatment of 
diabetic retinopathy in subjects enrolled into the trial
58.
2.[ADDRESS_153918]. This 
includes adequate glycaemic control, appropriate risk factor modification such as optimal 
treatment of hypertension, dyslipi[INVESTIGATOR_36268], as well as regular 
monitoring and treatment of diabetic kidney disease and diabetic retinopathy according to the 
principles outlined in (Diabetes Care 2016 Standards of Medical Care in Diabetes)58
2.19 Section 27 References 
37. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid 
Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task 
Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133.CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 18 November 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 1.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.:2015-005622-19 Page: 14 of 15
52. Dahl-Jørgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O. 
Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin 
dependent diabetes mellitus: the Oslo study. Br Med J (Clin Res Ed). 1985;290(6471):811-5.
53. The Diabetes Control and Complications Trial Research Group. Early worsening of 
diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol. 
1998;116(7):874-86.
54. Varadhan L, Humphreys T, Walker AB, Varughese GI. The impact of improved 
glycaemic control with GLP-[ADDRESS_153919]. 2014;103(3):e37-9.
55. Intensive blood-glucose control with sulphonylureas or insulin compared with 
conventional treatment and risk of complications in patients with type 2 diabetes ([LOCATION_006]PDS 33). [LOCATION_006] 
Prospective Diabetes Study ([LOCATION_006]PDS) Group. Lancet. 1998;352(9131):837-53, Erratum 1999; 354: 
602.
56. The Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) 
Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On 
(ACCORDION) Study Group. Persistent Effects of Intensive Glycemic Control on Retinopathy in 
Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On 
Study. Diabetes Care. 2016;39(7):1089-100.
57. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. 
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016.
58. American Diabetes Association. Standards of medical care in diabetes - 2016. 
Diabetes Care. 2016;39 (Suppl. 1):S1-S109.
59. Association AD. Standards of medical care in diabetes -2016. Diabetes Care. 2016;[ADDRESS_153920]. 1:S13-S22.
2.[ADDRESS_153921] be 
completed in the eCRF in addition to the AE form:
!Acute coronary syndrome (myocardial infarction or hospi[INVESTIGATOR_36193])CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 18 November 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 1.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.:2015-005622-19 Page: 15 of 15
!Cerebrovascular event (stroke or TIA)
!Heart failure 
!Pancreatitis
!Neoplasm (excluding thyroid neoplasm)
!Thyroid disease (including thyroid neoplasm)
!Renal event
!Hypersensitivity reaction
!Acute gallstone disease
!Medication error (concerning trial products):
!Administration of wrong drug
!Note: Use of wrong DUN is not considered a medication error
!Wrong route of administration
!Administration of an overdose with the intention to cause harm (e.g. suicide attempt), 
misuse or abuse of trial product
!Accidental administration of a higher dose than intended. A higher dose is a dose of at least 
one tablet more than the intended dose; however the administered dose must deviate from 
the intended dose to an extent where clinical consequences for the trial subject were likely 
to happen as judged by [CONTACT_093], although they did not necessarily occur
!Lactic acidosis
!Creatine kinase (CK) > 10x upper normal limit (UNL)
!Hepatic events:
!ALT or AST > 5x UNL and total bilirubin ≤ 2x UNL
!ALT or AST > 3x UNL and total bilirubin > 2x UNL* 
!Hepatic events leading to trial product discontinuation 
!Diabetic retinopathy and related complications
2.21.1 Appendix B, new section 1.14 Diabetic retinopathy
If an event of diabetic retinopathy (or related complications) is observed during the trial the 
following additional information must be reported, if available:
!Signs and symptoms associated with the event
!Results of the eye examination 
!Treatment for and complications of the event
!Contributing conditions CONFIDENTIAL
Protocol Amendment 
CONFIDENTIALDate: 10 November 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 1.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.: 2015-005622-19 Page: 1 of 3
Protocol Amendment
no 3
to Protocol, final version 2.0
dated 20 April 2016
Trial ID: NN9924-4233
Efficacy and safety of oral semaglutide versus placebo in 
subjects with type 2 diabetes mellitus treated with
diet and exercise only
Trial phase: 3a
Applicable to Serbia
Amendment originator:
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol Amendment 
CONFIDENTIALDate: 10 November 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 1.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.: 2015-005622-19 Page: 2 of 3
Table of Contents   
Page
Table of Contents.............................................................................................................. ................................2
1 Introduction including rationa le for the protocol  amendment .............................................................3
2 Changes ....................................................................................................................... ...............................3
2.1 Changes to section 6.4 Rescue Criteria...................................................................................... ....3CONFIDENTIAL
Protocol Amendment 
CONFIDENTIALDate: 10 November 2016 Novo Nordisk
Trial ID: NN9924-4233 Version: 1.0
UTN: U1111-1177-5112 Status: Final
EudraCT No.: 2015-005622-19 Page: 3 of 3
1 Introduction including rationale for the protocol amendment
This protocol amendment was issued to incorporate changes requested by [CONTACT_135577] 2.0 dated 20 April 2016. 
In this protocol amendment:
!Any new text is written in italics.
!Any text deleted from the protocol is written using strike through.
[ADDRESS_153922] of treatment on
glycaemic parameters, rescue criteria will be applied from week 8 and onwards. If any of the FPG
values (including fasting SMPG) exceed the limits outlined below and no intercurrent cause of the
hyperglycaemia can be identified, a confirmatory FPG (at the central laboratory) should be obtained
by [CONTACT_36282] a re-test. If the confirmatory FPG also exceeds the values described below,
the subject should be offered rescue medication (i.e. initiation of anti-diabetic medication):
!13.3 mmol/L (240 mg/dL) from week 8 to the end of week 13
!11.1 mmol/L (200 mg/dL) from week 14 to the end-of-treatment
Guidance text requested by [CONTACT_135578]: The safety of the individual subject always 
has the highest priority. Thus, the rescue criteria represent the minimum criteria for when rescue 
medication should be initiated. At the investigator’s discretion, rescue medication can be initiated 
in case of FPG values lower than those stated in the rescue criteria or before week 8 in case of a 
specific safety concern.
It is important for the integrity of the trial that only subjects actually needing treatment
intensification (as defined above) are started on rescue medication. Subjects who are started on
rescue medication should continue to follow the protocol-specified visit schedule. Rescue
medication should be prescribed at investigator’s discretion as add-on to randomised treatment and
according to ADA/European Association for the Study of Diabetes guidelines25, 26 (excluding 
GLPRAs, DPP-4 inhibitors and amylin analogues).CONFIDENTIAL